BlackRock Enhanced Equity Dividend Trust Form N-CSRS September 04, 2018

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **FORM N-CSR**

# CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number: 811-21784

Name of Fund: BlackRock Enhanced Equity Dividend Trust (BDJ)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Enhanced Equity

Dividend Trust, 55 East 52<sup>nd</sup> Street, New York, NY 10055

Registrant s telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2018

Date of reporting period: 06/30/2018

Item 1 Report to Stockholders

JUNE 30, 2018

### SEMI-ANNUAL REPORT (UNAUDITED)

**BlackRock Energy and Resources Trust (BGR)** 

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

**BlackRock Health Sciences Trust (BME)** 

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Trust (BST)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Not FDIC Insured May Lose Value No Bank Guarantee

#### The Markets in Review

Dear Shareholder,

In the 12 months ended June 30, 2018, the strongest corporate profits in seven years drove the equity market higher, while rising interest rates constrained bond returns. Though the market s appetite for risk remained healthy, risk taking was tempered somewhat, as shorter-term, higher-quality securities led the bond market, and U.S. equities outperformed most international stock markets.

Strong equity performance worldwide was driven by synchronized economic growth across the most influential economies. However, volatility in emerging market stocks rose, as U.S.-China trade relations and debt concerns weighed heavily on the Chinese stock market.

Short-term U.S. Treasury interest rates rose the fastest, while longer-term rates slightly increased, leading to a substantial flattening of the yield curve. The annual return for the three-month U.S. Treasury bill surpassed 1.0%, but remained well below the annual headline inflation rate of 2.9%. In contrast, the ten-year U.S. Treasury a bellwether of the bond market posted a negative return, as rising inflation expectations drove yields higher. Although the fundamentals in credit markets remained relatively solid, investment-grade bonds declined slightly, and high-yield bonds posted modest returns.

In response to rising growth and inflation, the U.S. Federal Reserve (the Fed ) increased short-term interest rates three times during the reporting period. The Fed also announced plans to reduce its \$4.4 trillion balance sheet by \$420 billion in 2018, which began the process of gradually reversing its unprecedented stimulus measures after the financial crisis. Meanwhile, the European Central Bank announced that its bond-purchasing program would conclude at the end of the year, while also expressing an open-ended commitment to low interest rates. In contrast, the Bank of Japan continued to expand its balance sheet through bond purchasing while lowering its expectations for inflation.

The U.S. economy continued to gain momentum despite the Fed s modest reduction of economic stimulus; unemployment declined to 4.0%, wages increased, and the number of job openings reached a record high. Strong economic performance may justify a more rapid pace of rate hikes in 2018, as the headline inflation rate and investors expectations for inflation have already surpassed the Fed s target of 2.0%.

While U.S. monetary policy is seeking to restrain economic growth and inflation, fiscal policy has produced new sources of growth that could nourish the economy for the next few years. Corporate tax cuts and repatriation of capital held abroad could encourage a virtuous cycle of business spending. Lower individual tax rates coupled with the robust job market may refresh consumer spending. Proposed infrastructure spending would deliver growth from the government sector, generate demand, and improve economic activity in other sectors.

We continue to believe the primary risks to economic expansion are trade protectionism, rapidly rising interest rates, and geopolitical tension. Given the deflationary forces of technology and globalization, a substantial increase in inflation is unlikely to materialize as long as the unemployment rate remains above 3.0%. However, we are closely monitoring trade protectionism and the rise of populism in Western nations. In particular, the outcome of trade negotiations between the United States and China is likely to influence the global growth trajectory and set the tone for free trade in many other nations.

In this environment, investors need to think globally, extend their scope across a broad array of asset classes, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit **blackrock.com** for further insight about investing in today s markets.

Sincerely,

### Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

### Total Returns as of June 30, 2018

	6-month	12-month
U.S. large cap equities	2.65%	14.37%
(S&P 500 <sup>®</sup> Index)		
U.S. small cap equities	7.66	17.57
(Russell 2000® Index)		
International equities	(2.75)	6.84
(MSCI Europe, Australasia,		
Far East Index)		
Emerging market equities	(6.66)	8.20
(MSCI Emerging Markets Index)		
3-month Treasury bills	0.81	1.36
(ICE BofAML 3-Month U.S. Treasury Bill Index)		
U.S. Treasury securities	(2.68)	(2.69)
(ICE BofAML 10-Year U.S. Treasury Index)		
U.S. investment grade bonds	(1.62)	(0.40)
(Bloomberg Barclays U.S.		
Aggregate Bond Index)		
Tax-exempt municipal bonds	(0.02)	1.61
(S&P Municipal Bond Index)		
U.S. high yield bonds	0.16	2.62
(Bloomberg Barclays U.S. Corporate High Yield 2% Issuer		
Capped Index)		

Past performance is no guarantee of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.

THIS PAGE IS NOT PART OF YOUR FUND REPORT

Supplemental Information (unaudited)

### Section 19(a) Notices

BlackRock Energy and Resources Trust s (BGR), BlackRock Enhanced Capital and Income Fund, Inc. s (CII), BlackRock Enhanced Equity Dividend Trust s (BDJ), BlackRock Enhanced Global Dividend Trust s (BOE), BlackRock Enhanced International Dividend Trust s (BGY), BlackRock Health Sciences Trust s (BME), BlackRock Resources & Commodities Strategy Trust s (BCX), BlackRock Science and Technology Trust s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (each, a Trust and collectively, the Trusts), amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust s investment experience during the fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

### June 30, 2018

						Ġ	% Breal	kdown o	f th	e Tota	.1
		Total Cu	mulative Dist	tributions			(	Cumulat	ive		
		for	the Fiscal Per	riod		Dist	ribution	s for the	e Fis	scal Pe	eriod
	Net	Net Realized	Net Realized			Net	Net R	Realized			
					Total Per l	Net Red	alized				
	Investmen <b>C</b>	apital Gain <b>©</b>	apital Gains		Invest	apittal (	<b>Taips</b> ta	l Gains		Tot	al Per
				Return of	Common			$R\epsilon$	eturi	n ofCo	mmon
	Income	Short-Term	Long-Term	Capital	Sha <b>ta</b> c	Short-	Terbon	g-Term	Сар	ital	Share
BGR*	\$ 0.138969	\$	\$	\$ 0.326631	\$ 0.465600	30%		%	%	70%	100%
CII*	0.082050			0.414750	0.496800	17				83	100
BDJ	0.081478	0.008302	0.190420		0.280200	29	3	68			100
BOE	0.185780	0.097648		0.184572	0.468000	40	21			39	100
BGY*	0.113511		0.114489		0.228000	50		50			100
BME*	0.047943	0.009451	1.142607		1.200000	4	1	95			100
BCX*	0.108728			0.200872	0.309600	35				65	100
BST*			0.780000		0.780000	0		100			100
BUI	0.288398	0.047828	0.023475	0.366299	0.726000	40	7	3		50	100

<sup>\*</sup> Certain Trusts estimate that they have distributed more than the amount of earned income and net realized gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. When distributions exceed total return performance, the difference will reduce the Trust s net asset value per share.

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at http://www.blackrock.com.

#### Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (SEC) exemptive order and with the approval of each Trust's Board of Trustees/Directors (the Board), each have adopted a plan, consistent with its investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the Plan). In accordance with the Plans, the Trusts distribute the following fixed amounts per share on a monthly basis as of June 30, 2018:

	Amount Per	
Exchange Symbol	Common Share	
BGR	\$ 0.0776	
CII	0.0828	
BDJ	0.0467	
BOE	0.0780	
BGY	0.0380	
BME	0.2000	
BCX	0.0516	
BST	0.1300	
BUI	0.1210	

The fixed amounts distributed per share are subject to change at the discretion of each Trust s Board. Under its Plan, each Trust will distribute all available investment income to its shareholders, consistent with its primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the Code). If sufficient investment income is not available on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases or decreases to enable the Trusts to comply with the distribution requirements imposed by the Code.

Shareholders should not draw any conclusions about each Trust s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust s total return performance on net asset value is presented in its financial highlights table.

The Board may amend, suspend or terminate a Trust s Plan at any time without prior notice to the Trust s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BME s prospectus for a more complete description of its risks.

Supplemental Information

3

# Table of Contents

	Page
The Markets in Review	2
Section 19(a) Notices	3
Section 19(b) Disclosure	3
Semi-Annual Report:	
The Benefits and Risks of Option Over-Writing	5
Trust Summaries	6
Derivative Financial Instruments	24
Financial Statements:	
Schedules of Investments	25
Statements of Assets and Liabilities	91
Statements of Operations	93
Statements of Changes in Net Assets	95
Statements of Cash Flows	100
Financial Highlights	102
Notes to Financial Statements	111
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements	122
Trustee and Officer Information	127
Additional Information	128
Glossary of Terms Used in this Report	130

4

The Benefits and Risks of Option Over-Writing

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to enhance the Trusts distribution rate and total return performance. However, these objectives cannot be achieved in all market conditions.

The Trusts primarily write single stock covered call options, and may also from time to time write single stock put options. When writing (selling) a covered call option, the Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (strike price) within an agreed-upon time period. The Trusts receive cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trusts. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trusts realize gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by the Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Each Trust employs a plan to support a level distribution of income, capital gains and/or return of capital. The goal of the plan is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of the Trusts. Such distributions, under certain circumstances, may exceed a Trust s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust s total assets and net asset value per share (NAV) and, therefore, could have the effect of increasing the Trust s expense ratio and reducing the amount of assets, the Trust has available for long term investment. In order to make these distributions, a Trust may have to sell portfolio securities at less than opportune times.

The final tax characterization of distributions is determined after the fiscal year and is reported in the Trust s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. The Trust s taxable net investment income or net realized capital gains (taxable income) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital. Distributions that exceed a Trust s taxable income but do not exceed the Trust s current and accumulated earnings and profits, may be classified as ordinary income which are taxable to shareholders. Such distributions are reported as distributions in excess of net investment income.

A return of capital distribution does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. A return of capital is a return of a portion of an investor s original investment. A return

of capital is not taxable, but it reduces a shareholder s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital or as distributions in excess of net investment income for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at \$37.15 per share; (2) a three-month call option is written by a Trust with a strike price of \$40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives \$2.45, or 6.6% of the common stock s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to \$34.70 per share), the option strategy would break-even from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of \$40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above \$40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call options to varying degrees depending upon market conditions. Please refer to each Trust s Schedule of Investments and the Notes to Financial Statements for details of written options.

THE BENEFITS AND RISKS OF OPTION OVER-WRITING

Trust Information as of June 30, 2018

### **BlackRock Energy and Resources Trust**

### **Investment Objective**

BlackRock Energy and Resources Trust s (BGR) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on New York Stock Exchange ( NYSE )	BGR
Initial Offering Date	December 29, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$15.22) <sup>(a)</sup>	6.12%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0776
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9312

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
$BGR^{(a)(b)}$	10.89%	4.49%	
Lipper Natural Resources Funds <sup>(c)</sup>	(1.38)	(0.70)	

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

(c) Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s absolute performance based on NAV:

### What factors influenced performance?

Energy stocks experienced unusually high volatility in the first half of 2018. A strong advance in January gave way to a sharp sell-off in February, bringing the sector into negative territory for the year. After trading sideways for approximately two months, energy stocks staged a significant rally through April and early May. Although its performance cooled thereafter, energy nonetheless finished the second calendar quarter as the top performer among the stock market s eleven major sectors.

The Trust s position in the U.S. exploration and production (E&P) company ConocoPhillips made the largest positive contribution to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, boosting its stock price. The international E&P stock Anadarko Petroleum Corp. was also among the top contributors. Anadarko displayed capital discipline, and it reported robust growth stemming from higher production volume. The company further benefited from a more favorable backdrop in the liquified natural gas market. Other contributors of note include Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

On the negative side, the Trust s positions in E&Ps that emphasize natural gas generally lagged their more oil-focused peers. In this environment, Cabot Oil & Gas Corp. was a leading detractor from absolute performance. The energy distribution sub-sector also came under pressure as pipeline companies faced bottlenecks, leading to weakness in the Trust s position in TransCanada Corp. Other detractors of note include Cimarex Energy Co., Enbridge, Inc. and Halliburton Co.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

#### Describe recent portfolio activity.

The investment adviser shifted the Trust s positioning within the distribution subsector by initiating an investment in Williams Cos. and exiting its position in Enbridge, Inc. It also sold certain E&P stocks, including EOG Resources, Inc., Cimarex Energy Co., and Cabot Oil & Gas Corp., and initiated a new investment in the international E&P stock CNOOC Ltd.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

6

Trust Information as of June 30, 2018 (continued)

**BlackRock Energy and Resources Trust** 

### Describe portfolio positioning at period end.

The E&P sector represented the Trust s largest allocation, followed by the integrated, oil services, distribution, and refining & marketing industries, respectively. The investment adviser positioned the Trust with a higher-quality bias, focusing on companies with robust balance sheets and low costs of production.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 15.22	\$ 14.18	7.33%	\$ 15.63	\$12.85
Net Asset Value	15.97	15.79	1.14	16.54	14.24

Market Price and Net Asset Value History For the Past Five Years

### Overview of the Trust s Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
Royal Dutch Shell PLC ADR	10%
Exxon Mobil Corp.	9
BP PLC	7
Chevron Corp.	6
TOTAL SA	5
Suncor Energy, Inc.	5
ConocoPhillips	5
Valero Energy Corp.	4
EOG Resources, Inc.	4
Pioneer Natural Resources Co.	3

<sup>\*</sup> Excludes option positions and money market funds.

### INDUSTRY ALLOCATION

Industry	06/30/18	12/31/17
Oil, Gas & Consumable Fuels	92%	90%
Energy Equipment & Services	8	10

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information 7

Trust Information as of June 30, 2018

### BlackRock Enhanced Capital and Income Fund, Inc.

### **Investment Objective**

**BlackRock Enhanced Capital and Income Fund, Inc. s (CII) (the Trust**) investment objective is to provide investors with a combination of current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment policy by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	CII
Initial Offering Date	April 30, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$16.22) <sup>(a)</sup>	6.13%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0828
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9936

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Retu	Returns Based On		
	Market Price	Net Asset Value		
$CII^{(a)(b)}$	2.13%	1.76%		
S&P 500 <sup>®</sup> Index	N/A	2.65		

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

In the equity allocation of the Trust, the largest contributor to performance for the six-month period was stock selection in the health care sector. Specifically, selection decisions in the managed care industry provided strong relative returns. In financials, stock selection in capital markets and banks enhanced relative performance. Finally, an underweight allocation to as well as stock selection within industrials provided outperformance. In particular, selection among rail road operators contributed positively to return. At the stock level, the largest individual contributor was Urban Outfitters Inc., followed by a position in Humana Inc. and zero exposure to Johnson & Johnson.

In the equity allocation of the Trust, the largest detractor from relative performance for the six-month period was stock selection in the consumer discretionary sector. Most notably, positioning across homebuilders and underweight exposure to internet and direct marketing retail challenged relative performance. This was followed by positioning in information technology ( IT ) where electronic equipment and software holdings lagged. Finally, exposure to the tobacco industry hurt relative results in the consumer staples sector. Zero exposure to Amazon.com Inc. was the largest individual detractor, followed by a lack of exposure to Netflix Inc. and an overweight position to Altria Group Inc.

### Describe recent portfolio activity.

During the six-month period, the Trust significantly boosted exposure to the IT sector. Holdings within industrials and health care also were increased. Conversely, the Trust significantly reduced exposure to the financials sector. The Trust also reduced exposure to consumer discretionary and materials stocks. The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

#### Describe portfolio positioning at period end.

At period end, the Trust s largest allocations were in the IT, health care and financials sectors. Relative to the benchmark, the Trust s largest overweight positions were in the IT, health care, financials and consumer discretionary sectors. Conversely, the Trust s largest relative underweights were in the telecommunication services, real estate, and utilities sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

8

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced Capital and Income Fund, Inc.

### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 16.22	\$ 16.38	(0.98)%	\$ 17.07	\$ 14.75
Net Asset Value	16.96	17.19	(1.34)	18.04	16.21

### Market Price and Net Asset Value History For the Past Five Years

### Overview of the Trust s Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
Apple, Inc.	6%
Alphabet, Inc.	5
Microsoft Corp.	5
JPMorgan Chase & Co.	3
Bank of America Corp.	3
Pfizer, Inc.	3
Cisco Systems, Inc.	3
Lowe s Cos., Inc.	3
Comcast Corp.	2
United Health Group, Inc.	2

<sup>\*</sup> Excludes option positions and money market funds.

### SECTOR ALLOCATION

Sector	06/30/18 12	2/31/17
Information Technology	28%	26%
Health Care	18	16
Financials	14	17
Consumer Discretionary	12	14
Industrials	8	7
Consumer Staples	6	6
Energy	6	6
Materials	5	5

Utilities 3 3

For Trust compliance purposes, the Trust s sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Trust Information 9

Trust Information as of June 30, 2018

### **BlackRock Enhanced Equity Dividend Trust**

### **Investment Objective**

**BlackRock Enhanced Equity Dividend Trust** s (BDJ) (the Trust ) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

#### **Trust Information**

Symbol on NYSE	BDJ
Initial Offering Date	August 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.18)(a)	6.10%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0467
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.5604

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
$BDJ^{(a)(b)}$	2.59%	(0.38)%	
Russell 1000® Value Index	N/A	(1.69)	

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

The largest contribution to performance for the six-month period came from stock selection in the consumer staples sector. Notably, selection decisions within the beverages industry boosted relative return. In health care, stock selection within pharmaceuticals and health care equipment & services, and an overweight in health care providers & services enhanced relative performance. Lastly, stock selection within energy and utilities contributed, as did a combination of stock selection and an underweight in industrials.

The largest detractor from relative performance derived from stock selection in the financials sector. In particular, a combination of stock selection within and overweight exposure to the banking and insurance industries weighed on relative performance. Additionally, stock selection in the capital markets industry represented a headwind. Within the consumer discretionary sector, issue selection within the media industry had a negative impact. Finally, a lack of exposure to real estate acted as a constraint on returns.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio s holdings. Premiums generated are recognized as current gains that are intended to enhance distributions payable to shareholders in the form of dividends. The use of options detracted modestly from relative performance.

### Describe recent portfolio activity.

During the six-month period, the Trust increased exposure to the information technology sector. Holdings within health care and energy also were increased. Conversely, the Trust significantly lowered its exposure to industrials, and also reduced its positioning within financials and materials.

#### Describe portfolio positioning at period end.

The Trust s largest allocations were in the financials, health care and energy sectors. Relative to the benchmark, the Trust s largest overweight positions were in the health care, financials and energy sectors. Conversely, the Trust s largest relative underweights were in the real estate, consumer discretionary and materials sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Trust Information as of June 30, 2018 (continued)

### **BlackRock Enhanced Equity Dividend Trust**

### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 9.18	\$ 9.23	(0.54)%	\$ 9.64	\$8.03
Net Asset Value	9.62	9.96	(3.41)	10.42	9.33

### Market Price and Net Asset Value History For the Past Five Years

### Overview of the Trust s Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
JPMorgan Chase & Co.	4%
Bank of America Corp.	4
Pfizer, Inc.	4
Citigroup, Inc.	4
Wells Fargo & Co.	3
Oracle Corp.	3
Anthem, Inc.	3
Microsoft Corp.	3
Suncor Energy, Inc.	2
Verizon Communications, Inc.	2

<sup>\*</sup> Excludes option positions and money market funds.

### SECTOR ALLOCATION

Sector	06/30/18	12/31/17
Financials	28%	29%
Health Care	20	19
Energy	13	12
Information Technology	11	10
Industrials	7	8
Consumer Staples	7	7
Utilities	5	5
Consumer Discretionary	4	4

Telecommunication Services	3	3
Materials	2	3

For Trust compliance purposes, the Trust s sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Trust Information 11

Trust Information as of June 30, 2018

#### **BlackRock Enhanced Global Dividend Trust**

### **Investment Objective**

BlackRock Enhanced Global Dividend Trust s (BOE) (the Trust) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

#### **Trust Information**

Symbol on NYSE	BOE
Initial Offering Date	May 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$11.12) <sup>(a)</sup>	8.42%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0780
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9360

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The monthly distribution per Common Share, declared on July 2, 2018, was decreased to \$0.0630 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Return	Returns Based On		
	Market Price	Net Asset Value		
$BOE^{(a)(b)}$	(7.44)%	(6.19)%		
MSCI All Country World Index	N/A	(0.43)		

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

Security selection within and overweight exposure to consumer staples represented the largest detractors from performance. Stock selection within industrials also weighed on returns. Two tobacco companies, British American Tobacco PLC and Altria Group, Inc., were among the top individual detractors. Tobacco stocks suffered due to a market rotation out of defensive sectors, coupled with the FDA s announcement that it would be looking to limit nicotine levels in traditional cigarettes, along with questions about Next Generation smoking products. In addition, the German postal and international courier company Deutsche Post AG detracted after the company lowered its earnings forecast as it launched a series of measures aimed at stemming a decline in profitability at its post, e-commerce and parcel division.

During the six-month period, the Trust s significant underweight to financials contributed to relative return as the sector was one of the worst-performing segments of the index. An underweight to real estate also contributed to performance. The Trust s position in the technology conglomerate Cisco Systems, Inc. was the top individual contributor after the company reported earnings that exceeded expectations and also announced a share buyback. Additionally, the British pharmaceutical firm GlaxoSmithKline PLC was among the top contributors to returns after Novartis AG announced that they will be selling their stake in a consumer health care joint venture to GlaxoSmithKline. Holdings of Chinese sportswear company Anta Sports Products Ltd. also helped performance with positive sentiment driven by the company s continued strong retail sales.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy contributed to Trust performance.

### Describe recent portfolio activity.

12

The Trust s allocation to tobacco stocks was reduced in May, with the proceeds reinvested in high quality, dividend-paying names in which the investment adviser has high conviction. These included health care, consumer staples and industrials stocks.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Trust Information as of June 30, 2018 (continued)

#### **BlackRock Enhanced Global Dividend Trust**

### Describe portfolio positioning at period end.

At period end, the Trust s largest sector overweight positions were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweights were to information technology and financials. The Trust had no exposure to real estate, utilities or energy at the end of the period. From a regional perspective, a majority of portfolio assets was invested either within the United States or Europe, with significant exposure in the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 11.12	\$ 12.51	(11.11)%	\$ 13.08	\$10.96
Net Asset Value	11.91	13.22	(9.91)	13.71	11.78

Market Price and Net Asset Value History For the Past Five Years

#### Overview of the Trust s Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
Johnson & Johnson	4%
TELUS Corp.	4
Altria Group, Inc.	3
Sanofi	3
Novartis AG, Registered Shares	3
Coca-Cola Co.	3
Rogers Communications, Inc., Class B	3
Cisco Systems, Inc.	3
Nestle SA	3
Unilever PLC	3

<sup>\*</sup> Excludes option positions and money market funds.

#### GEOGRAPHIC ALLOCATION

Country	06/30/18	12/31/17
United States	43%	42%
United Kingdom	17	16
Australia	6	4
Switzerland	6	10
France	4	3
India	4	(a)
Singapore	3	
Taiwan	3	3
Netherlands	3	
Germany	3	2
Canada	3	6
Japan	2	2
Belgium	1	2
Denmark	1	
Finland	1	2
China	(a)	(a)
Sweden	(a)	(a)
Ireland	(a)	
Other <sup>(b)</sup>		5

 $<sup>^{(</sup>a)}$  Representing less than 1% of the Trust  $\,$  s total investments.

Trust Information 13

<sup>(</sup>b) Other includes a 1% holding or less in each of the following countries: Denmark, Hong Kong, India, Italy, Netherlands and Spain.

Trust Information as of June 30, 2018

#### **BlackRock Enhanced International Dividend Trust**

### **Investment Objective**

BlackRock Enhanced International Dividend Trust s (BGY) (the Trust) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

### **Trust Information**

Symbol on NYSE	BGY
Initial Offering Date	May 30, 2007
Current Distribution Rate on Closing Market Price as of as of June 30, 2018 (\$5.74)(a)	7.94%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0380
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.4560

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
$BGY^{(a)(b)}$	(8.61)%	(6.49)%	
MSCI All Country World Index ex-USA	N/A	(3.77)	

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

Security selection within and an overweight to consumer staples were the largest detractors from performance. Additionally, selection within industrials detracted, including positions in international courier companies Deutsche Post AG (Germany) and bpost SA (Belgium). The Trust s lack of holdings in energy stocks also subtracted from returns.

The leading contributor to relative performance during the period was the Trust s overweight to the health care sector. Additionally, an underweight to financials contributed to performance. Lastly, stock selection within consumer discretionary added to returns, in particular from holdings in the Chinese sportswear company Anta Sports Products Ltd. and the Macau-based resort firm Sands China Ltd.

During the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy contributed to relative return.

### Describe recent portfolio activity.

14

The Trust reduced its exposure to tobacco stocks over the period, while retaining an overweight in the industry. The Trust also increased exposure to financials by purchasing two Singapore bank stocks.

### Describe portfolio positioning at period end.

At period end, the Trust s largest sector overweights were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweight exposure was to financials, particularly banks. The Trust had no exposure to real estate, utilities or energy. In regional terms, the majority of portfolio assets was invested in European equities, with significant exposure to the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Trust Information as of June 30, 2018 (continued)

**BlackRock Enhanced International Dividend Trust** 

### Market Price and Net Asset Value Per Share Summary

	06/	/30/18	12/	31/17	Change	High	Low
Market Price	\$	5.74	\$	6.52	(11.96)%	\$ 6.85	\$ 5.64
Net Asset Value		6.36		7.06	(9.92)	7.32	6.27

Market Price and Net Asset Value History For the Past Five Years

### Overview of the Trust s Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
TELUS Corp.	6%
Sanofi	5
Novartis AG, Registered Shares	5
Rogers Communications, Inc., Class B	5
Nestle SA	5
Amcor	5
Imperial Brands PLC	5
Unilever PLC	5
British American Tobacco PLC	4
Deutsche Post AG, Registered Shares	4

<sup>\*</sup> Excludes option positions and money market funds.

### **GEOGRAPHIC ALLOCATION**

Country	06/30/18	12/31/17
United Kingdom	24%	19%
Switzerland	13	12
Canada	11	7
Australia	9	5
France	7	6
United States	5	6
Germany	4	3
Netherlands	4	6

Taiwan	4	3
Finland	4	2
Singapore	3	
China	2	5
Sweden	2	2
Belgium	2	3
India	2	2
Japan	2	5
Denmark	2	(a)
Hong Kong		2
South Korea		2
South Africa		2
Other		2 <sup>(b)</sup>

TRUST INFORMATION 15

 <sup>(</sup>a) Representing less than 1% of the Trust s total investments.
 (b) Other includes a 1% holding or less in each of the following countries: Ireland and Portugal.

Trust Information as of June 30, 2018

**BlackRock Health Sciences Trust** 

### **Investment Objective**

**BlackRock Health Sciences Trust** s (BME) (the Trust ) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	BME
Initial Offering Date	March 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$38.58)(a)	6.22%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.2000
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$2.4000

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Retu	Returns Based On		
	Market Price	Net Asset Value		
$BME^{(a)(b)}$	9.33%	5.90%		
Russell 3000® Healthcare Index	N/A	4.15		

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust s premium to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

#### What factors influenced performance?

The Trust added value through its effective individual stock selection. An out-of-benchmark position in Sarepta Therapeutics, Inc., a biotechnology company focused on orphan drugs, was among the largest contributors to relative performance. Sarepta presented preliminary data for its experimental treatment for patients with Duchenne muscular dystrophy, sparking a rally in its shares.

Merger-and-acquisition activity was also a key driver of the Trust s performance. Avexis, Inc., a clinical-stage gene therapy biotechnology company, announced that it would be acquired at a substantial premium by the Swiss pharmaceutical giant Novartis AG. Toward the end of the period, shares of Boston Scientific Corp. rallied on the rumor that the company had received a takeover bid from Stryker Corp.

Other contributors of note included overweight positions in the health care services companies Humana, Inc, and Teladoc, Inc. The Trust s overweight position in the biotechnology stock Alnylam Pharmaceuticals, Inc. was among the largest detractors from returns, as the company came under pressure after Pfizer, Inc. released positive data on a competing drug.

A zero weighting in Align Technology, Inc. was among the largest detractors from relative performance in the medical devices & supplies sub-sector. The stock rallied following an analyst event that dispelled concerns about rising competition and outlined a strong growth outlook.

Other detractors of note included overweight positions in Cigna Corp., Novo Nordisk A/S and Insmed, Inc.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. This strategy detracted from performance in the period.

### Describe recent portfolio activity.

The Trust increased its allocation to the medical devices & supplies subsector and slightly reduced its weightings in the healthcare providers & services area. Its allocation to biotechnology decreased, while its weighting in pharmaceuticals was largely unchanged.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

16

Trust Information as of June 30, 2018 (continued)

**BlackRock Health Sciences Trust** 

### Describe portfolio positioning at period end.

The Trust continued to employ a bottom-up, fundamental investment process in an effort to construct a balanced, diversified portfolio of health care stocks. The portfolio continues to reflect two broad themes: innovation and value-based health care.

Innovation in medical technology remains a secular growth driver for the health care sector as companies continue to develop new therapies or products that are either fulfilling an unmet medical need or are an improvement over current treatments. This encompasses not only the biotechnology industry, but also the pharmaceuticals and medical devices & supplies sub-sectors.

With respect to value-based health care, the Trust has an above-benchmark weighting in the health care providers & services sub-sector largely due to its sizeable overweight in the managed care industry. The investment adviser continues to find a number of companies in this area that it believes are well positioned to leverage their scale and analytical capabilities to reduce health care costs. Additionally, select holdings in the health care services industry feature business models that are benefiting from the shift to lower-cost options such as home health care.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 38.58	\$ 36.50	5.70%	\$ 39.83	\$ 32.89
Net Asset Value	36.54	35.69	2.38	38.56	34.33

Market Price and Net Asset Value History For the Past Five Years

#### Overview of the Trust s Total Investments

#### TEN LARGEST HOLDINGS

Security	06/30/18
UnitedHealth Group, Inc.	9%
Pfizer, Inc.	5
Medtronic PLC	4

Abbott Laboratories	4
Stryker Corp.	3
Boston Scientific Corp.	4
Quest Diagnostics, Inc.	3
Anthem, Inc.	3
Humana, Inc.	2
Baxter International, Inc.	2

<sup>\*</sup> Excludes option positions and money market funds.

### INDUSTRY ALLOCATION

Industry	06/30/18	12/31/17
Health Care Equipment & Supplies	28%	23%
Health Care Providers & Services	25	25
Biotechnology	20	25
Pharmaceuticals	22	24
Life Sciences Tools & Services	3	2
Diversified Consumer Services	1	1
Health Care Technology	1	

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information 17

Trust Information as of June 30, 2018

### BlackRock Resources & Commodities Strategy Trust

### **Investment Objective**

BlackRock Resources & Commodities Strategy Trust s (BCX) (the Trust) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option overwriting strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objectives will be achieved.

#### **Trust Information**

Symbol on NYSE	BCX
Initial Offering Date	March 30, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.29)(a)	6.67%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0516
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.6192

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	Market Price	Net Asset Value
$BCX^{(a)(b)}$	(1.71)%	0.07%
Lipper Natural Resources Funds <sup>(c)</sup>	(1.38)	(0.70)

<sup>(</sup>a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

(c)

<sup>(</sup>b) The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

Average return. Returns reflect investment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s absolute performance based on NAV:

### What factors influenced performance?

The Trust s allocation to energy stocks made a positive contribution to its six-month results. Oil prices rallied behind the combination of tighter supplies and higher-than-expected demand, leading to strong returns for the energy sector. In this environment, the U.S. exploration and production company ConocoPhillips was among the largest contributors to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, which boosted its stock price. Other contributors of note within energy included Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

The mining stock Nevsun Resources Ltd., which was bid for by a competitor in May, was also a large contributor to returns.

After performing strongly in 2017, the battery materials industry came under pressure in early 2018 as lithium prices retreated. The downturn stemmed from supply concerns that arose after the lithium miner Sociedad Química y Minera de Chile SA reached an agreement with the Chilean government that would allow it to significantly increase production. The Trust s position in Neo Lithium Corp. detracted from performance as a result. The investment adviser retained the position on the belief that the long-term demand for lithium from electric vehicle sales is likely to outweigh the available supply.

The Brazil-based food producer BRF SA also detracted. The Brazilian Federal Police announced it was investigating the company for manipulating food/meat sample tests that are required to meet export regulatory standards. The company s former chief executive officer was arrested, along with ten other employees. This news introduced significant risk into the BRF investment case, prompting the Trust to sell the position. Other detractors of note included Glencore PLC, Nutrien Ltd. and Arcelormittal.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

#### Describe recent portfolio activity.

The Trust exited three of its positions in the agriculture industry, including Monsanto Co. The investment adviser believed the stock had limited upside since its price was close to the level at which the company was bid for by Bayer AG. The Trust also sold BRF and AGCO Corp., and initiated a position in the agricultural supply-chain company Archer Daniels Midland Co. on the expectation that the company s restructuring effort will lead to higher earnings growth.

Trust Information as of June 30, 2018 (continued)

BlackRock Resources & Commodities Strategy Trust

The investment adviser rotated some of the portfolio s positions in the mining industry based on relative valuations. In addition, the Trust s allocation to the industry was increased through additions to BHP Billiton Ltd. and Glencore.

#### Describe portfolio positioning at period end.

The mining industry represented the largest allocation following the Trust s purchases in this area. Energy and agriculture were the second- and third-largest weightings, respectively.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 9.29	\$ 9.77	(4.91)%	\$ 10.49	\$8.69
Net Asset Value	10.30	10.64	(3.20)	11.05	9.68
BE I OB . INT A A STATE TO A	D 4 E9 E7				

### Market Price and Net Asset Value History For Past Five Years

#### Overview of the Trust s Total Investments

#### TEN LARGEST HOLDINGS

Security	06/30/18
Nutrien LTD	6%
Royal Dutch Shell PLC ADR	6
Glencore PLC	5
BP PLC ADR	5
BHP Billiton PLC	5
TOTAL SA	5
Rio Tinto PLC ADR	4
Suncor Energy, Inc.	4
Vale SA ADR	4
Archer-Daniels-Midland Co.	3

<sup>\*</sup> Excludes option positions and money market funds.

Industry	06/30/18	12/31/17
Metals & Mining	36%	34%
Oil, Gas & Consumable Fuels	34	34
Chemicals	12	13
Food Products	8	11
Containers & Packaging	5	3
Energy Equipment & Services	2	3
Paper & Forest Products	1	1
Machinery	1	1
Electronic Equipment, Instruments & Components	1	

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information 19

Trust Information as of June 30, 2018

#### **BlackRock Science and Technology Trust**

#### **Investment Objective**

BlackRock Science and Technology Trust s (BST) (the Trust) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of science and technology companies. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	BST
Initial Offering Date	October 30, 2014
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$33.65) <sup>(a)</sup>	4.64%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.1300
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$1.5600

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The monthly distribution per Common Share, declared on July 2, 2018, was increased to \$0.1500 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
$BST^{(a)(b)}$	29.37%	15.46%	
MSCI World Information Technology Index	N/A	9.44	

<sup>(</sup>a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

N/A Not applicable as the index does not have a market price.

<sup>(</sup>b) The Trust moved from a discount to NAV to a premium to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

Global markets were flat during the period, as the MSCI World Index returned 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risk.

The Trust s non-benchmark position in Amazon.com, Inc. was the largest contributor to relative performance, as strong e-commerce sales helped Amazon surpass first quarter earnings expectations, boosting the company s share price. Holdings in Netflix, Inc. represented the second largest contributor, as the company beat expectations for growth in subscribers. A non-benchmark position in the mobile payment company Square Inc. was also additive. Square has benefited from an improving macroeconomic backdrop as well as significant growth in mobile payment utilization rates.

The largest detractors from relative performance were the Trust s underweight positions in Facebook, Inc. and Apple, Inc. Facebook shares rallied after strong earnings helped ease fears surrounding the possible impact of user privacy concerns on Facebook s business model. Elsewhere, a non-benchmark position in Linx, a Brazilian management software company, was among the largest detractors from performance as recent political unrest in Brazil weighed on the company s share price.

Also, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy detracted from returns.

#### Describe recent portfolio activity.

During the six-month period, the Trust took profits on a position in a semiconductor company that had performed particularly well. Proceeds from the sale were rotated into a value opportunity within the internet software & services sub-industry.

#### Describe portfolio positioning at period end.

At period end, the Trust held its largest allocation within the software & services industry group, with a focus on idiosyncratic opportunities within the internet software & services and application software sub-industries. Regionally, the Trust maintained most of its exposure in North America, with smaller allocations to the emerging markets and Europe.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

**BlackRock Science and Technology Trust** 

# Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 33.65	\$ 26.69	26.08%	\$35.71	\$ 26.00
Net Asset Value	31.20	27.73	12.51	32.73	27.48

**Market Price and Net Asset Value History Since Inception** 

# Overview of the Trust's Total Investments

### TEN LARGEST HOLDINGS

Security	06/30/18
Amazon.com, Inc.	6%
Microsoft Corp.	5
Tencent Holdings Ltd.	5
Alphabet Inc.	5
Apple, Inc.	4
Alibaba Group Holding LTD. ADR.	3
Mastercard, Inc.	3
Square, Inc.	2
Visa, Inc.	2
salesforce.com, Inc.	2

<sup>\*</sup> Excludes option positions and money market funds.

### INDUSTRY ALLOCATION

Industry	06/30/18	12/31/17
Software	30%	22%
Internet Software & Services	28	28
Semiconductors & Semiconductor Equipment	13	18
IT Services	12	10
Internet & Direct Marketing Retail	8	6

<sup>(</sup>a) Commencement of operations.

Technology Hardware, Storage & Peripherals	4	7
Electronic Equipment, Instruments & Components	1	2
Media	1	1
Other	3(a)	6 <sup>(a)</sup>

(a) Other includes a 1% holding or less in each of the following industries: Automobiles, Chemicals, Consumer Finance, Household Durables, Health Care Technology, Professional Services and Diversified Consumer Services.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information 21

Trust Information as of June 30, 2018

BlackRock Utilities, Infrastructure & Power Opportunities Trust

### **Investment Objective**

BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by utilizing an option writing (selling) strategy in an effort to seek total return performance and enhance distributions. The Trust considers the Utilities business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the Infrastructure business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the Power Opportunities business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	BUI
Initial Offering Date	November 25, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$20.01)(a)	7.26%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.1210
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$1.4520

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### **Performance and Portfolio Management Commentary**

Returns for the six-months ended June 30, 2018:

Returns Based On

Market Price Net Asset Value
(4.06)% (0.56)%

Lipper Utility Funds $^{(c)}$  (2.54)

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust moved from a premium to NAV to a discount to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- (c) Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

#### The following discussion relates to the Trust s absolute performance based on NAV:

### What factors influenced performance?

Markets were essentially flat during the period, as the MSCI World Index returning 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risks.

A position in Spanish renewable energy company EDP Renovaveis was the largest contributor to the Trust s performance during the six-month period. The company s shares rose on speculation that one or more companies were looking to acquire all or part of the business. Another renewable energy holding, China Longyuan, was among the leading contributors for the period. China is introducing a national emissions trading scheme for carbon dioxide that will incentivize the move to cleaner technologies, boosting the company s shares in the period. Other contributors of note included clean energy company NextEra Energy Inc., Macquarie Infrastructure Corp. and electric utility FirstEnergy Corp.

Exposure to multinational automotive supplier Valeo was the largest detractor from the Trust s absolute performance during the period. Despite a stronger-than-expected order book, the company reported lower year-on-year profits for 2017, especially in the autonomous driving and electric vehicle segments, while lowering forward guidance for organic growth. The Trust has maintained the position on a positive view of both the company and the broader vehicle electrification theme, particularly given the regulatory support emerging from many countries. Elsewhere within the automotive space, temporary disruption related to the move to real world driving testing standards negatively impacted our positions in component manufacturers Continental AG and Osram Licht AG. Other detractors of note included European energy company Enel SpA and Denmark-based wind energy manufacturer Vestas Wind Systems A/S.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy had a negative impact on results.

22

Trust Information as of June 30, 2018 (continued) BlackRock Utilities, Infrastructure & Power Opportunities Trust

#### Describe recent portfolio activity.

During the period, the Trust reduced exposure to midstream energy companies, exiting Shell Midstream Partners and Plains All American Pipeline in the process. Capital was rotated into the electric vehicle exposed companies, such as semiconductor manufacturer Infineon Technologies AG and Continental AG.

#### Describe portfolio positioning at period end.

At period end, the utilities sector accounted for approximately 63.5% of the Trust s assets, with holdings concentrated in U.S. electric and multi-utilities. Approximately 16% of the portfolio was invested in the industrials sector, with roughly another 12% in the energy sector. The remainder was invested in other infrastructure- and power-related sectors.

Against a backdrop of historically low interest rates, the demand for equity yield has led to valuations for U.S. utilities that are high relative to their historical levels, placing even greater importance on stock selection. As such, the Trust was focused on owning companies with strong management teams that offer the potential for above-sector growth in earnings and dividends. The Trust had a preference for regulated utilities over their non-regulated counterparts given their existing barriers to entry, strong balance sheets, and lower sensitivity to commodity prices.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 20.01	\$ 21.62	(7.45)%	\$21.73	\$ 19.09
Net Asset Value	20.26	21.12	(4.07)	21.27	19.69

Market Price and Net Asset Value History For the Past Five Years

#### Overview of the Trust s Total Investments

#### TEN LARGEST HOLDINGS

Security	06/30/18
NextEra Energy, Inc.	11%
Enel SpA	5
EDP Renovaveis SA	5

National Grid PLC	4
Public Service Enterprise Group	4
Duke Energy Corp.	4
Dominion Energy, Inc.	3
Atlantia SpA	3
Exelon Corp.	3
TransCanada Corp.	3

<sup>\*</sup> Excludes option positions and money market funds.

#### INDUSTRY ALLOCATION

Industry	06/30/18	12/31/17
Electric Utilities	36%	33%
Multi-Utilities	20	20
Oil, Gas & Consumable Fuels	12	12
Transportation Infrastructure	11	15
Independent Power and Renewable Electricity Producers	8	8
Electrical Equipment	4	3
Chemicals	4	3
Water Utilities	1	1
Construction & Engineering		3
Gas Utilities		1
Auto Components	2	
Other	2 <sup>(a)</sup>	1 <sup>(a)</sup>

<sup>(</sup>a) Other includes a 1% holding or less in each of the following industries: Building Products and Semiconductors & Semiconductor Equipment.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information 23

#### **Derivative Financial Instruments**

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. The Trusts successful use of a derivative financial instrument depends on the investment adviser s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

24

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Schedule of Investments (unaudited)	BlackRock Energy and Resources Trust (BGR)				
June 30, 2018	(Percentages shown are based	on Net Assets)			
Security	Shares	Value			
Common Stocks 99.8%	Shares	v anne			
Energy Equipment & Services 7.6%					
Baker Hughes a GE Co. <sup>(a)</sup>	•	\$ 8,445,771			
Halliburton Co. <sup>(a)</sup>	306,900	13,828,914			
Patterson-UTI Energy, Inc. <sup>(a)</sup>	192,557	3,466,026			
Schlumberger Ltd. <sup>(a)</sup>	156,674	10,501,858			
		36,242,569			
Oil, Gas & Consumable Fuels 92.2%					
Anadarko Petroleum Corp. (a)	165,033	12,088,667			
Andeavor <sup>(a)</sup>	103,050	13,518,099			
BP PLC	4,427,650	33,687,851			
Cairn Energy PLC <sup>(b)</sup>	1,747,695	5,738,664			
Canadian Natural Resources Ltd.	418,540	15,106,472			
Chevron Corp. (a)(c)	242,585 65,550	30,670,022			
Cimarex Energy Co. <sup>(a)</sup> CNOOC Ltd.	4,423,000	6,669,057 7,579,007			
Concho Resources, Inc. (a)(b)	26,750	3,700,862			
ConocoPhillips <sup>(a)</sup>	314,800	21,916,376			
Devon Energy Corp.(a)	339,050	14,904,638			
Encana Corp.	849,530	11,095,295			
EOG Resources, Inc.(a)	142,700	17,756,161			
EQT Corp.	180,450	9,957,231			
Exxon Mobil Corp.(a)(c)	487,002	40,289,675			
Galp Energia SGPS SA	14,335	273,455			
Kosmos Energy Ltd.(b)	720,108	5,955,293			
Marathon Oil Corp. (a)	191,748	3,999,863			
Noble Energy, Inc. <sup>(a)</sup>	303,842	10,719,546			
Oil Search Ltd.	911,863	5,990,891			
Pioneer Natural Resources Co.(a)	82,876	15,683,454			
Royal Dutch Shell PLC ADR, Class (A)	713,800	49,416,374			
Royal Dutch Shell PLC, Class A	273,248	9,456,815			
Suncor Energy, Inc.	548,400	22,317,271			
Security Oil Cos & Consumable Evels (continued)	Shares	Value			
Oil, Gas & Consumable Fuels (continued) TOTAL SA	425,553 \$	25,842,019			
TransCanada Corp.	306,250	13,250,295			
Valero Energy Corp. (a)	168,800	18,708,104			
Williams Cos., Inc. <sup>(a)</sup>	482,900	13,091,419			
Williams Cos., Inc.	702,700	10,071,717			
		439,382,876			

475,625,445

# Total Long-Term Investments 99.8% (Cost \$404,613,943)

Short-Term Securities 1.0% BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(d)(e)</sup>	4,599,459	4,599,459
Total Short-Term Securities 1.0% (Cost \$4,599,459)		4,599,459
Total Investments Before Options Written 100.8% (Cost \$409,213,402)		480,224,904
Options Written (0.7)% (Premiums Received \$3,574,813)		(3,538,539)
Total Investments, Net of Options Written 100.1% (Cost \$405,638,589) Liabilities in Excess of Other Assets (0.1)%		476,686,365 (381,317)
Net Assets 100.0%	\$	6 476,305,048

<sup>(</sup>e) During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change
							in
	Shares		Shares				NeUnrealized
	Held at	Net	Held at	Value at		Reali	<b>App</b> preciation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inc <b>Gunie</b> n	(Loss	<b>D</b> &preciation)
BlackRock Liquidity Funds,							
T-Fund, Institutional Class	3,870,844	728,615	4,599,459	\$4,599,459	\$ 28,875	\$	\$

<sup>(</sup>a) Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

<sup>(</sup>a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(</sup>b) Non-income producing security.

<sup>(</sup>c) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

<sup>(</sup>d) Annualized 7-day yield as of period end.

# **Derivative Financial Instruments Outstanding as of Period End**

# **Exchange-Traded Options Written**

	Number of	Expiration	i	Exercise	N	otional	
Description	Contracts	Date		Price	Amour	it (000)	Value
Call							
Chevron Corp.	154	07/06/18	USD	128.00	USD	1,947	\$ (9,086)
ConocoPhillips	164	07/06/18	USD	70.00	USD	1,142	(11,890)
Devon Energy Corp.	114	07/06/18	USD	43.50	USD	501	(11,856)
Devon Energy Corp.	130	07/06/18	USD	41.00	USD	571	(39,975)
EOG Resources, Inc.	89	07/06/18	USD	119.00	USD	1,107	(53,400)
Halliburton Co.	290	07/06/18	USD	51.50	USD	1,307	(870)
Williams Cos., Inc.	460	07/06/18	USD	27.50	USD	1,247	(5,750)
Anadarko Petroleum Corp.	70	07/13/18	USD	72.00	USD	513	(16,450)

SCHEDULES OF INVESTMENTS 25

**BlackRock Energy and Resources Trust (BGR)** 

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Ex	ercise	N	otional	
Description	Contracts	Date		Price	Amoun	at (000)	Value
Call (continued)							
Chevron Corp.	154	07/13/18	USD 1	129.00	USD	1,947	\$ (13,013)
ConocoPhillips	202	07/13/18	USD	70.00	USD	1,406	(24,139)
EOG Resources, Inc.	38	07/13/18	USD 1	120.00	USD	473	(20,900)
Exxon Mobil Corp.	356	07/13/18	USD	83.00	USD	2,945	(36,312)
Pioneer Natural Resources Co.	111	07/13/18	USD 1	197.50	USD	2,101	(15,817)
Royal Dutch Shell PLC ADR,							
Class A	205	07/13/18	USD	71.00	USD	1,419	(7,175)
Valero Energy Corp.	60	07/13/18	USD 1	116.00	USD	665	(4,080)
Williams Cos., Inc.	576	07/13/18	USD	27.00	USD	1,562	(29,088)
Anadarko Petroleum Corp.	259	07/20/18	USD	72.50	USD	1,897	(63,196)
Andeavor	104	07/20/18	USD 1	145.00	USD	1,364	(4,160)
Baker Hughes a GE Co.	287	07/20/18	USD	39.00	USD	948	(2,870)
Baker Hughes a GE Co.	233	07/20/18	USD	36.00	USD	770	(5,825)
Canadian Natural Resources Ltd.	165	07/20/18	CAD	48.00	CAD	783	(10,605)
Chevron Corp.	353	07/20/18	USD 1	130.00	USD	4,463	(33,712)
Cimarex Energy Co.	74	07/20/18	USD	90.00	USD	753	(92,130)
Concho Resources, Inc.	38	07/20/18	USD 1	152.75	USD	526	(2,011)
ConocoPhillips	227	07/20/18	USD	72.50	USD	1,580	(13,393)
ConocoPhillips	164	07/20/18	USD	70.50	USD	1,142	(20,582)
Devon Energy Corp.	152	07/20/18	USD	38.00	USD	668	(93,860)
Devon Energy Corp.	70	07/20/18	USD	44.00	USD	308	(10,465)
Devon Energy Corp.	92	07/20/18	USD	46.00	USD	404	(6,348)
EOG Resources, Inc.	116	07/20/18	USD 1	125.00	USD	1,443	(33,756)
Encana Corp.	1,255	07/20/18	CAD	17.00	CAD	2,155	(69,210)
Noble Energy, Inc.	492	07/20/18	USD	37.50	USD	1,736	(17,220)
Royal Dutch Shell PLC ADR,							
Class A	289	07/20/18	USD	70.00	USD	2,001	(26,733)
Royal Dutch Shell PLC ADR,							
Class A	405	07/20/18	USD	75.00	USD	2,804	(3,037)
Schlumberger Ltd.	326	07/20/18	USD	73.45	USD	2,185	(3,376)
Suncor Energy, Inc.	982	07/20/18	CAD	54.00	CAD	5,254	(61,625)
Andeavor	131	07/27/18	USD 1	152.50	USD	1,718	(2,882)
Chevron Corp.	65	07/27/18	USD 1	130.00	USD	822	(9,782)
ConocoPhillips	108	07/27/18	USD	69.00	USD	752	(25,326)
Devon Energy Corp.	1	07/27/18	USD	44.00	USD	4	(175)
Devon Energy Corp.	92	07/27/18		45.50	USD	404	(9,982)
Devon Energy Corp.	141	07/27/18	USD	45.00	USD	620	(18,118)
EOG Resources, Inc.	91	07/27/18		119.00	USD	1,132	(65,748)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

F M 1 1 C	410	07/07/10	Hab	05.00	LICD	2 202	(22,000)
Exxon Mobil Corp.	410	07/27/18	USD	85.00	USD	3,392	(32,800)
Halliburton Co.	392	07/27/18	USD	49.50	USD	1,766	(11,172)
Pioneer Natural Resources Co.	52	07/27/18	USD	202.50	USD	984	(9,880)
Royal Dutch Shell PLC ADR,							
Class A	296	07/27/18	USD	71.00	USD	2,049	(23,680)
Royal Dutch Shell PLC ADR,							
Class A	405	07/27/18	USD	69.50	USD	2,804	(57,713)
Williams Cos., Inc.	139	07/27/18	USD	28.50	USD	377	(2,363)
Williams Cos., Inc.	257	07/27/18	USD	28.00	USD	697	(7,453)
Concho Resources, Inc.	55	07/30/18	USD	128.25	USD	761	(67,595)
Chevron Corp.	58	08/03/18	USD	130.00	USD	733	(10,498)
Devon Energy Corp.	71	08/03/18	USD	43.50	USD	312	(17,821)
Exxon Mobil Corp.	471	08/03/18	USD	83.00	USD	3,897	(92,081)
Pioneer Natural Resources Co.	31	08/03/18	USD	190.00	USD	587	(21,855)
Pioneer Natural Resources Co.	64	08/03/18	USD	200.00	USD	1,211	(20,320)
Valero Energy Corp.	197	08/03/18	USD	116.00	USD	2,183	(41,567)
Chevron Corp.	65	08/10/18	USD	128.00	USD	822	(19,370)
Devon Energy Corp.	141	08/10/18	USD	46.00	USD	620	(21,925)
EOG Resources, Inc.	165	08/10/18	USD	129.00	USD	2,053	(48,180)
Valero Energy Corp.	128	08/10/18	USD	115.00	USD	1,419	(32,832)
Anadarko Petroleum Corp.	248	08/17/18	USD	72.50	USD	1,817	(97,340)
Andeavor	90	08/17/18	USD	140.00	USD	1,181	(15,390)
Canadian Natural Resources Ltd.	670	08/17/18	CAD	44.00	CAD	3,179	(214,049)
Cimarex Energy Co.	167	08/17/18	USD	100.00	USD	1,699	(105,210)
ConocoPhillips	236	08/17/18	USD	70.00	USD	1,643	(60,298)
Devon Energy Corp.	90	08/17/18	USD	42.00	USD	396	(33,525)
Devon Energy Corp.	92	08/17/18	USD	46.00	USD	404	(15,778)
Encana Corp.	2,268	08/17/18	CAD	17.00	CAD	3,894	(187,181)
Exxon Mobil Corp.	467	08/17/18	USD	82.50	USD	3,863	(113,481)
Zanon Moon Corp.	107	50/1//10	COD	02.50		5,005	(113,101)

26

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

**BlackRock Energy and Resources Trust (BGR)** 

June 30, 2018

# **Exchange-Traded Options Written (continued)**

Description	Number of Contracts	Expiration Date			Notional ınt (000)	Value
Call (continued)					( )	
Halliburton Co.	392	08/17/18	USD 5	0.00 USD	1,766	\$ (20,580)
Patterson-UTI Energy, Inc.	210	08/17/18	USD 1	9.00 USD	378	(15,750)
Pioneer Natural Resources Co.	32	08/17/18	USD 18	5.00 USD	606	(38,240)
Royal Dutch Shell PLC ADR,	,					
Class A	206	08/17/18	USD 7	2.50 USD	1,426	(14,420)
Schlumberger Ltd.	187	08/17/18	USD 6	7.50 USD	1,253	(42,169)
Suncor Energy, Inc.	937	08/17/18	CAD 5	54.00 CAE	5,013	(103,347)
TransCanada Corp.	1,071	08/17/18	CAD 5	8.00 CAL	6,092	(68,839)
Valero Energy Corp.	205	08/17/18	USD 11	5.00 USD	2,272	(59,245)
Williams Cos., Inc.	258	08/17/18	USD 2	28.00 USD	699	(13,674)

\$ (2,763,549)

# **OTC Options Written**

Description Call	Counterparty	Number of Contracts	Expiration Date	E	xercise Price	No.	otional t (000)	Value
Noble								
Energy, Inc.	Bank of America N.A.	59,000	07/09/18	USD	35.40	USD	2,082	\$ (42,265)
BP PLC	Goldman Sachs International	311,600	07/10/18	GBP	5.83	GBP	1,798	(23,239)
Oil Search								
Ltd.	Morgan Stanley & Co. International PLC	157,000	07/10/18	AUD	8.81	AUD	1,394	(21,568)
Patterson-UTI								
Energy, Inc.	UBS AG	35,300	07/10/18	USD	23.63	USD	635	
TOTAL SA	Credit Suisse International	10,700	07/11/18	EUR	53.41	EUR	556	(2,456)
TOTAL SA	UBS AG	18,600	07/11/18	EUR	54.88	EUR	967	(524)
Canadian								
Natural								
Resources								
Ltd.	Credit Suisse International	67,900	07/16/18	CAD	46.25	CAD	3,222	(91,397)
BP PLC	Barclays Bank PLC	262,800	07/18/18	GBP	5.85	GBP	1,516	(25,083)
CNOOC Ltd.	Goldman Sachs International	207,000	07/18/18	HKD	14.07	HKD	2,782	(3,447)
TOTAL SA	Goldman Sachs International	26,500	07/25/18	EUR	53.15	EUR	1,378	(13,724)
BP PLC	Citibank N.A.	230,000	07/26/18	GBP	5.96	GBP	1,327	(15,927)
CNOOC Ltd.	JPMorgan Chase Bank N.A.	261,000	07/26/18	HKD	14.07	HKD	3,508	(6,498)

Royal Dutch								
Shell PLC,								
Class A	Goldman Sachs International	95,700	07/26/18	GBP	25.93	GBP	2,509	(94,603)
TOTAL SA	Citibank N.A.	47,000	07/26/18	EUR	53.63	EUR	2,444	(19,103)
BP PLC	Barclays Bank PLC	213,300	07/27/18	GBP	5.86	GBP	1,231	(26,684)
BP PLC	Citibank N.A.	221,000	07/27/18	GBP	5.70	GBP	1,275	(50,760)
CNOOC Ltd.	Societe Generale	300,000	08/01/18	HKD	12.78	HKD	4,032	(32,136)
TOTAL SA	UBS AG	30,000	08/01/18	EUR	53.87	EUR	1,560	(16,207)
Patterson-UTI								
Energy, Inc.	UBS AG	11,000	08/06/18	USD	20.20	USD	198	(3,321)
Royal Dutch								
Shell PLC								
ADR,								
Class A	Citibank N.A.	34,600	08/06/18	USD	70.97	USD	2,395	(39,852)
Oil Search								
Ltd.	Citibank N.A.	190,000	08/07/18	AUD	8.35	AUD	1,687	(86,874)
BP PLC	Goldman Sachs International	311,000	08/08/18	GBP	5.85	GBP	1,794	(55,006)
TOTAL SA	Goldman Sachs International	16,100	08/08/18	EUR	52.17	EUR	837	(21,605)
Baker Hughes								
a GE Co.	Citibank N.A.	31,300	08/13/18	USD	33.93	USD	1,034	(39,343)
Royal Dutch								
Shell PLC								
ADR,								
Class A	Citibank N.A.	34,600	08/20/18	USD	70.97	USD	2,395	(43,368)
								+ ( <b></b> + 0 0 0)

# Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premiums	Premiums	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 966,746	\$ (930,472)	\$ (3,538,539)
D · · · D· · · · · · · · · · · ·	4 • 11	D' L E			

# **Derivative Financial Instruments Categorized by Risk Exposure**

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity	Credit		Foreign Currency Exchange	y Interest	Other	
Liabilities Derivative Financial Instruments Options written	Contracts (	Contracts	Contracts C	ontract.	s Contracts (	Contracts	Total
Options written at value	\$	\$	\$3,538,539	\$	\$	\$	\$3,538,539

\$ (774,990)

Schedules of Investments 27

**BlackRock Energy and Resources Trust (BGR)** 

June 30, 2018

For the six months ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

				Foreign Currency	Interest		
	Commodity Contract <b>.</b> C			xchange	Rate	Other ontracts	Total
Net Realized Gain (Loss) from:							
Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (841) (14,337,904)		\$	\$	\$ (841) (14,337,904)
	\$	\$	\$ (14,338,745)	\$	\$	\$	\$ (14,338,745)
(a)Options purchased are inc	luded in net re	alized gai	n (loss) from inv	estments			
Net Change in Unrealized Appreciation (Depreciation	n)						
on: Options written	\$	\$	\$ 4,386,198	\$	\$	\$	\$ 4,386,198

### **Average Quarterly Balances of Outstanding Derivative Financial Instruments**

nti	

Average value of option contracts purchased	\$	(a)
Average value of option contracts written	\$3,136	,477

<sup>(</sup>a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Assets Liabilities

#### **Derivative Financial Instruments:**

Options	\$	\$ 3,538,539
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(2,763,549)
Total derivative assets and liabilities subject to an MNA	\$	\$ 774,990

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collater received (and pledged) by the Trust:

Counterparty	1 S an	Derivative Liabilities Subject to MNA by nterparty	Derivatives Available for Offset	Non-cash Collateral Pledged <sup>(a)</sup>	Cash Collateral Pledged	of L	et Amount Derivative iabilities
Bank of America N.A.	\$	42,265	\$	\$	\$	\$	42,265
Barclays Bank PLC	,	51,767	*	(51,767)	*	_	,
Citibank N.A.		295,227		(295,227)			
Credit Suisse International		93,853		(93,240)			613
Goldman Sachs International		211,624		(211,624)			
JPMorgan Chase Bank N.A.		6,498					6,498
Morgan Stanley & Co. International							
PLC		21,568					21,568
Societe Generale		32,136					32,136
UBS AG		20,052		(20,052)			
	\$	774,990	\$	\$ (671,910)	\$	\$	103,080

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

28

<sup>(</sup>a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(</sup>b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

**BlackRock Energy and Resources Trust (BGR)** 

June 30, 2018

### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Energy Equipment & Services	\$ 36,242,569	\$	\$	\$ 36,242,569
Oil, Gas & Consumable Fuels	350,814,174	88,568,702		439,382,876
Short-Term Securities	4,599,459			4,599,459
	\$ 391,656,202	\$88,568,702	\$	\$480,224,904
Derivative Financial Instruments <sup>(a)</sup> Liabilities:				
Equity contracts	\$ (2,690,567)	\$ (847,972)	\$	\$ (3,538,539)

<sup>(</sup>a) Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

SCHEDULES OF INVESTMENTS 29

Schedule of Investments (unaudited)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)				
June 30, 2018	(Percentages shown are based	on Net Assets)			
Security Common Stocks 100.3%	Shares	Value			
Airlines 1.4% Delta Air Lines, Inc.	204,085	\$ 10,110,371			
Banks 10.4% Bank of America Corp. (a)(b) JPMorgan Chase & Co.(b) Regions Financial Corp. SunTrust Banks, Inc. U.S. Bancorp	710,271 239,356 327,605 205,255 263,202	20,022,540 24,940,895 5,824,817 13,550,935 13,165,364			
<b>Biotechnology</b> 3.5% Biogen, Inc. <sup>(c)</sup> Gilead Sciences, Inc.	55,904 138,969	77,504,551 16,225,577 9,844,564			
Capital Markets 1.2% E*Trade Financial Corp.(c)	150,986	26,070,141 9,234,304			
Chemicals 2.1% DowDuPont, Inc.	243,080	16,023,834			
Commercial Services & Supplies 1.1% KAR Auction Services, Inc.	154,771	8,481,451			
Communications Equipment 2.7% Cisco Systems, Inc.	474,074	20,399,404			
Consumer Finance 1.6% Ally Financial, Inc. SLM Corp. (c)	213,891 537,693	5,618,916 6,156,585			
Containers & Packaging 1.2% Packaging Corp. of America	82,529	11,775,501 9,225,917			
Electric Utilities 2.9% FirstEnergy Corp. PG&E Corp.	363,947 206,492	13,069,337 8,788,299			
Electronic Equipment, Instruments & Components	3 2.5%	21,857,636			

CDW Corp. Flex Ltd. <sup>(c)</sup>	154,847 443,330	12,510,089 6,255,386
Food & Staples Retailing 2.2%		18,765,475
Walmart, Inc.	191,513	16,403,088
Food Products 1.3% J.M. Smucker Co.	89,440	9,613,011
Health Care Equipment & Supplies 1.5% Baxter International, Inc.	150,208	11,091,359
Health Care Providers & Services 9.1%		
Centene Corp.(c)	79,887	9,842,877
CVS Health Corp.(a)	124,485	8,010,610
Humana, Inc.	57,029	16,973,541
Laboratory Corp. of America Holdings <sup>(c)</sup> UnitedHealth Group, Inc.	81,168 77,355	14,572,091 18,978,276
Officureatin Group, inc.	11,555	10,970,270
		68,377,395
Hotels, Restaurants & Leisure 1.1%		
Carnival Corp.	147,293	8,441,362
Household Durables 2.9%		
D.R. Horton, Inc.	337,430	13,834,630
Lennar Corp., Class A	90,366	4,744,215
NVR, Inc.(c)	1,081	3,210,948
		21 700 702
	CI	21,789,793
Security Household Products 0.2%	Shares	Value
Energizer Holdings, Inc.	22,475 \$	1,415,026
Energizer Holdings, file.	22,413 \$	1,413,020
Industrial Conglomerates 0.9%		
General Electric Co.	481,941	6,559,217
	,	, ,
Insurance 1.4%		
Assured Guaranty Ltd.	105,887	3,783,343
Hartford Financial Services Group, Inc.	135,210	6,913,287
		10.606.620
T. 4 C. C		10,696,630
Internet Software & Services 5.0%	22.202	27 402 406
Alphabet, Inc., Class A <sup>(c)</sup>	33,203	37,492,496
IT Services 3.0%		
Amdocs Ltd.	83,760	5,544,075
Cognizant Technology Solutions Corp., Class A	209,862	16,576,999
C	,	- , ,- /
		22,121,074
Machinery 2.3%		

Allison Transmission Holdings, Inc. 142,313 Fortive Corp. 150,060	5,762,253 11,571,127
	17,333,380
Media 2.5% Comcast Corp., Class A <sup>(a)</sup> 565,618	18,557,927
Metals & Mining 1.5%	
Freeport-McMoRan, Inc. 433,357 Rio Tinto PLC ADR 59,686	7,479,742 3,311,379
	10,791,121
Oil, Gas & Consumable Fuels 6.6% BP PLC ADR 202,348	9,239,210
	16,970,193
Marathon Oil Corp. 239,650	4,999,099
	16,442,571
TOTAL SA ADR 32,322	1,957,420
	49,608,493
Pharmaceuticals 4.1%	
Novo Nordisk A/S ADR 188,798	8,707,364
Pfizer, Inc. 608,765	22,085,994
	30,793,358
Road & Rail 2.1%	15 422 050
Norfolk Southern Corp. 102,299	15,433,850
Software 8.7%	
	10,352,000
	39,014,751
Oracle Corp. 351,281	15,477,441
	64,844,192
Specialty Retail 5.2%	
Home Depot, Inc. 45,995	8,973,625
	19,502,683 10,407,860
Urban Outritiers, nic. 5	10,407,800
	38,884,168
Technology Hardware, Storage & Peripherals 5.9% Apple, Inc. (b) 237,136	43,896,245
Tobacco 2.2%	
	16,395,726
Total Long-Term Investments 100.3% (Cost \$584,059,977) 7-4	49,987,496

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Schedule of Investments (unaudited) (continued)	${\bf BlackRock\ Enhanced\ Capital\ and\ Income\ Fund,\ Inc.\ (CII)}$
June 30, 2018	(Percentages shown are based on Net Assets)
Security Short-Term Securities 0.6%	Shares Value
BlackRock Liquidity Funds, T-Fund, Institutional Class 1.80% <sup>(d)(e)</sup>	4,630,300 \$ 4,630,300
Total Short-Term Securities 0.6% (Cost \$4,630,300)	4,630,300
Options Purchased 0.0% (Cost \$1,360)	1,605
Total Investments Before Options Written 100.9% (Cost \$588,691,637)	754,619,401
Options Written (0.9)% (Premiums Received \$8,067,614)	(6,477,238)
Total Investments, Net of Options Written 100.0% (Cost \$580,624,023) Liabilities in Excess of Other Assets (0.0)%	748,142,163 (18,462)
Net Assets 100.0%	\$ 748,123,701

<sup>(</sup>a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

- (b) All or a portion of security has been pledged as collateral in connection with OTC derivatives.
- (c) Non-income producing security.
- (d) Annualized 7-day yield as of period end.
- (e) During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change
							in
	Shares		Shares				Net Unrealized
	Held at	Net	Held at	Value at		Real	iz <b>A</b> ppreciation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inco <b>Gre</b> in	ı (Los	(Depreciation)
BlackRock Liquidity							
Funds, T-Fund,							
Institutional Class	3,142,974	1,487,326	4,630,300	\$4,630,300	\$ 29,997	\$	\$

For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

# **Derivative Financial Instruments Outstanding as of Period End**

# **Exchange-Traded Options Purchased**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call					
General Electric Co.	321	07/13/18	USD 14.50	USD 437	\$ 1,605

### **Exchange-Traded Options Written**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amour	<i>it (000)</i>	Value
Call							
Bank of America Corp.	188	07/02/18	USD	31.35	USD	530	\$
Pfizer, Inc.	38	07/02/18	USD	36.25	USD	138	(755)
General Electric Co.	414	07/05/18	USD	14.75	USD	563	(213)
Bank of America Corp.	669	07/06/18	USD	30.50	USD	1,886	(1,003)
Baxter International, Inc.	37	07/06/18	USD	73.50	USD	273	(3,108)
CVS Health Corp.	278	07/06/18	USD	66.00	USD	1,789	(8,479)
Carnival Corp.	285	07/06/18	USD	64.00	USD	1,633	(1,425)
Chevron Corp.	104	07/06/18	USD	128.00	USD	1,315	(6,136)
Cisco Systems, Inc.	610	07/06/18	USD	44.50	USD	2,625	(1,525)
Cognizant Technology Solutions							
Corp., Class A	337	07/06/18	USD	77.00	USD	2,662	(75,825)
Comcast Corp., Class A	368	07/06/18	USD	32.00	USD	1,207	(35,880)
D.R. Horton, Inc.	114	07/06/18	USD	43.50	USD	467	(627)
Delta Air Lines, Inc.	284	07/06/18	USD	56.00	USD	1,407	(852)

Schedules of Investments 31

<sup>(</sup>a) Includes net capital gain distributions, if applicable.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call (continued)							
DowDuPont, Inc.	54	07/06/18	USD	67.50	USD	356	\$ (1,026)
Flex Ltd.	372	07/06/18	USD	14.00	USD	525	(9,300)
General Electric Co.	82	07/06/18	USD	15.25	USD	112	(12)
General Electric Co.	146	07/06/18	USD	14.50	USD	199	(292)
Gilead Sciences, Inc.	82	07/06/18	USD	69.50	USD	581	(13,489)
Hartford Financial Services							
Group, Inc.	178	07/06/18	USD	54.00	USD	910	(712)
Humana, Inc.	43	07/06/18	USD	297.50	USD	1,280	(14,513)
Microsoft Corp.	327	07/06/18	USD	101.00	USD	3,225	(7,357)
Norfolk Southern Corp.	135	07/06/18	USD	160.00	USD	2,037	(1,350)
Oracle Corp.	123	07/06/18	USD	48.00	USD	542	(246)
Pfizer, Inc.	78	07/06/18	USD	36.00	USD	283	(3,471)
Pfizer, Inc.	103	07/06/18	USD	36.50	USD	374	(1,339)
Pfizer, Inc.	39	07/06/18	USD	37.00	USD	141	(175)
Suncor Energy, Inc.	256	07/06/18	USD	40.00	USD	1,041	(23,936)
U.S. Bancorp	154	07/06/18	USD	52.50	USD	770	(308)
U.S. Bancorp	43	07/06/18	USD	53.00	USD	215	(430)
UnitedHealth Group, Inc.	57	07/06/18	USD	245.00	USD	1,398	(14,421)
Urban Outfitters, Inc.	278	07/06/18	USD	42.50	USD	1,238	(56,295)
Novo Nordisk A/S ADR	124	07/09/18	USD	50.00	USD	572	(46)
Suncor Energy, Inc.	8	07/09/18	USD	38.40	USD	33	(1,920)
FirstEnergy Corp.	442	07/11/18	USD	34.01	USD	1,587	(87,636)
Alphabet, Inc., Class A	18	07/13/18	USD	1,145.00	USD	2,033	(19,980)
Altria Group, Inc.	383	07/13/18	USD	57.50	USD	2,175	(21,257)
Apple, Inc.	129	07/13/18	USD	192.50	USD	2,388	(5,160)
Apple, Inc.	101	07/13/18	USD	187.50	USD	1,870	(18,685)
BP PLC ADR	133	07/13/18	USD	46.00	USD	607	(7,315)
Bank of America Corp.	318	07/13/18	USD	30.50	USD	896	(1,431)
Bank of America Corp.	161	07/13/18	USD	31.00	USD	454	(563)
Biogen, Inc.	28	07/13/18	USD	295.00	USD	813	(9,660)
Carnival Corp.	70	07/13/18	USD	65.00	USD	401	(350)
Carnival Corp.	70	07/13/18	USD	66.50	USD	401	(350)
Chevron Corp.	104	07/13/18	USD	129.00	USD	1,315	(8,788)
Cisco Systems, Inc.	81	07/13/18	USD	45.00	USD	349	(486)
D.R. Horton, Inc.	114	07/13/18	USD	44.00	USD	467	(1,425)
DowDuPont, Inc.	189	07/13/18	USD	67.00	USD	1,246	(13,136)
DowDuPont, Inc.	126	07/13/18	USD	69.00	USD	831	(2,331)
FirstEnergy Corp.	154	07/13/18	USD	34.50	USD	553	(24,476)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Flex Ltd.	378	07/13/18	USD	14.50	USD	533	(5,103)
Hartford Financial Services							
Group, Inc.	152	07/13/18	USD	54.00	USD	777	(1,216)
Humana, Inc.	88	07/13/18	USD	307.50	USD	2,619	(9,020)
JPMorgan Chase & Co.	128	07/13/18	USD	111.00	USD	1,334	(2,560)
Microsoft Corp.	71	07/13/18	USD	103.00	USD	700	(1,704)
Microsoft Corp.	260	07/13/18	USD	102.00	USD	2,564	(10,400)
Oracle Corp.	45	07/13/18	USD	49.00	USD	198	(90)
Oracle Corp.	303	07/13/18	USD	48.00	USD	1,335	(1,212)
PG&E Corp.	522	07/13/18	USD	42.50	USD	2,222	(126,585)
Pfizer, Inc.	155	07/13/18	USD	36.50	USD	562	(4,417)
Pfizer, Inc.	38	07/13/18	USD	37.00	USD	138	(418)
SunTrust Banks, Inc.	389	07/13/18	USD	70.00	USD	2,568	(5,815)
U.S. Bancorp	360	07/13/18	USD	50.50	USD	1,801	(17,460)
U.S. Bancorp	43	07/13/18	USD	52.50	USD	215	(236)
U.S. Bancorp	129	07/13/18	USD	51.00	USD	645	(3,805)
U.S. Bancorp	65	07/13/18	USD	51.50	USD	325	(1,105)
Urban Outfitters, Inc.	165	07/13/18	USD	43.00	USD	735	(36,713)
Walmart Inc.	374	07/13/18	USD	85.00	USD	3,203	(55,726)
SunTrust Banks, Inc.	97	07/18/18	USD	70.50	USD	640	(1,880)
Allison Transmission Holdings,							
Inc.	200	07/20/18	USD	42.51	USD	810	(5,899)
Ally Financial, Inc.	348	07/20/18	USD	27.00	USD	914	(12,180)
Ally Financial, Inc.	120	07/20/18	USD	26.00	USD	315	(9,600)
Alphabet, Inc., Class A	34	07/20/18	USD	1,100.00	USD	3,839	(146,030)
Alphabet, Inc., Class A	7	07/20/18	USD	1,190.00	USD	790	(3,185)
Altria Group, Inc.	470	07/20/18	USD	57.50	USD	2,669	(38,540)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional		
Description	Contracts	Date		Price	Amoun	ıt (000)		Value
Call (continued)								
Apple, Inc.	520	07/20/18	USD	190.00	USD	9,626	\$	(68,380)
Assured Guaranty Ltd.	200	07/20/18	USD	37.00	USD	715		(4,400)
Assured Guaranty Ltd.	200	07/20/18	USD	39.00	USD	715		(600)
BP PLC ADR	357	07/20/18	USD	47.00	USD	1,630		(12,138)
Bank of America Corp.	297	07/20/18	USD	32.00	USD	837		(1,336)
Bank of America Corp.	274	07/20/18	USD	31.00	USD	772		(1,781)
Baxter International, Inc.	121	07/20/18	USD	72.50	USD	893		(25,592)
Biogen, Inc.	58	07/20/18	USD	280.00	USD	1,683		(80,040)
CDW Corp.	645	07/20/18	USD	80.00	USD	5,211	(	(158,025)
CVS Health Corp.	283	07/20/18	USD	72.50	USD	1,821		(4,103)
Carnival Corp.	154	07/20/18	USD	64.50	USD	883		(770)
Centene Corp.	211	07/20/18	USD	125.00	USD	2,600		(41,145)
Chevron Corp.	310	07/20/18	USD	130.00	USD	3,919		(29,605)
Cisco Systems, Inc.	344	07/20/18	USD	45.00	USD	1,480		(4,816)
Cisco Systems, Inc.	240	07/20/18	USD	44.00	USD	1,033		(8,040)
Cognizant Technology Solutions								
Corp., Class A	239	07/20/18	USD	80.00	USD	1,888		(23,900)
Comcast Corp., Class A	141	07/20/18	USD	33.01	USD	463		(12,455)
Comcast Corp., Class A	389	07/20/18	USD	32.50	USD	1,276		(43,374)
D.R. Horton, Inc.	114	07/20/18	USD	45.00	USD	467		(1,482)
Dell Technologies, Inc., Class V	434	07/20/18	USD	90.00	USD	3,671		(77,035)
DowDuPont, Inc.	231	07/20/18	USD	70.00	USD	1,523		(4,504)
DowDuPont, Inc.	94	07/20/18	USD	67.50	USD	620		(7,332)
E*Trade Financial Corp.	113	07/20/18	USD	65.00	USD	691		(5,819)
Energizer Holdings, Inc.	150	07/20/18	USD	60.00	USD	944		(53,250)
FirstEnergy Corp.	242	07/20/18	USD	35.00	USD	869		(29,645)
Flex Ltd.	372	07/20/18	USD	14.00	USD	525		(15,066)
Fortive Corp.	464	07/20/18	USD	80.00	USD	3,578		(25,520)
Freeport-McMoRan, Inc.	414	07/20/18	USD	16.00	USD	715		(62,100)
Freeport-McMoRan, Inc.	213	07/20/18	USD	16.50	USD	368		(23,856)
Freeport-McMoRan, Inc.	267	07/20/18	USD	17.50	USD	461		(14,819)
General Electric Co.	113	07/20/18	USD	15.00	USD	154		(734)
General Electric Co.	52	07/20/18	USD	13.50	USD	71		(2,600)
Gilead Sciences, Inc.	167	07/20/18	USD	67.50	USD	1,183		(64,713)
Hartford Financial Services Group	,							
Inc.	135	07/20/18	USD	55.00	USD	690		(1,080)
J.M. Smucker Co.	227	07/20/18	USD	115.00	USD	2,440		(13,052)
JPMorgan Chase & Co.	103	07/20/18	USD	113.85	USD	1,073		(1,060)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

JPMorgan Chase & Co.	79	07/20/18	USD	110.00	USD	823	(4,108)
KAR Auction Services, Inc.	272	07/20/18	USD	55.00	USD	1,491	(23,120)
Laboratory Corp. of America							
Holdings	15	07/20/18	USD	195.00	USD	269	(450)
Lennar Corp., Class A	188	07/20/18	USD	57.50	USD	987	(3,478)
Lennar Corp., Class A	128	07/20/18	USD	52.50	USD	672	(18,304)
Lowe s Cos., Inc.	281	07/20/18	USD	86.20	USD	2,686	(287,158)
Marathon Oil Corp.	83	07/20/18	USD	21.00	USD	173	(5,893)
Marathon Oil Corp.	125	07/20/18	USD	22.00	USD	261	(4,312)
Microsoft Corp.	200	07/20/18	USD	100.00	USD	1,972	(40,400)
Norfolk Southern Corp.	223	07/20/18	USD	155.00	USD	3,364	(31,778)
Novo Nordisk A/S ADR	295	07/20/18	USD	48.90	USD	1,361	(5,578)
Oracle Corp.	301	07/20/18	USD	48.00	USD	1,326	(903)
Packaging Corp. of America	128	07/20/18	USD	125.00	USD	1,431	(1,280)
Pfizer, Inc.	2	07/20/18	USD	36.00	USD	7	(137)
Pfizer, Inc.	105	07/20/18	USD	35.00	USD	381	(15,540)
Pfizer, Inc.	159	07/20/18	USD	37.00	USD	577	(3,100)
Regions Financial Corp.	348	07/20/18	USD	19.00	USD	619	(6,090)
Rio Tinto PLC ADR	47	07/20/18	USD	60.00	USD	261	(705)
SLM Corp.	863	07/20/18	USD	11.55	USD	988	(24,351)
SunTrust Banks, Inc.	177	07/20/18	USD	70.00	USD	1,169	(5,133)
Suncor Energy, Inc.	34	07/20/18	USD	40.00	USD	138	(4,658)
TOTAL SA ADR	75	07/20/18	USD	60.00	USD	454	(11,250)
TOTAL SA ADR	60	07/20/18	USD	62.50	USD	363	(2,100)
U.S. Bancorp	130	07/20/18	USD	51.50	USD	650	(4,810)
Walmart Inc.	77	07/20/18	USD	87.50	USD	660	(4,889)
FirstEnergy Corp.	154	07/24/18	USD	34.75	USD	553	(24,317)

SCHEDULES OF INVESTMENTS 33

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	t (000)	Value
Call (continued)							
CDW Corp.	219	07/25/18	USD	79.65	USD	1,769	\$ (63,069)
Alphabet, Inc., Class A	18	07/27/18	USD	1,160.00	USD	2,033	(42,750)
Apple, Inc.	101	07/27/18	USD	190.00	USD	1,870	(22,523)
Apple, Inc.	101	07/27/18	USD	187.50	USD	1,870	(28,028)
BP PLC ADR	133	07/27/18	USD	47.00	USD	607	(6,450)
BP PLC ADR	82	07/27/18	USD	46.00	USD	374	(7,257)
Bank of America Corp.	275	07/27/18	USD	31.00	USD	775	(2,612)
Baxter International, Inc.	121	07/27/18	USD	76.00	USD	893	(11,313)
Biogen, Inc.	57	07/27/18	USD	310.00	USD	1,654	(18,668)
Carnival Corp.	154	07/27/18	USD	64.50	USD	883	(1,540)
Chevron Corp.	39	07/27/18	USD	130.00	USD	493	(5,869)
Cisco Systems, Inc.	163	07/27/18	USD	45.00	USD	701	(3,423)
Cognizant Technology Solutions							
Corp., Class A	167	07/27/18	USD	80.00	USD	1,319	(20,875)
Comcast Corp., Class A	96	07/27/18	USD	33.00	USD	315	(11,088)
D.R. Horton, Inc.	137	07/27/18	USD	45.00	USD	562	(4,589)
Delta Air Lines, Inc.	169	07/27/18	USD	52.00	USD	837	(11,745)
DowDuPont, Inc.	117	07/27/18	USD	72.00	USD	771	(1,345)
DowDuPont, Inc.	139	07/27/18	USD	67.50	USD	916	(13,831)
DowDuPont, Inc.	35	07/27/18	USD	66.50	USD	231	(5,040)
E*Trade Financial Corp.	372	07/27/18	USD	65.50	USD	2,275	(55,428)
Flex Ltd.	380	07/27/18	USD	14.50	USD	536	(19,190)
Freeport-McMoRan, Inc.	400	07/27/18	USD	18.00	USD	690	(22,000)
Freeport-McMoRan, Inc.	213	07/27/18	USD	17.00	USD	368	(21,407)
General Electric Co.	578	07/27/18	USD	14.50	USD	787	(9,826)
General Electric Co.	52	07/27/18	USD	14.00	USD	71	(1,664)
Gilead Sciences, Inc.	317	07/27/18	USD	72.00	USD	2,246	(58,487)
Hartford Financial Services Group	p,						
Inc.	152	07/27/18	USD	54.00	USD	777	(5,320)
JPMorgan Chase & Co.	149	07/27/18	USD	112.00	USD	1,553	(6,034)
Lowe s Cos., Inc.	199	07/27/18	USD	101.00	USD	1,902	(9,552)
Marathon Oil Corp.	125	07/27/18	USD	22.00	USD	261	(5,875)
Marathon Oil Corp.	121	07/27/18	USD	21.00	USD	252	(10,406)
Microsoft Corp.	71	07/27/18	USD	103.00	USD	700	(8,023)
Microsoft Corp.	133	07/27/18	USD	101.00	USD	1,312	(24,273)
Oracle Corp.	179	07/27/18	USD	49.00	USD	789	(895)
Pfizer, Inc.	324	07/27/18	USD	37.00	USD	1,175	(8,748)
Pfizer, Inc.	60	07/27/18	USD	36.50	USD	218	(2,910)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Suncor Energy, Inc.	393	07/27/18	USD	40.00	USD	1,599	(63,666)
U.S. Bancorp	138	07/27/18	USD	52.00	USD	690	(4,554)
UnitedHealth Group, Inc.	155	07/27/18	USD	255.00	USD	3,803	(38,053)
Urban Outfitters, Inc.	340	07/27/18	USD	46.50	USD	1,515	(33,150)
Walmart Inc.	75	07/27/18	USD	86.50	USD	642	(9,262)
Walmart Inc.	153	07/27/18	USD	86.00	USD	1,310	(22,568)
	59	07/27/18	USD	36.75	USD	214	
Pfizer, Inc.							(2,580)
Pfizer, Inc.	385	07/30/18	USD	36.50	USD	1,397	(18,691)
Bank of America Corp.	88	07/31/18	USD	30.25	USD	248	(1,845)
Cisco Systems, Inc.	240	07/31/18	USD	44.60	USD	1,033	(8,113)
FirstEnergy Corp.	302	07/31/18	USD	34.75	USD	1,084	(50,824)
Altria Group, Inc.	266	08/03/18	USD	58.50	USD	1,511	(24,738)
BP PLC ADR	164	08/03/18	USD	46.00	USD	749	(19,106)
Bank of America Corp.	146	08/03/18	USD	30.00	USD	412	(3,723)
Bank of America Corp.	90	08/03/18	USD	29.00	USD	254	(5,040)
Baxter International, Inc.	82	08/03/18	USD	75.00	USD	605	(10,619)
Baxter International, Inc.	43	08/03/18	USD	73.50	USD	318	(8,772)
Biogen, Inc.	19	08/03/18	USD	300.00	USD	551	(13,205)
Chevron Corp.	92	08/03/18	USD	130.00	USD	1,163	(16,652)
Comcast Corp., Class A	141	08/03/18	USD	34.00	USD	463	(11,844)
D.R. Horton, Inc.	291	08/03/18	USD	42.50	USD	1,193	(32,738)
Delta Air Lines, Inc.	500	08/03/18	USD	55.00	USD	2,477	(13,250)
E*Trade Financial Corp.	128	08/03/18	USD	66.00	USD	783	(7,680)
Freeport-McMoRan, Inc.	267	08/03/18	USD	17.50	USD	461	(22,695)
General Electric Co.	205	08/03/18	USD	13.50	USD	279	(12,300)
General Electric Co.	295	08/03/18	USD	15.00	USD	401	(3,392)
General License Co.	273	00/03/10	OSD	13.00	OSD	701	(3,3)(2)

34

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	t (000)	Value
Call (continued)							
JPMorgan Chase & Co.	35	08/03/18	USD	110.00	USD	365	\$ (3,045)
JPMorgan Chase & Co.	79	08/03/18	USD	111.00	USD	823	(5,411)
Lowe s Cos., Inc.	245	08/03/18	USD	99.00	USD	2,341	(27,563)
Marathon Oil Corp.	245	08/03/18	USD	21.50	USD	511	(20,213)
Microsoft Corp.	133	08/03/18	USD	102.00	USD	1,312	(22,145)
Oracle Corp.	155	08/03/18	USD	44.00	USD	683	(15,810)
Pfizer, Inc.	100	08/03/18	USD	36.50	USD	363	(6,050)
Suncor Energy, Inc.	7	08/03/18	USD	41.00	USD	28	(850)
Urban Outfitters, Inc.	250	08/03/18	USD	47.50	USD	1,114	(20,625)
Novo Nordisk A/S ADR	567	08/06/18	USD	45.01	USD	2,615	(111,182)
SunTrust Banks, Inc.	368	08/06/18	USD	68.30	USD	2,430	(40,062)
UnitedHealth Group, Inc.	107	08/09/18	USD	255.00	USD	2,625	(38,690)
Bank of America Corp.	516	08/10/18	USD	30.10	USD	1,455	(15,495)
Bank of America Corp.	305	08/10/18	USD	29.01	USD	860	(18,629)
Chevron Corp.	39	08/10/18	USD	128.00	USD	493	(11,622)
Comcast Corp., Class A	344	08/10/18	USD	33.50	USD	1,129	(39,904)
DowDuPont, Inc.	247	08/10/18	USD	66.00	USD	1,628	(57,428)
FirstEnergy Corp.	301	08/10/18	USD	33.75	USD	1,081	(71,285)
Flex Ltd.	379	08/10/18	USD	14.50	USD	535	(18,950)
General Electric Co.	118	08/10/18	USD	14.00	USD	161	(4,838)
Hartford Financial Services G	roup,						
Inc.	63	08/10/18	USD	52.00	USD	322	(7,497)
JPMorgan Chase & Co.	60	08/10/18	USD	108.25	USD	625	(9,219)
Lowe s Cos., Inc.	116	08/10/18	USD	98.50	USD	1,109	(17,284)
Marathon Oil Corp.	121	08/10/18	USD	21.50	USD	252	(11,192)
Microsoft Corp.	133	08/10/18	USD	102.00	USD	1,312	(24,871)
Oracle Corp.	551	08/10/18	USD	45.10	USD	2,428	(35,791)
PG&E Corp.	200	08/10/18	USD	44.00	USD	851	(52,000)
Pfizer, Inc.	385	08/10/18	USD	36.50	USD	1,397	(25,025)
U.S. Bancorp	191	08/10/18	USD	50.00	USD	955	(26,072)
Urban Outfitters, Inc.	251	08/10/18	USD	47.50	USD	1,118	(26,983)
Ally Financial, Inc.	348	08/17/18	USD	27.00	USD	914	(24,360)
Ally Financial, Inc.	120	08/17/18	USD	26.00	USD	315	(14,400)
Alphabet, Inc., Class A	39	08/17/18	USD	1,105.00	USD	4,404	(234,585)
Altria Group, Inc.	468	08/17/18	USD	59.20	USD	2,658	(48,271)
Apple, Inc.	352	08/17/18	USD	190.00	USD	6,516	(147,840)
BP PLC ADR	161	08/17/18	USD	46.00	USD	735	(19,964)
BP PLC ADR	82	08/17/18	USD	47.00	USD	374	(6,724)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Bank of America Corp.	274	08/17/18	USD	31.00	USD	772	(5,343)
Bank of America Corp.	305	08/17/18	USD	29.00	USD	860	(20,893)
Baxter International, Inc.	121	08/17/18	USD	72.50	USD	893	(36,300)
Biogen, Inc.	33	08/17/18	USD	300.00	USD	958	(28,875)
CVS Health Corp.	128	08/17/18	USD	72.50	USD	824	(5,952)
Chevron Corp.	50	08/17/18	USD	130.00	USD	632	(11,625)
Comcast Corp., Class A	501	08/17/18	USD	35.00	USD	1,644	(34,820)
D.R. Horton, Inc.	137	08/17/18	USD	43.00	USD	562	(14,454)
D.R. Horton, Inc.	274	08/17/18	USD	41.00	USD	1,123	(55,896)
Delta Air Lines, Inc.	169	08/17/18	USD	52.50	USD	837	(15,126)
DowDuPont, Inc.	34	08/17/18	USD	70.00	USD	224	(2,958)
DowDuPont, Inc.	70	08/17/18	USD	67.50	USD	461	(12,145)
E*Trade Financial Corp.	217	08/17/18	USD	63.75	USD	1,327	(29,719)
Flex Ltd.	557	08/17/18	USD	15.00	USD	786	(19,774)
Fortive Corp.	61	08/17/18	USD	76.01	USD	470	(23,071)
Freeport-McMoRan, Inc.	210	08/17/18	USD	17.00	USD	362	(25,935)
Freeport-McMoRan, Inc.	400	08/17/18	USD	18.00	USD	690	(31,800)
General Electric Co.	175	08/17/18	USD	15.00	USD	238	(2,887)
Gilead Sciences, Inc.	217	08/17/18	USD	75.00	USD	1,537	(29,512)
Hartford Financial Services Group,							
Inc.	63	08/17/18	USD	53.05	USD	322	(6,152)
Home Depot, Inc.	274	08/17/18	USD	200.00	USD	5,346	(104,120)
Humana, Inc.	68	08/17/18	USD	300.00	USD	2,024	(63,580)
J.M. Smucker Co.	264	08/17/18	USD	110.00	USD	2,837	(76,560)
JPMorgan Chase & Co.	204	08/17/18	USD	115.00	USD	2,126	(9,792)
KAR Auction Services, Inc.	269	08/17/18	USD	55.00	USD	1,474	(45,730)

SCHEDULES OF INVESTMENTS 35

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	1	Exercise		otional	
Description	Contracts	Date		Price	Amour	ıt (000)	Value
Call (continued)							
Lowe s Cos., Inc.	281	08/17/18	USD	97.50	USD	2,686	\$ (59,572)
Marathon Oil Corp.	373	08/17/18	USD	22.00	USD	778	(30,027)
Marathon Oil Corp.	125	08/17/18	USD	23.00	USD	261	(6,437)
Microsoft Corp.	56	08/17/18	USD	105.00	USD	552	(6,272)
Oracle Corp.	275	08/17/18	USD	44.00	USD	1,212	(34,513)
Packaging Corp. of America	160	08/17/18	USD	120.00	USD	1,789	(20,800)
Pfizer, Inc.	100	08/17/18	USD	37.00	USD	363	(4,600)
SunTrust Banks, Inc.	97	08/17/18	USD	72.50	USD	640	(3,492)
Suncor Energy, Inc.	35	08/17/18	USD	41.00	USD	142	(5,075)
TOTAL SA ADR	42	08/17/18	USD	62.50	USD	254	(4,095)
U.S. Bancorp	194	08/17/18	USD	52.50	USD	970	(9,118)
Walmart Inc.	374	08/17/18	USD	85.00	USD	3,203	(108,460)
UnitedHealth Group, Inc.	107	08/20/18	USD	255.00	USD	2,625	(47,841)

\$ (5,814,712)

## **OTC Options Written**

Description Call	Counterparty	Number of Contracts	Expiration Date		Exercise Price		Totional nt (000)	Value
Allison								
Transmission								
Holdings, Inc.	Credit Suisse International	20,300	07/06/18	USD	43.10	USD	822	\$ (358)
SLM Corp.	Citibank N.A.	30,400	07/09/18	USD	11.42	USD	348	(7,273)
Suncor								
Energy, Inc.	Citibank N.A.	68,100	07/09/18	USD	38.95	USD	2,770	(128,037)
Amdocs Ltd.	JPMorgan Chase Bank N.A.	23,500	07/10/18	USD	66.43	USD	1,555	(17,802)
Laboratory	-							
Corp. of								
America								
Holdings	UBS AG	21,000	07/10/18	USD	177.00	USD	3,770	(87,241)
Ally		,					ŕ	, , ,
Financial,								
Inc.	Citibank N.A.	24,000	07/11/18	USD	27.24	USD	630	(3,578)
	UBS AG	21,000	07/19/18	USD	177.00	USD	3,770	(107,192)
		•					•	/

Laboratory								
Corp. of								
America								
Holdings								
Centene								
Corp.	Citibank N.A.	22,800	07/23/18	USD	118.90	USD	2,809	(146,941)
Regions								
Financial								
Corp.	Morgan Stanley & Co. International PLC	75,000	07/24/18	USD	19.58	USD	1,334	(8,423)
SLM Corp.	UBS AG	81,500	07/24/18	USD	12.01	USD	933	(12,623)
Novo Nordisk								
A/S ADR	Barclays Bank PLC	5,200	07/26/18	USD	45.41	USD	240	(7,887)
Rio Tinto								
PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/03/18	USD	58.75	USD	1,171	(12,758)
SLM Corp.	Morgan Stanley & Co. International PLC	97,500	08/07/18	USD	12.15	USD	1,116	(19,150)
Assured								
Guaranty Ltd.	Citibank N.A.	18,200	08/13/18	USD	36.51	USD	650	(11,926)
Amdocs Ltd.	JPMorgan Chase Bank N.A.	22,500	08/16/18	USD	67.10	USD	1,489	(27,933)
Regions								
Financial								
Corp.	JPMorgan Chase Bank N.A.	35,200	08/16/18	USD	19.45	USD	626	(7,458)
Rio Tinto		<b>21</b> 100	00/00/40	*****	<b></b>	*****		(10.000)
PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/20/18	USD	58.75	USD	1,171	(12,288)
Regions								
Financial		25.100	00/05/10	Hab	10.01	Hab	60.4	(1.4.0.65)
Corp.	Morgan Stanley & Co. International PLC	35,100	08/27/18	USD	18.81	USD	624	(14,867)
FirstEnergy	IDM CI D I MA	10.600	00/00/10	HOD	26.65	HOD	1 450	(20.701)
Corp.	JPMorgan Chase Bank N.A.	40,600	08/29/18	USD	36.65	USD	1,458	(28,791)

\$ (662,526)

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

36

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 2,911,349	\$ (1,320,973)	\$ (6,477,238)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

#### **Derivative Financial Instruments Categorized by Risk Exposure**

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

					Foreigi Eurrenc			
	Commodity Contracts	Credit Contracts	Co	Equity E.	xchange	Other		Total
Assets Derivative Finan Instruments Options purchased Investments at value unaffiliated <sup>(a)</sup>	cial \$	\$	\$	1,605	\$	\$ \$	\$	1,605
Liabilities Derivative Financial Instruments Options written Options written at value	\$	\$	\$ 6,4	477,238	\$	\$ \$	\$ 6,	477,238

<sup>&</sup>lt;sup>(a)</sup> Includes options purchased at value as reported in the schedule of Investments. For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts C	Credit Contracts		0	Interest Rate	Other	Total
Net Realized Gain (Loss) from: Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (2,570) (4,323,450)	\$	\$	\$	\$ (2,570) (4,323,450)
	\$	\$	\$ (4,326,020)	\$	\$	\$	\$ (4,326,020)

<sup>(</sup>a) Options purchased are included in net realized gain (loss) from investments.

# **Net Change in Unrealized Appreciation**

(Depreciation) on:

Options purchased	\$ \$	\$ 24	5 \$	\$ \$	\$	245
Options written		3,616,46	9		3,6	16,469
	\$ \$	\$ 3,616,71	4 \$	\$ \$	\$ 3.6	16.714

Options:

Average value of option contracts purchased

\$ 803

Average value of option contracts written

\$ 5,340,856

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities	
Derivative Financial Instruments: Options	\$ 1,605 <sup>(a)</sup>	\$ 6,477,238	
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(1,605)	(5,814,712)	
Total derivative assets and liabilities subject to an MNA	\$	\$ 662,526	

<sup>(</sup>a) Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

SCHEDULES OF INVESTMENTS 37

<sup>(</sup>a) Options purchased are included in net change in unrealized appreciation (depreciation) from investments. Average Quarterly Balances of Outstanding Derivative Financial Instruments

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

Counterparty	1 S ar	Derivative Liabilities Subject to MNA by nterparty	Derivatives Available for Offset	Non-cash Collateral Pledged <sup>(a)</sup>	Cash Collateral Pledged	of L	et Amount Derivative iabilities
Barclays Bank PLC	\$	7,887	\$	\$	\$	\$	7,887
Citibank N.A.		297,755		(297,755)			
Credit Suisse International		358					358
JPMorgan Chase Bank N.A.		81,984					81,984
Morgan Stanley & Co. International							
PLC		67,486					67,486
UBS AG		207,056		(207,056)			
	\$	662,526	\$	\$ (504,811)	\$	\$	157,715

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks <sup>(a)</sup>	\$ 749,987,496	\$	\$	\$749,987,496
Short-Term Securities	4,630,300			4,630,300
Options Purchased:				
Equity Contracts	1,605			1,605

<sup>(</sup>a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(</sup>b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

	\$ 754,619,401	\$	\$ \$ 754,619,401
Derivative Financial Instruments <sup>(b)</sup> Liabilities:			
Equity contracts	\$ (4,690,612)	\$ (1,786,626)	\$ \$ (6,477,238)

See notes to financial statements.

38

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

<sup>(</sup>a) See above Schedule of Investments for values in each industry.

<sup>(</sup>b) Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

Schedule of Investments (unaudited)	BlackRock Enhanced Equity Dividend Trust (BDJ)
June 30, 2018	(Percentages shown are based on Net Assets)
Security Common Stocks 100.2%	Shares Value
Aerospace & Defense 1.1% Lockheed Martin Corp. <sup>(a)</sup> Northrop Grumman Corp. <sup>(a)</sup>	20,920 \$ 6,180,396 46,090 14,181,893
Banks 17.8% Bank of America Corp.(a)(b) Citigroup, Inc.(a)(b) JPMorgan Chase & Co.(a)(b) KeyCorp(a) SunTrust Banks, Inc.(a) U.S. Bancorp(a) Wells Fargo & Co.(a)	20,362,289  2,540,170 71,607,392 983,479 65,814,415 696,148 72,538,622 501,280 9,795,011 293,049 19,347,095 479,743 23,996,745 1,033,491 57,296,741
Beverages 2.2% Diageo PLC Dr. Pepper Snapple Group, Inc. <sup>(a)</sup> PepsiCo, Inc. <sup>(a)</sup>	320,396,021 507,609 18,236,314 84,850 10,351,700 110,300 12,008,361
Capital Markets 3.4% Charles Schwab Corp. <sup>(a)</sup> Goldman Sachs Group, Inc. <sup>(a)</sup> Morgan Stanley <sup>(a)</sup>	40,596,375 170,420 8,708,462 106,920 23,583,344 621,970 29,481,378
Chemicals 1.2% DowDuPont, Inc. <sup>(a)</sup>	61,773,184 315,265 20,782,269
Communications Equipment 1.7% Cisco Systems, Inc. <sup>(a)</sup> Motorola Solutions, Inc. <sup>(a)</sup>	236,610 10,181,328 171,600 19,969,092
Construction Materials 0.8% CRH PLC	30,150,420 387,800 13,602,955
Containers & Packaging 0.4% International Paper Co.(a)	135,700 7,067,256
Diversified Financial Services 0.3%	

AXA Equitable Holdings, Inc.(a)(c)	273,200	5,630,652
Diversified Telecommunication Services 2.9%	27.460	1 202 120
AT&T, Inc. BCE, Inc. <sup>(a)</sup>	37,469 122,500	1,203,130 4,960,025
Verizon Communications, Inc.(a)	911,410	45,853,037
verizon Communications, inc.	911, <del>4</del> 10	45,655,057
		52,016,192
Electric Utilities 3.8%		- ,, -
Edison International <sup>(a)</sup>	80,393	5,086,465
FirstEnergy Corp. (a)	673,530	24,186,462
NextEra Energy, Inc.(a)	115,512	19,293,969
PG&E Corp.(a)	481,290	20,483,703
		69,050,599
Electrical Equipment 0.1%		07,030,377
nVent Electric PLC <sup>(c)</sup>	109,190	2,740,669
Electronic Equipment, Instruments & Components 0.7%		
CDW Corp. <sup>(a)</sup>	161,890	13,079,093
Food & Staples Retailing 0.7%		
Food & Staples Retailing 0.7% Kroger Co. <sup>(a)</sup>	436,290	12,412,451
Kluger Co.	430,290	12,412,431
Food Products 1.4%		
Danone SA	58,500	4,271,230
General Mills, Inc. <sup>(a)</sup>	193,760	8,575,817
Security	Shares	Value
Food Products (continued)		
Kellogg Co. <sup>(a)</sup>	165,540 \$	11,566,280
		04 412 227
Health Care Equipment & Supplies 3.1%		24,413,327
Koninklijke Philips NV	716,440	30,354,090
Medtronic PLC <sup>(a)</sup>	301,650	25,824,257
Neddollie I Be	301,030	23,021,237
		56,178,347
Health Care Providers & Services 8.7%		•
Aetna, Inc. <sup>(a)</sup>	167,946	30,818,091
Anthem, Inc. (a)	205,890	49,007,997
Cardinal Health, Inc. <sup>(a)</sup>	169,200	8,262,036
CVS Health Corp.(a)	206,260	13,272,831
Humana, Inc.(a)	27,590	8,211,612
McKesson Corp. (a)  Overt Diagnostics, Inc. (a)	120,390	16,060,026
Quest Diagnostics, Inc.(a) United Health Group, Inc.(a)	75,810 90,460	8,334,551 22,193,456
UnitedHealth Group, Inc. <sup>(a)</sup>	70, <del>4</del> 00	44,175,430
		156,160,600
Household Products 0.9%		,,
Procter & Gamble Co. <sup>(a)</sup>	209,320	16,339,519

Industrial Conglomerates 3.0%		
3M Co. <sup>(a)</sup>	44,990	8,850,433
General Electric Co. <sup>(a)</sup>	1,710,590	23,281,130
Honeywell International, Inc.(a)	152,390	21,951,779
		54,083,342
Insurance 6.2%		5-1,005,5-12
American International Group, Inc.(a)	681,330	36,124,116
Arthur J Gallagher & Co.	23,433	1,529,706
Brighthouse Financial, Inc. (a)(c)	44,511	1,783,556
Lincoln National Corp.(a)	46,320	2,883,420
Marsh & McLennan Cos., Inc.(a)	183,800	15,066,086
MetLife, Inc. <sup>(a)</sup>	798,253	34,803,831
Travelers Cos., Inc. <sup>(a)</sup>	165,150	20,204,451
		112,395,166
IT Services 0.4%		
Cognizant Technology Solutions Corp., Class A <sup>(a)</sup>	82,580	6,522,994
Leisure Products 0.5%		
Mattel, Inc.(a)(d)	586,956	9,637,818
	2 2 3 , 2 2 3	2,000,000
Machinery 0.3%		
Pentair PLC <sup>(a)</sup>	109,190	4,594,715
Media 2.1%		
Comcast Corp., Class A <sup>(a)</sup>	895,110	29,368,559
Interpublic Group of Cos., Inc. (a)	397,970	9,328,417
interpoent Group of Cost, inc.	65.,5.0	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		38,696,976
Multi-Utilities 1.3%		
Public Service Enterprise Group, Inc.(a)	437,430	23,682,460
Multiline Retail 0.3%		
Dollar General Corp.(a)	54,587	5,382,278
2 chair Canada Corp.	2 1,2 3 7	c,cc_,c
Oil, Gas & Consumable Fuels 13.0%		
Anadarko Petroleum Corp.(a)	51,700	3,787,025
BP PLC	5,057,210	38,477,869
Chevron Corp. (a)	118,260	14,951,612
Devon Energy Corp. (a)	536,160	23,569,594
Enterprise Products Partners LP <sup>(a)</sup>	758,400	20,984,928
Hess Corp. (a)	411,110	27,499,148
Marathon Oil Corp.(a)	169,820	3,542,445
Marathon Petroleum Corp.(a)	201,459	14,134,364
ONEOK, Inc.(a)	138,180	9,649,109
Royal Dutch Shell PLC ADR, Class (A)	156,710	10,849,033
Suncor Energy, Inc. <sup>(a)</sup>	1,141,580	46,439,474

SCHEDULES OF INVESTMENTS 39

Schedule of Investments (unaudited) (continued)	e of Investments (unaudited) (continued)  BlackRock Enhanced Equity Dividend Trust (				
June 30, 2018	(Percentages shown are based on Net Asse				
Security	Shares	Value			
Oil, Gas & Consumable Fuels (continued) TOTAL SA AD®	211,897	\$ 12,832,482			
Williams Cos., Inc.(a)	259,552	7,036,455			
		233,753,538			
Personal Products 0.8%					
Unilever NV NY Sharé®	255,590	14,241,475			
Pharmaceuticals 8.5%					
AstraZeneca PLC	480,846	33,258,762			
Bayer AG, Registered Shares	107,845	11,843,916			
Merck & Co., Inc.(a)	413,570	25,103,699			
Novo Nordisk A/S ADR)	298,910	13,785,729			
Pfizer, Inc. <sup>(a)(b)</sup>	1,911,740	69,357,927			
		153,350,033			
Professional Services 1.3%	520 700	12.002.606			
Experian PLC	530,780	13,093,606			
Nielsen Holdings PLC <sup>(a)</sup>	343,020	10,609,609			
		23,703,215			
Road & Rail 0.7% Union Pacific Corp. (a)	83,780	11,869,950			
emon rueme corp.	55,760	11,000,000			
Semiconductors & Semiconductor Equipment 1.8%					
QUALCOMM, Inc.(a)	418,240	23,471,629			
Taiwan Semiconductor Manufacturing Co. Ltd. ADR)	237,560	8,685,193			
		32,156,822			
Software 5.9%	14240	11.042.540			
Constellation Software, Inc.	14,240	11,043,542			
Microsoft Corp. (a)	476,210	46,959,068			
Oracle Corp.(a)	1,118,660	49,288,159			
G . I. I. D . II. 0.79		107,290,769			
Specialty Retail 0.7% Lowe s Cos., Iné <sup>a</sup> )	137,050	13,097,869			
Tashnalagu Handwaya Stanaga & Davida Larada 0.00					
Technology Hardware, Storage & Peripherals 0.8%	12 220 000	7 115 700			
Lenovo Group Ltd.	13,220,000	7,115,799			
Samsung Electronics Co. Ltd. GDR	7,819	8,109,582			
		15,225,381			
Security	Shares	Value			

<b>Tobacco 1.4%</b> Altria Group, Inc. <sup>(a)</sup> Philip Morris International, Inc. <sup>(a)</sup>	340,020 69,830	\$ 19,309,736 5,638,074 24,947,810
Total Long-Term Investments 100.2% (Cost \$1,400,287,297)		1,807,384,829
Short-Term Securities 0.8%  BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(e)(g)</sup> SL Liquidity Series, LLC, Money Market Series, 2.16% <sup>(e)(f)(g)</sup>	13,793,172 12,294	13,793,172 12,294
Total Short-Term Securities 0.8% (Cost \$13,805,466)		13,805,466
Options Purchased 0.0% (Cost \$3,195)		3,770
Total Investments Before Options Written 101.0% (Cost \$1,414,095,958)		1,821,194,065
Options Written (0.9)% (Premiums Received \$17,508,135)		(15,288,978)
Total Investments, Net of Options Written 100.1% (Cost \$1,396,587,823) Liabilities in Excess of Other Assets (0.1)%		1,805,905,087 (1,936,617)
Net Assets 100.0%		\$ 1,803,968,470

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- (c) Non-income producing security.
- (d) Security, or a portion of the security, is on loan.
- (e) Annualized 7-day yield as of period end.
- (f) Security was purchased with the cash collateral from loaned securities.
- (g) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares	Net	Shares	Value at	Income	Net	Change
	Held at	Activity	Held at	06/30/18		Realized	in
	12/31/17		06/30/18		Gair	n (Loss) 🕅	realized

							preciation preciation)
BlackRock Liquidity Funds, T-Fund,						, 1	,
Institutional Class SL Liquidity Series, LLC, Money Market	4,967,189	8,825,983	13,793,172	\$ 13,793,172	\$ 67,095	\$	\$
Series		12,294	12,294	12,294	7 <sup>(b)</sup>		
				\$ 13,805,466	\$67,102	\$	\$

40

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

<sup>(</sup>a) Includes net capital gain distributions, if applicable.

<sup>(</sup>b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

#### **Derivative Financial Instruments Outstanding as of Period End**

### **Exchange-Traded Options Purchased**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call					
General Electric Co.	754	07/13/18	USD 14.50	USD 1,026	\$3,770

#### **Exchange-Traded Options Written**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call							
Bank of America Corp.	722	07/02/18	USD	31.35	USD	2,035	\$
Pfizer, Inc.	253	07/02/18	USD	36.25	USD	918	(5,028)
General Electric Co.	992	07/05/18	USD	14.75	USD	1,350	(511)
Aetna, Inc.	131	07/06/18	USD	232.50	USD	3,118	(84,168)
Bank of America Corp.	2,146	07/06/18	USD	30.50	USD	6,050	(3,219)
CVS Health Corp.	279	07/06/18	USD	66.00	USD	1,795	(8,509)
Charles Schwab Corp.	205	07/06/18	USD	59.00	USD	1,048	(1,025)
Citigroup, Inc.	351	07/06/18	USD	69.50	USD	2,349	(4,036)
Comcast Corp., Class A	224	07/06/18	USD	32.00	USD	735	(21,840)
Devon Energy Corp.	64	07/06/18	USD	43.50	USD	281	(6,656)
Devon Energy Corp.	72	07/06/18	USD	41.00	USD	317	(22,140)
DowDuPont, Inc.	56	07/06/18	USD	67.50	USD	369	(1,064)
General Electric Co.	177	07/06/18	USD	15.25	USD	241	(25)
General Electric Co.	339	07/06/18	USD	14.50	USD	461	(678)
Goldman Sachs Group, Inc.	162	07/06/18	USD	235.00	USD	3,573	(1,053)
Hess Corp.	655	07/06/18	USD	62.00	USD	4,381	(324,225)
Honeywell International, Inc.	113	07/06/18	USD	152.50	USD	1,628	(452)
Humana, Inc.	27	07/06/18	USD	297.50	USD	804	(9,112)
Marathon Oil Corp.	181	07/06/18	USD	82.00	USD	1,270	(5,792)
McKesson Corp.	108	07/06/18	USD	146.00	USD	1,441	(1,620)
MetLife, Inc.	570	07/06/18	USD	48.00	USD	2,485	(6,270)
Microsoft Corp.	492	07/06/18	USD	101.00	USD	4,852	(11,070)
Morgan Stanley	206	07/06/18	USD	54.00	USD	976	(1,648)
Morgan Stanley	136	07/06/18	USD	52.00	USD	645	(816)
Oracle Corp.	475	07/06/18	USD	48.00	USD	2,093	(950)
Pfizer, Inc.	514	07/06/18	USD	36.00	USD	1,865	(22,873)
Pfizer, Inc.	470	07/06/18	USD	36.50	USD	1,705	(6,110)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Pfizer, Inc.	176	07/06/18	USD	37.00	USD	639	(792)
QUALCOMM, Inc.	440	07/06/18	USD	60.00	USD	2,469	(3,740)
QUALCOMM, Inc.	605	07/06/18	USD	62.00	USD	3,395	(4,840)
Suncor Energy, Inc.	215	07/06/18	USD	40.00	USD	875	(20,102)
U.S. Bancorp	338	07/06/18	USD	52.50	USD	1,691	(676)
U.S. Bancorp	69	07/06/18	USD	53.00	USD	345	(690)
Union Pacific Corp.	188	07/06/18	USD	147.00	USD	2,664	(1,786)
Verizon Communications, Inc.	495	07/06/18	USD	49.00	USD	2,490	(72,270)
Wells Fargo & Co.	470	07/06/18	USD	55.50	USD	2,606	(28,905)
Wells Fargo & Co.	873	07/06/18	USD	55.00	USD	4,840	(79,007)
Williams Cos., Inc.	224	07/06/18	USD	27.50	USD	607	(2,800)
BCE, Inc.	251	07/09/18	USD	42.45	USD	1,016	(264)
Interpublic Group of Cos., Inc.	450	07/09/18	USD	23.20	USD	1,055	(25,440)
Novo Nordisk A/S ADR	451	07/09/18	USD	50.00	USD	2,080	(168)
Suncor Energy, Inc.	366	07/09/18	USD	38.40	USD	1,489	(87,819)
Pentair PLC	545	07/10/18	USD	46.51	USD	2,293	(96)
FirstEnergy Corp.	368	07/11/18	USD	34.01	USD	1,321	(72,964)
Altria Group, Inc.	253	07/13/18	USD	57.50	USD	1,437	(14,041)
American International Group, Inc.	719	07/13/18	USD	54.00	USD	3,812	(26,603)
Anthem, Inc.	217	07/13/18	USD	235.00	USD	5,165	(124,233)
Bank of America Corp.	987	07/13/18	USD	30.50	USD	2,782	(4,441)
Bank of America Corp.	484	07/13/18	USD	31.00	USD	1,364	(1,694)
Cisco Systems, Inc.	108	07/13/18	USD	45.00	USD	465	(648)
Citigroup, Inc.	186	07/13/18	USD	70.50	USD	1,245	(5,301)
Dollar General Corp.	354	07/13/18	USD	97.50	USD	3,490	(79,650)

Schedules of Investments 41

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercis	se Notional	
Description	Contracts	Date	Prio	e Amount (000)	Value
Call (continued)					
DowDuPont, Inc.	220	07/13/18	USD 67.0	0 USD 1,450	\$ (15,290)
DowDuPont, Inc.	136	07/13/18	USD 69.0	0 USD 897	(2,516)
FirstEnergy Corp.	239	07/13/18	USD 34.5	0 USD 858	(37,985)
Goldman Sachs Group, Inc.	93	07/13/18	USD 237.5	0 USD 2,051	(1,953)
JPMorgan Chase & Co.	679	07/13/18	USD 111.0	0 USD 7,075	(13,580)
KeyCorp	270	07/13/18	USD 20.5	0 USD 528	(2,160)
Kroger Co.	823	07/13/18	USD 25.0	0 USD 2,341	(288,050)
Marathon Petroleum Corp.	136	07/13/18	USD 78.0	0 USD 954	(1,020)
McKesson Corp.	65	07/13/18	USD 148.0	0 USD 867	(975)
Medtronic PLC	146	07/13/18	USD 88.5	0 USD 1,250	(1,606)
Microsoft Corp.	201	07/13/18	USD 103.0	0 USD 1,982	(4,824)
Microsoft Corp.	369	07/13/18	USD 102.0	0 USD 3,639	(14,760)
Morgan Stanley	225	07/13/18	USD 53.0	0 USD 1,067	(900)
Morgan Stanley	257	07/13/18	USD 54.0	0 USD 1,218	(5,654)
ONEOK, Inc.	138	07/13/18	USD 69.5	0 USD 964	(18,285)
Oracle Corp.	141	07/13/18	USD 49.0	0 USD 621	(282)
Oracle Corp.	961	07/13/18	USD 48.0	0 USD 4,234	(3,844)
PG&E Corp.	1,334	07/13/18	USD 42.5	0 USD 5,678	(323,495)
PepsiCo, Inc.	191	07/13/18	USD 102.0	0 USD 2,079	(137,520)
Pfizer, Inc.	704	07/13/18	USD 36.5	0 USD 2,554	(20,064)
Pfizer, Inc.	176	07/13/18	USD 37.0	0 USD 639	(1,936)
Procter & Gamble Co.	226	07/13/18	USD 74.0	0 USD 1,764	(97,745)
SunTrust Banks, Inc.	466	07/13/18	USD 70.0	0 USD 3,077	(6,966)
U.S. Bancorp	640	07/13/18	USD 50.5	0 USD 3,201	(31,040)
U.S. Bancorp	69	07/13/18	USD 52.5	0 USD 345	(379)
U.S. Bancorp	189	07/13/18	USD 51.0		(5,575)
U.S. Bancorp	94	07/13/18	USD 51.5		(1,598)
Wells Fargo & Co.	539	07/13/18	USD 56.5	,	(36,113)
Williams Cos., Inc.	224	07/13/18	USD 27.0	0 USD 607	(11,312)
SunTrust Banks, Inc.	118	07/18/18	USD 70.5		(2,287)
Wells Fargo & Co.	873	07/19/18	USD 56.2	5 USD 4,840	(83,303)
3M Co.	105	07/20/18	USD 200.0	,	(23,258)
AXA Equitable Holdings, Inc.	437	07/20/18	USD 22.5		(4,370)
Aetna, Inc.	218	07/20/18	USD 180.0	0 USD 4,000	(116,085)
Aetna, Inc.	415	07/20/18	USD 195.0	·	(25,730)
Altria Group, Inc.	391	07/20/18	USD 57.5	·	(32,062)
Anadarko Petroleum Corp.	129	07/20/18	USD 72.5		(31,476)
Anthem, Inc.	144	07/20/18	USD 240.0	0 USD 3,428	(57,600)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Anthem, Inc.	262	07/20/18	USD	245.00	USD	6,236	(55,675)
Bank of America Corp.	1,190	07/20/18	USD	32.00	USD	3,355	(5,355)
Bank of America Corp.	822	07/20/18	USD	31.00	USD	2,317	(5,343)
Brighthouse Financial, Inc.	155	07/20/18	USD	50.00	USD	621	(1,550)
CDW Corp.	445	07/20/18	USD	80.00	USD	3,595	(109,025)
CVS Health Corp.	349	07/20/18	USD	72.50	USD	2,246	(5,060)
Charles Schwab Corp.	205	07/20/18	USD	60.00	USD	1,048	(1,025)
Chevron Corp.	425	07/20/18	USD	130.00	USD	5,373	(40,588)
Cisco Systems, Inc.	404	07/20/18	USD	45.00	USD	1,738	(5,656)
Cisco Systems, Inc.	336	07/20/18	USD	44.00	USD	1,446	(11,256)
Citigroup, Inc.	757	07/20/18	USD	72.50	USD	5,066	(12,490)
Cognizant Technology Solutions							
Corp., Class A	103	07/20/18	USD	77.50	USD	814	(25,235)
Cognizant Technology Solutions							
Corp., Class A	103	07/20/18	USD	80.00	USD	814	(10,300)
Comcast Corp., Class A	254	07/20/18	USD	33.01	USD	833	(22,436)
Comcast Corp., Class A	568	07/20/18	USD	32.50	USD	1,864	(63,332)
Devon Energy Corp.	182	07/20/18	USD	38.00	USD	800	(112,385)
Devon Energy Corp.	153	07/20/18	USD	44.00	USD	673	(22,874)
Devon Energy Corp.	99	07/20/18	USD	46.00	USD	435	(6,831)
DowDuPont, Inc.	244	07/20/18	USD	70.00	USD	1,608	(4,758)
DowDuPont, Inc.	108	07/20/18	USD	67.50	USD	712	(8,424)
Enterprise Products Partners LP	1,264	07/20/18	USD	29.00	USD	3,497	(12,640)
FirstEnergy Corp.	311	07/20/18	USD	35.00	USD	1,117	(38,098)
General Electric Co.	244	07/20/18	USD	15.00	USD	332	(1,586)
General Electric Co.	120	07/20/18	USD	13.50	USD	163	(6,000)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

42

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Е	Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	at (000)	Value
Call (continued)							
General Mills, Inc.	301	07/20/18	USD	45.00	USD	1,332	\$ (14,147)
General Mills, Inc.	667	07/20/18	USD	47.50	USD	2,952	(6,336)
Goldman Sachs Group, Inc.	279	07/20/18	USD	240.00	USD	6,154	(14,508)
Hess Corp.	485	07/20/18	USD	65.00	USD	3,244	(155,200)
Honeywell International, Inc.	75	07/20/18	USD	149.00	USD	1,080	(7,275)
International Paper Co.	176	07/20/18	USD	57.50	USD	917	(1,056)
Interpublic Group of Cos., Inc.	770	07/20/18	USD	24.00	USD	1,805	(28,875)
JPMorgan Chase & Co.	516	07/20/18	USD	113.85	USD	5,377	(5,310)
JPMorgan Chase & Co.	218	07/20/18	USD	110.00	USD	2,272	(11,336)
Kellogg Co.	349	07/20/18	USD	65.00	USD	2,438	(184,970)
KeyCorp	387	07/20/18	USD	21.00	USD	756	(3,483)
Kroger Co.	1,005	07/20/18	USD	26.00	USD	2,859	(260,798)
Lincoln National Corp.	116	07/20/18	USD	72.50	USD	722	(812)
Lincoln National Corp.	115	07/20/18	USD	67.50	USD	716	(1,610)
Lowe s Cos., Inc.	46	07/20/18	USD	86.20	USD	440	(47,008)
Marathon Oil Corp.	419	07/20/18	USD	77.50	USD	2,940	(7,961)
Marathon Oil Corp.	269	07/20/18	USD	22.00	USD	561	(9,280)
Marsh & McLennan Cos., Inc.	596	07/20/18	USD	83.50	USD	4,885	(30,611)
Mattel, Inc.	144	07/20/18	USD	16.00	USD	236	(12,600)
Medtronic PLC	138	07/20/18	USD	87.50	USD	1,181	(6,141)
Medtronic PLC	147	07/20/18	USD	90.00	USD	1,258	(1,323)
Merck & Co., Inc.	339	07/20/18	USD	60.00	USD	2,058	(51,698)
Merck & Co., Inc.	537	07/20/18	USD	62.50	USD	3,260	(20,675)
MetLife, Inc.	248	07/20/18	USD	50.00	USD	1,081	(3,720)
Microsoft Corp.	238	07/20/18	USD	100.00	USD	2,347	(48,076)
Morgan Stanley	284	07/20/18	USD	53.15	USD	1,346	(2,317)
Motorola Solutions, Inc.	214	07/20/18	USD	110.00	USD	2,490	(150,335)
Motorola Solutions, Inc.	429	07/20/18	USD	115.00	USD	4,992	(126,555)
NextEra Energy, Inc.	247	07/20/18	USD	166.25	USD	4,126	(71,079)
NextEra Energy, Inc.	83	07/20/18	USD	165.00	USD	1,386	(29,880)
Nielsen Holdings PLC	570	07/20/18	USD	32.00	USD	1,763	(12,825)
Northrop Grumman Corp.	73	07/20/18	USD	340.00	USD	2,246	(1,460)
Novo Nordisk A/S ADR	352	07/20/18	USD	48.90	USD	1,623	(6,655)
ONEOK, Inc.	138	07/20/18	USD	70.00	USD	964	(17,940)
Oracle Corp.	818	07/20/18	USD	48.00	USD	3,604	(2,454)
Pepsico, Inc.	112	07/20/18	USD	102.95	USD	1,219	(69,128)
Pfizer, Inc.	821	07/20/18	USD	36.00	USD	2,979	(56,239)
Pfizer, Inc.	894	07/20/18	USD	35.00	USD	3,243	(132,312)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Pfizer, Inc.	736	07/20/18	USD	37.00	USD	2,670	(14,352)
Philip Morris International, Inc.	349	07/20/18	USD	85.00	USD	2,818	(22,685)
Procter & Gamble Co.	220	07/20/18	USD	76.00	USD	1,717	(55,000)
QUALCOMM, Inc.	605	07/20/18	USD	62.50	USD	3,395	(11,495)
Quest Diagnostics, Inc.	216	07/20/18	USD	106.90	USD	2,375	(81,583)
SunTrust Banks, Inc.	235	07/20/18	USD	70.00	USD	1,551	(6,815)
Suncor Energy, Inc.	534	07/20/18	USD	40.00	USD	2,172	(73,158)
TOTAL SA ADR	530	07/20/18	USD	62.50	USD	3,210	(18,550)
Taiwan Semiconductor							
Manufacturing Co. Ltd. ADR	1,030	07/20/18	USD	41.00	USD	3,766	(10,300)
Travelers Cos., Inc.	272	07/20/18	USD	135.00	USD	3,328	(2,720)
Travelers Cos., Inc.	276	07/20/18	USD	130.00	USD	3,377	(11,730)
U.S. Bancorp	189	07/20/18	USD	51.50	USD	945	(6,993)
Unilever NV NY Shares	639	07/20/18	USD	57.50	USD	3,561	(19,170)
Union Pacific Corp.	120	07/20/18	USD	150.00	USD	1,700	(7,500)
Verizon Communications, Inc.	477	07/20/18	USD	50.00	USD	2,400	(38,160)
Wells Fargo & Co.	540	07/20/18	USD	55.00	USD	2,994	(85,320)
Williams Cos., Inc.	369	07/20/18	USD	28.00	USD	1,000	(7,933)
FirstEnergy Corp.	238	07/24/18	USD	34.75	USD	855	(37,581)
Public Service Enterprise Group,							
Inc.	514	07/24/18	USD	52.01	USD	2,783	(119,901)
CDW Corp.	366	07/25/18	USD	79.65	USD	2,957	(105,402)
Nextera Energy, Inc.	247	07/25/18	USD	156.00	USD	4,126	(280,248)
Aetna, Inc.	150	07/27/18	USD	185.00	USD	2,753	(41,625)
American International Group, Inc.	289	07/27/18	USD	56.00	USD	1,532	(5,057)
Anthem, Inc.	131	07/27/18	USD	235.00	USD	3,118	(108,730)

SCHEDULES OF INVESTMENTS 43

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	j	Exercise	N	otional	
Description	Contracts	Date		Price	Amour	ıt (000)	Value
Call (continued)							
Bank of America Corp.	823	07/27/18	USD	31.00	USD	2,320	\$ (7,818)
Cardinal Health, Inc.	303	07/27/18	USD	55.00	USD	1,480	(6,817)
Charles Schwab Corp.	196	07/27/18	USD	58.00	USD	1,002	(1,960)
Chevron Corp.	177	07/27/18	USD	127.00	USD	2,238	(49,560)
Cisco Systems, Inc.	215	07/27/18	USD	45.00	USD	925	(4,515)
Citigroup, Inc.	538	07/27/18	USD	70.00	USD	3,600	(37,391)
Citigroup, Inc.	139	07/27/18	USD	67.50	USD	930	(22,171)
Comcast Corp., Class A	241	07/27/18	USD	33.00	USD	791	(27,836)
Devon Energy Corp.	455	07/27/18	USD	44.00	USD	2,000	(79,625)
Devon Energy Corp.	99	07/27/18	USD	45.50	USD	435	(10,741)
Devon Energy Corp.	353	07/27/18	USD	45.00	USD	1,552	(45,361)
DowDuPont, Inc.	144	07/27/18	USD	72.00	USD	949	(1,656)
DowDuPont, Inc.	204	07/27/18	USD	67.50	USD	1,345	(20,298)
DowDuPont, Inc.	51	07/27/18	USD	66.50	USD	336	(7,344)
Enterprise Products Partners LP	1,264	07/27/18	USD	29.00	USD	3,497	(15,800)
General Electric Co.	1,316	07/27/18	USD	14.50	USD	1,791	(22,372)
General Electric Co.	122	07/27/18	USD	14.00	USD	166	(3,904)
Honeywell International, Inc.	460	07/27/18	USD	152.50	USD	6,626	(22,540)
International Paper Co.	149	07/27/18	USD	59.00	USD	776	(1,341)
JPMorgan Chase & Co.	473	07/27/18	USD	112.00	USD	4,929	(19,156)
KeyCorp	855	07/27/18	USD	21.50	USD	1,671	(11,970)
Lockheed Martin Corp.	52	07/27/18	USD	310.00	USD	1,536	(15,470)
Lowe s Cos., Inc.	150	07/27/18	USD	101.00	USD	1,434	(7,200)
Marathon Oil Corp.	269	07/27/18	USD	22.00	USD	561	(12,643)
Marsh & McLennan Cos., Inc.	598	07/27/18	USD	82.60	USD	4,902	(57,753)
Mattel, Inc.	1,479	07/27/18	USD	19.00	USD	2,429	(162,690)
Medtronic PLC	170	07/27/18	USD	86.50	USD	1,455	(16,830)
Merck & Co., Inc.	537	07/27/18	USD	63.50	USD	3,260	(25,239)
MetLife, Inc.	1,274	07/27/18	USD	48.00	USD	5,555	(14,014)
Microsoft Corp.	201	07/27/18	USD	103.00	USD	1,982	(22,713)
Microsoft Corp.	180	07/27/18	USD	101.00	USD	1,775	(32,850)
Morgan Stanley	731	07/27/18	USD	53.00	USD	3,465	(8,772)
Motorola Solutions, Inc.	215	07/27/18	USD	112.00	USD	2,502	(123,124)
ONEOK, Inc.	276	07/27/18	USD	70.00	USD	1,927	(42,780)
Oracle Corp.	278	07/27/18	USD	49.00	USD	1,225	(1,390)
PepsiCo, Inc.	248	07/27/18	USD	106.00	USD	2,700	(101,680)
Pfizer, Inc.	1,535	07/27/18	USD	37.00	USD	5,569	(41,445)
Pfizer, Inc.	299	07/27/18	USD	36.50	USD	1,085	(14,501)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Royal Dutch Shell PLC ADR,							
Class A	783	07/27/18	USD	71.00	USD	5,421	(62,640)
Suncor Energy, Inc.	2,098	07/27/18	USD	40.00	USD	8,535	(339,876)
U.S. Bancorp	241	07/27/18	USD	52.00	USD	1,205	(7,953)
Union Pacific Corp.	126	07/27/18	USD	146.00	USD	1,785	(24,759)
UnitedHealth Group, Inc.	173	07/27/18	USD	255.00	USD	4,244	(42,472)
Verizon Communications, Inc.	157	07/27/18	USD	50.00	USD	790	(16,720)
Verizon Communications, Inc.	675	07/27/18	USD	49.00	USD	3,396	(113,738)
Wells Fargo & Co.	245	07/27/18	USD	56.50	USD	1,358	(24,255)
Williams Cos., Inc.	251	07/27/18	USD	28.00	USD	680	(7,279)
Pfizer, Inc.	295	07/30/18	USD	36.75	USD	1,070	(12,902)
Pfizer, Inc.	591	07/30/18	USD	36.50	USD	2,144	(28,692)
Travelers Cos., Inc.	277	07/30/18	USD	133.00	USD	3,389	(10,994)
Bank of America Corp.	244	07/31/18	USD	30.25	USD	688	(5,115)
Cisco Systems, Inc.	337	07/31/18	USD	44.60	USD	1,450	(11,393)
FirstEnergy Corp.	366	07/31/18	USD	34.75	USD	1,314	(61,595)
Kellogg Co.	362	07/31/18	USD	67.00	USD	2,529	(150,416)
Altria Group, Inc.	423	08/03/18	USD	58.50	USD	2,402	(39,339)
Anthem, Inc.	144	08/03/18	USD	242.50	USD	3,428	(74,520)
Bank of America Corp.	912	08/03/18	USD	30.00	USD	2,571	(23,256)
Bank of America Corp.	274	08/03/18	USD	29.00	USD	772	(15,344)
Citigroup, Inc.	1,162	08/03/18	USD	68.50	USD	7,776	(165,585)
Comcast Corp., Class A	254	08/03/18	USD	34.00	USD	833	(21,336)
Devon Energy Corp.	507	08/03/18	USD	43.50	USD	2,229	(127,257)
General Electric Co.	461	08/03/18	USD	13.50	USD	627	(27,660)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Ε	Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	at (000)	Value
Call (continued)							
General Electric Co.	663	08/03/18	USD	15.00	USD	902	\$ (7,624)
International Paper Co.	176	08/03/18	USD	54.50	USD	917	(14,256)
JPMorgan Chase & Co.	305	08/03/18	USD	110.00	USD	3,178	(26,535)
JPMorgan Chase & Co.	217	08/03/18	USD	111.00	USD	2,261	(14,864)
Lowe s Cos., Inc.	139	08/03/18	USD	99.00	USD	1,328	(15,637)
Medtronic PLC	361	08/03/18	USD	86.50	USD	3,091	(43,140)
Microsoft Corp.	360	08/03/18	USD	102.00	USD	3,550	(59,940)
Morgan Stanley	161	08/03/18	USD	52.00	USD	763	(4,186)
Northrop Grumman Corp.	73	08/03/18	USD	317.50	USD	2,246	(43,070)
Oracle Corp.	493	08/03/18	USD	44.00	USD	2,172	(50,286)
Pfizer, Inc.	751	08/03/18	USD	36.50	USD	2,725	(45,436)
Procter & Gamble Co.	190	08/03/18	USD	78.50	USD	1,483	(26,125)
Suncor Energy, Inc.	727	08/03/18	USD	41.00	USD	2,957	(88,331)
Verizon Communications, Inc.	1,181	08/03/18	USD	50.00	USD	5,942	(137,587)
Wells Fargo & Co.	572	08/03/18	USD	55.00	USD	3,171	(103,246)
Novo Nordisk A/S ADR	339	08/06/18	USD	45.01	USD	1,563	(66,474)
SunTrust Banks, Inc.	528	08/06/18	USD	68.30	USD	3,486	(57,480)
UnitedHealth Group, Inc.	140	08/09/18	USD	255.00	USD	3,435	(50,622)
American International Group, Inc.	145	08/10/18	USD	55.00	USD	769	(12,832)
Anadarko Petroleum Corp.	129	08/10/18	USD	76.50	USD	945	(24,188)
Bank of America Corp.	989	08/10/18	USD	30.10	USD	2,788	(29,699)
Bank of America Corp.	1,142	08/10/18	USD	29.01	USD	3,219	(69,751)
CVS Health Corp.	283	08/10/18	USD	66.50	USD	1,821	(47,120)
Comcast Corp., Class A	587	08/10/18	USD	33.50	USD	1,926	(68,092)
Devon Energy Corp.	353	08/10/18	USD	46.00	USD	1,552	(54,892)
DowDuPont, Inc.	260	08/10/18	USD	66.00	USD	1,714	(60,450)
FirstEnergy Corp.	367	08/10/18	USD	33.75	USD	1,318	(86,915)
General Electric Co.	265	08/10/18	USD	14.00	USD	361	(10,865)
Hess Corp.	915	08/10/18	USD	70.50	USD	6,120	(161,955)
JPMorgan Chase & Co.	386	08/10/18	USD	108.25	USD	4,022	(59,311)
Mattel, Inc.	287	08/10/18	USD	17.00	USD	471	(25,113)
McKesson Corp.	124	08/10/18	USD	138.00	USD	1,654	(47,120)
Medtronic PLC	361	08/10/18	USD	87.00	USD	3,091	(42,598)
MetLife, Inc.	1,448	08/10/18	USD	44.00	USD	6,313	(187,516)
Microsoft Corp.	181	08/10/18	USD	102.00	USD	1,785	(33,847)
Morgan Stanley	806	08/10/18	USD	50.00	USD	3,820	(55,614)
Oracle Corp.	1,550	08/10/18	USD	45.10	USD	6,829	(100,682)
PG&E Corp.	350	08/10/18	USD	44.00	USD	1,490	(91,000)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Pfizer, Inc.	592	08/10/18	USD	36.50	USD	2,148	(38,480)
QUALCOMM, Inc.	441	08/10/18	USD	58.00	USD	2,475	(78,498)
U.S. Bancorp	1,006	08/10/18	USD	50.00	USD	5,032	(137,319)
Union Pacific Corp.	110	08/10/18	USD	142.00	USD	1,558	(47,300)
Verizon Communications, Inc.	620	08/10/18	USD	52.00	USD	3,119	(31,620)
Wells Fargo & Co.	483	08/10/18	USD	58.00	USD	2,678	(31,154)
3M Co.	119	08/17/18	USD	210.00	USD	2,341	(21,658)
AXA Equitable Holdings, Inc.	465	08/17/18	USD	22.50	USD	958	(11,625)
Altria Group, Inc.	633	08/17/18	USD	59.20	USD	3,595	(65,290)
American International Group, Inc.	1,231	08/17/18	USD	57.50	USD	6,527	(32,622)
Bank of America Corp.	823	08/17/18	USD	31.00	USD	2,320	(16,048)
Bank of America Corp.	1,142	08/17/18	USD	29.00	USD	3,219	(78,227)
CVS Health Corp.	120	08/17/18	USD	72.50	USD	772	(5,580)
Cardinal Health, Inc.	289	08/17/18	USD	55.00	USD	1,411	(17,340)
Charles Schwab Corp.	32	08/17/18	USD	55.00	USD	164	(2,160)
Chevron Corp.	166	08/17/18	USD	130.00	USD	2,099	(38,595)
Cisco Systems, Inc.	137	08/17/18	USD	44.00	USD	590	(14,248)
Citigroup, Inc.	309	08/17/18	USD	67.50	USD	2,068	(61,800)
Cognizant Technology Solutions							
Corp., Class A	206	08/17/18	USD	80.00	USD	1,627	(48,410)
Comcast Corp., Class A	1,004	08/17/18	USD	35.00	USD	3,294	(69,778)
Devon Energy Corp.	244	08/17/18	USD	42.00	USD	1,073	(90,890)
Devon Energy Corp.	99	08/17/18	USD	46.00	USD	435	(16,978)
DowDuPont, Inc.	51	08/17/18	USD	70.00	USD	336	(4,437)
DowDuPont, Inc.	102	08/17/18	USD	67.50	USD	672	(17,697)

Schedules of Investments 45

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call (continued)					
Dr. Pepper Snapple Group, Inc.	424	08/17/18	USD 120.00	USD 5,173	\$ (125,080)
Enterprise Products Partners LP	1,264	08/17/18	USD 29.00	USD 3,497	(25,280)
FirstEnergy Corp.	468	08/17/18	USD 36.00	USD 1,681	(43,290)
General Electric Co.	406	08/17/18	USD 15.00	USD 553	(6,699)
Honeywell International, Inc.	113	08/17/18	USD 148.75	USD 1,628	(21,857)
Humana, Inc.	41	08/17/18	USD 300.00	USD 1,220	(38,335)
Humana, Inc.	69	08/17/18	USD 305.00	USD 2,054	(48,645)
International Paper Co.	177	08/17/18	USD 55.00	USD 922	(14,425)
Interpublic Group of Cos., Inc.	769	08/17/18	USD 24.00	USD 1,803	(61,520)
JPMorgan Chase & Co.	686	08/17/18	USD 115.00	USD 7,148	(32,928)
Kellogg Co.	116	08/17/18	USD 68.75	USD 810	(38,802)
KeyCorp	994	08/17/18	USD 20.45	USD 1,942	(36,752)
Kroger Co.	353	08/17/18	USD 30.00	USD 1,004	(16,414)
Lockheed Martin Corp.	52	08/17/18	USD 315.00	USD 1,536	(17,420)
Lowe s Cos., Inc.	144	08/17/18	USD 97.50	USD 1,376	(30,528)
Marathon Oil Corp.	42	08/17/18	USD 22.00	USD 88	(3,381)
Marathon Oil Corp.	269	08/17/18	USD 23.00	USD 561	(13,853)
Marathon Petroleum Corp.	271	08/17/18	USD 72.50	USD 1,901	(59,620)
Mattel, Inc.	144	08/17/18	USD 18.00	USD 236	(8,280)
McKesson Corp.	124	08/17/18	USD 140.00	USD 1,654	(38,750)
Medtronic PLC	186	08/17/18	USD 87.50	USD 1,592	(21,111)
Merck & Co., Inc.	335	08/17/18	USD 62.50	USD 2,033	(38,358)
Merck & Co., Inc.	537	08/17/18	USD 65.00	USD 3,260	(24,434)
MetLife, Inc.	451	08/17/18	USD 47.50	USD 1,966	(12,177)
Microsoft Corp.	159	08/17/18	USD 105.00	USD 1,568	(17,808)
Morgan Stanley	303	08/17/18	USD 51.75	USD 1,436	(12,875)
Northrop Grumman Corp.	84	08/17/18	USD 335.00	USD 2,585	(20,370)
ONEOK, Inc.	138	08/17/18	USD 70.00	USD 964	(27,255)
Oracle Corp.	877	08/17/18	USD 44.00	USD 3,864	(110,064)
Pfizer, Inc.	751	08/17/18	USD 37.00	USD 2,725	(34,546)
Procter & Gamble Co.	410	08/17/18	USD 77.50	USD 3,200	(87,535)
Quest Diagnostics, Inc.	216	08/17/18	USD 106.90	USD 2,375	(107,635)
SunTrust Banks, Inc.	118	08/17/18	USD 72.50	USD 779	(4,248)
Suncor Energy, Inc.	534	08/17/18	USD 41.00	USD 2,172	(77,430)
TOTAL SA ADR	530	08/17/18	USD 62.50	USD 3,210	(51,675)
Taiwan Semiconductor					
Manufacturing Co. Ltd. ADR	514	08/17/18	USD 39.50	USD 1,879	(20,770)
U.S. Bancorp	283	08/17/18	USD 52.50	USD 1,416	(13,301)

Unilever NV NY Shares	638	08/17/18	USD	55.00	USD	3,555	(108,460)
Verizon Communications, Inc.	952	08/17/18	USD	49.00	USD	4,790	(187,068)
Wells Fargo & Co.	572	08/17/18	USD	55.00	USD	3,171	(113,828)
Williams Cos., Inc.	251	08/17/18	USD	28.00	USD	680	(13,303)
UnitedHealth Group, Inc.	140	08/20/18	USD	255.00	USD	3,435	(62,596)
Public Service Enterprise Group,							
Inc.	421	08/22/18	USD	54.05	USD	2,279	(65,209)
Edison International	281	08/27/18	USD	63.25	USD	1,778	(59,496)
Wells Fargo & Co. Williams Cos., Inc. UnitedHealth Group, Inc. Public Service Enterprise Group, Inc.	572 251 140 421	08/17/18 08/17/18 08/20/18 08/22/18	USD USD USD	55.00 28.00 255.00 54.05	USD USD USD	3,171 680 3,435 2,279	(113,8: (13,3: (62,5: (65,2:

\$ (13,659,306)

## **OTC Options Written**

46

Description Call	Counterparty	Number of Contracts	Expiration Date	i	Exercise Price		Notional nt (000)	Value
Suncor								
Energy, Inc.	Citibank N.A.	123,300	07/09/18	USD	38.95	USD	5,016	\$ (231,820)
BP PLC	Goldman Sachs International	88,400	07/10/18	GBP	5.83	GBP	510	(6,593)
Bayer AG,		,						
Registered								
Shares	Credit Suisse International	19,917	07/10/18	EUR	102.39	EUR	1,873	(572)
Constellation								
Software,								
Inc.	Citibank N.A.	7,700	07/10/18	CAD	981.42	CAD	7,850	(240,823)
Diageo PLC	Goldman Sachs International	28,400	07/10/18	GBP	26.86	GBP	773	(22,641)
AstraZeneca								
PLC	Morgan Stanley & Co. International PLC	99,800	07/11/18	GBP	54.55	GBP	5,231	(14,525)
CRH PLC	UBS AG	72,500	07/11/18	GBP	28.27	GBP	1,927	(911)
Experian								
PLC	Credit Suisse International	121,000	07/11/18	GBP	19.04	GBP	2,261	(20,653)
Koninklijke								
Philips N.V.	Morgan Stanley & Co. International PLC	222,400	07/12/18	EUR	37.12	EUR	8,069	(62,386)
Lenovo								
Group Ltd.	UBS AG	3,306,000	07/12/18	HKD	3.96	HKD	13,951	(111,388)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **OTC Options Written (continued)**

Description	Counterparty	Number of Contracts	Expiration Date		Exercise Price		Totional at (000)	Value
Call	Counterparty	Communicis	Bute		17166	111110111	<i>ii</i> (000)	, and
(continued)								
Public								
Service								
Enterprise								
Group, Inc.	Bank of America N.A.	125,200	07/16/18	USD	53.44	USD	6,778	\$ (137,595)
BCE, Inc.	Barclays Bank PLC	36,100	07/17/18	USD	41.90	USD	1,462	(3,955)
AstraZeneca								
PLC	Goldman Sachs International	33,000	07/18/18	GBP	54.00	GBP	1,730	(14,138)
CRH PLC	Morgan Stanley & Co. International PLC	25,500	07/18/18	GBP	28.61	GBP	678	(577)
Danone SA	Credit Suisse International	29,300	07/18/18	EUR	65.87	EUR	1,832	(2,155)
Diageo PLC	Goldman Sachs International	56,350	07/18/18	GBP	27.45	GBP	1,534	(27,917)
Experian		101.000	07/10/10	CDD	10.00	CDD	2 202	(40.211)
PLC	Goldman Sachs International	181,000	07/18/18	GBP	19.09	GBP	3,383	(40,311)
Diageo PLC BP PLC	Goldman Sachs International Citibank N.A.	44,600	07/25/18 07/26/18	GBP	27.90	GBP	1,214	(14,539)
CRH PLC	Citibank N.A.	1,175,000 36,000	07/26/18	GBP GBP	5.96 29.14	GBP GBP	6,780 957	(81,367)
Koninklijke	Citibalik N.A.	30,000	07/20/18	GBF	29.14	GBF	937	(637)
Philips N.V.	Goldman Sachs International	135,800	07/26/18	EUR	37.04	EUR	4,927	(74,385)
Novo	Goldman Sachs International	133,000	07720710	LOK	37.04	LOK	7,721	(77,505)
Nordisk A/S								
ADR	Barclays Bank PLC	35,200	07/26/18	USD	45.41	USD	1,623	(53,392)
BP PLC	Barclays Bank PLC	1,176,000	07/27/18	GBP	5.86	GBP	6,786	(147,117)
Bayer AG,	,	, ,					,	, , ,
Registered								
Shares	UBS AG	30,500	07/27/18	EUR	103.22	EUR	2,868	(7,642)
TOTAL SA								
ADR	Barclays Bank PLC	31,700	07/31/18	USD	61.39	USD	1,920	(35,273)
Samsung								
Electronics								
Co. Ltd.								
GDR	UBS AG	5,000	08/02/18	USD	1,158.42	USD	5,186	(34,431)
AstraZeneca				~		~		(54.40.5)
PLC	Goldman Sachs International	35,500	08/08/18	GBP	52.35	GBP	1,861	(64,406)
BP PLC	Goldman Sachs International	89,200	08/08/18	GBP	5.85	GBP	515	(15,777)
Diageo PLC	Morgan Stanley & Co. International PLC	124,500	08/08/18	GBP	27.03	GBP	3,389	(136,100)
CRH PLC	UBS AG	59,900	08/09/18	GBP	28.20	GBP	1,592	(12,848)
Charles Schwab	Citibank N.A.	46,900	08/14/18	USD	57.40	USD	2,397	(12,798)
Schwab								

Corp.

\$ (1,629,672)

#### Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap								
	Premium	Premium	Unrealized	Unrealized						
	Paid	Received	Appreciation	Depreciation	Value					
Options Written	N/A	N/A	\$ 6,136,175	\$ (3,917,018)	\$ (15,288,978)					
Derivative Financial Instruments Categorized by Risk Exposure										

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodit	y Credit			•	v Interes			
	Contract	<b>S</b> Contracts	C	ContractsCo	ontracts	Contract.	<b>C</b> ontracts		Total
Assets Derivative Financia	al								
Instruments									
Options purchased									
Investments at value									
unaffiliated <sup>(a)</sup>	\$	\$	\$	3,770	\$	\$	\$	\$	3,770
<b>Liabilities Derivative Fina Instruments</b> Options written	ncial								
Options written, at value	\$	\$	\$ 15	,288,978	\$	\$	\$	\$ 15	,288,978

				Ì	Foreign	!			
				C	urrency	Interest			
	Commodity	Credit		Equity Ex	change	Rate	Other		
	Contracts C	ontracts	$C\alpha$	ontracts Co	ontracts	ContractsC	Contracts		Total
Net Realized Gain (Loss)									
from:									
Options purchased(a)	\$	\$	\$	(10,020)	\$	\$	\$	\$	(10,020)
Options written			(9,6	659,803)				(9	9,659,803)

<sup>&</sup>lt;sup>(a)</sup> Includes options purchased at value as reported in the Schedule of Investments. For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

\$ \$ (9,669,823) \$ \$ \$ (9,669,823)

(a) Options purchased are included in net realized gain (loss) from investments.

Schedules of Investments 47

**BlackRock Enhanced Equity Dividend Trust (BDJ)** 

June 30, 2018

	Commodity Contracts (	Credit Contracts		<i>Equity E</i>	0	y Interest		Total
Net Change in Unrealized Appreciation on: Options purchased(a) Options written	\$	\$	\$ 6,3	575 23,305	\$	\$	\$ \$ 6,3	575 323,305
	\$	\$	\$ 6,3	23,880	\$	\$	\$ \$ 6,3	323,880

#### Options:

Average value of option contracts purchased

\$ 3,218

Average value of option contracts written

\$13,467,680

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) were as follows:

	Assets	Liabilities
Derivative Financial Instruments: Options	\$ 3,770 <sup>(a)</sup>	\$ 15,288,978
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA )	(3,770)	(13,659,306)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,629,672

<sup>(</sup>a) Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

<sup>(</sup>a) Options purchased are included in net change in unrealized appreciation (depreciation) from investments. Average Quarterly Balances of Outstanding Derivative Financial Instruments

	Deri	vative						
	Lial	oilities					Ne	et Amount
	Sub	ject to	Derivatives	Non-	cash	Cash	of $I$	Derivative
	an M	NA by	Available	Collai	teral	Collateral	J	iabilities
Counterparty	Counte	rparty	for Offset	Pledge	ed (a)	Pledged		(b)
Bank of America N.A.	\$ 13	7,595	\$	\$		\$	\$	137,595
Barclays Bank PLC	23	9,737		(239	,737)			
Citibank N.A.	56	7,445		(567	,445)			
Credit Suisse International	2	23,380		(23	,380)			
Goldman Sachs International	28	30,707		(242	,630)			38,077
Morgan Stanley & Co.								
International PLC	21	3,588		(213	,588)			
UBS AG	16	57,220		(167	,220)			
	\$ 1,62	29,672	\$	\$ (1,454	,000)	\$	\$	175,672

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

48

<sup>(</sup>a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(</sup>b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

**BlackRock Enhanced Equity Dividend Trust (BDJ)** 

June 30, 2018

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Aerospace & Defense	\$ 20,362,289	\$	\$	\$ 20,362,289
Banks	320,396,021			320,396,021
Beverages	22,360,061	18,236,314		40,596,375
Capital Markets	61,773,184			61,773,184
Chemicals	20,782,269			20,782,269
Communications Equipment	30,150,420			30,150,420
Construction Materials		13,602,955		13,602,955
Containers & Packaging	7,067,256			7,067,256
Diversified Financial Services	5,630,652			5,630,652
Diversified Telecommunication Services	52,016,192			52,016,192
Electric Utilities	69,050,599			69,050,599
Electrical Equipment	2,740,669			2,740,669
Electronic Equipment, Instruments &				
Components	13,079,093			13,079,093
Food & Staples Retailing	12,412,451			12,412,451
Food Products	20,142,097	4,271,230		24,413,327
Health Care Equipment & Supplies	25,824,257	30,354,090		56,178,347
Health Care Providers & Services	156,160,600			156,160,600
Household Products	16,339,519			16,339,519
IT Services	6,522,994			6,522,994
Industrial Conglomerates	54,083,342			54,083,342
Insurance	112,395,166			112,395,166
Leisure Products	9,637,818			9,637,818
Machinery	4,594,715			4,594,715
Media	38,696,976			38,696,976
Multi-Utilities	23,682,460			23,682,460
Multiline Retail	5,382,278			5,382,278
Oil, Gas & Consumable Fuels	195,275,669	38,477,869		233,753,538
Personal Products	14,241,475			14,241,475
Pharmaceuticals	108,247,355	45,102,678		153,350,033

Professional Services	10,609,609	13,093,606	23,703,215
Road & Rail	11,869,950		11,869,950
Semiconductors & Semiconductor			
Equipment	32,156,822		32,156,822
Software	107,290,769		107,290,769
Specialty Retail	13,097,869		13,097,869
Technology Hardware, Storage &			
Peripherals		15,225,381	15,225,381
Tobacco	24,947,810		24,947,810
Short-Term Securities	13,793,172		13,793,172
Options Purchased:			
Equity Contracts	3,770		3,770
	\$ 1,642,817,648	\$ 178,364,123	\$ \$1,821,181,771
Investments Valued at NAV(a)			12,294
			\$ 1,821,194,065
Derivative Financial Instruments <sup>(b)</sup>			
Liabilities:			
Equity contracts	\$ (10,982,991)	\$ (4,305,987)	\$ \$ (15,288,978)

<sup>(</sup>a) As of June 30, 2018, certain of the Trust s Investments were fair valued using net asset value ( NAV ) per share and have been excluded from the fair value hierarchy.

During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedules of Investments 49

<sup>(</sup>b) Derivative financial instruments are options written, which are shown at value.

Schedule of Investments (unaudited)	BlackRock Enhanced Global Dividend Trust (BOE)			
June 30, 2018	(Percentages shown are based on Net Assets)			
Security Common Stocks 98.9%	Shares	Value		
Australia 5.4% Amcor Ltd. Ansell Ltd. Ensogo Ltd. <sup>(a)(b)</sup> Sonic Healthcare Ltd.	2,166,058 476,285 418,198 666,385	\$ 23,078,661 9,569,000 3 12,088,268 44,735,932		
Belgium 1.5% Anheuser-Busch InBev SA bpost SA	60,431 373,254	6,095,366 5,897,538		
Canada 6.7% Rogers Communications, Inc., Class B TELUS Corp.	541,683 815,027	11,992,904 25,727,522 28,952,011		
China 1.0% ANTA Sports Products Ltd.	1,514,000	54,679,533 7,983,785		
<b>Denmark 1.0%</b> Novo Nordisk A/S, Class B	186,453	8,612,368		
Finland 2.3% Kone OYJ, Class B	368,057	18,714,053		
France 4.4% Sanofi Schneider Electric SE	334,985 111,650	26,885,729 9,285,566		
Germany 2.2% Deutsche Post AG, Registered Shares	545,851	36,171,295 17,734,889		
India 1.0% Hero MotoCorp Ltd.	167,596	8,497,945		
<b>Ireland 1.5%</b> Medtronic PLC <sup>(c)</sup>	143,502	12,285,206		
Japan 1.0% Japan Tobacco, Inc.	310,500	8,677,361		

Netherlands 2.6%		
Heineken NV	111,338	11,154,782
Koninklijke Philips NV	237,749	10,072,937
Trommanghe 1 maps 1 ( )	237,713	10,072,937
		21,227,719
Singapore 2.7%		
DBS Group Holdings Ltd.	575,568	11,193,081
United Overseas Bank Ltd.	557,900	10,934,131
		22,127,212
Sweden 1.3%		
Svenska Handelsbanken AB, Class A	937,035	10,378,079
Switzerland 7.8%		
Switzerland 7.8% Nestle SA, Registered Shares	305,978	23,713,541
Novartis AG, Registered Shares	303,978	26,342,460
SGS SA, Registered Shares	5,218	13,865,236
505 5A, Registered Shares	3,210	15,605,250
		63,921,237
Taiwan 2.4%		, . ,
Far EasTone Telecommunications Co. Ltd.	2,705,000	6,987,454
Taiwan Semiconductor Manufacturing Co. Ltd.	1,796,000	12,753,528
		19,740,982
United Kingdom 14.4%		
AstraZeneca PLC	241,470	16,701,799
British American Tobacco PLC	447,851	22,559,764
Diageo PLC	384,545	13,815,128
Security	Shares	Value
United Kingdom (continued)	010.050 ф	10.262.626
GlaxoSmithKline PLC	910,852 \$	18,363,626
Imperial Brands PLC	626,898	23,281,806
Unilever PLC	427,866	23,635,512
		118,357,635
United States 39.7%		110,557,655
3M Co. (c)	75,958	14,942,458
AbbVie, Inc.(c)	95,833	8,878,927
Altria Group, Inc. (c)(d)	491,905	27,935,285
Cisco Systems, Inc. (c)(d)	573,725	24,687,387
Citizens Financial Group, Inc.(c)	167,555	6,517,889
Coca-Cola Co. <sup>(c)</sup>	589,989	25,876,943
FirstSun Capital Bancorp, (Acquired 3/10/14, cost \$5,461,692) <sup>(a)(e)</sup>	120,312	4,411,841
Genuine Parts Co.(c)	242,320	22,242,553
International Paper Co.(c)	303,694	15,816,384
Johnson & Johnson <sup>(c)(d)</sup>	250,145	30,352,594
M&T Bank Corp. (c)	69,614	11,844,822
Microsoft Corp.(c)	84,489	8,331,460
PepsiCo, Inc. (c)	199,047	21,670,247
Pfizer, Inc.(c)(d)	463,707	16,823,290

Philip Morris International, Inc. (c)(d)	219,915	17,755,937
Procter & Gamble Co. <sup>(c)</sup>	220,742	17,231,121
	•	
U.S. Bancorp <sup>(c)</sup>	249,836	12,496,797
United Parcel Service, Inc., Class B <sup>(c)</sup>	76,232	8,098,125
United Technologies Corp.(c)	138,181	17,276,770
Wells Fargo & Co.(c)	228,446	12,665,046
		325,855,876
Total Common Stocks 98.9%		323,033,070
		011 604 011
(Cost \$840,788,043)		811,694,011
Preferred Stocks 1.0%		
T 12 0.46		
India 0.1%		
Jasper Infotech Private Ltd., Series F, (Acquired 05/07/14,		
cost 1,895,230), 0.00%(a)(b)(e)	266	465,324
Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14,		
$\cos t 741,913), 0.00\%^{(a)(b)(e)}$	88	187,962
		,
		653,286
United States 0.9%		055,200
Palantir Technologies, Inc., Series I (Acquired 3/27/14,		
	£00 000	2 0 4 0 9 6 4
cost \$3,118,944), 0.00% <sup>(a)(b)(e)</sup>	508,800	2,940,864
Uber Technologies, Inc., Series D (Acquired 06/01/14,		
$cost $1,611,693), 0.00\%^{(a)(b)(e)}$	103,893	4,155,720
		7,096,584
Total Preferred Stocks 1.0%		
(Cost \$7,367,781)		7,749,870
		.,,
Total Long-Term Investments 99.9%		
(Cost \$848,155,824)		819,443,881
(Cost \$640,133,624)		017,773,001
<b>Total Investments Before Options Written 99.9%</b>		
(Cost \$848,155,824)		819,443,881
		, - , - ,
Options Written (0.8)%		
(Premiums Received \$6,227,625)		(6,213,872)
(1 Telliums Received \$0,227,023)		(0,213,672)
<b>Total Investments, Net of Options Written</b> 99.1%		
(Cost \$841,928,199)		813,230,009
Other Assets Less Liabilities 0.9%		7,377,581
		.,,
Net Assets 100.0%		\$ 820,607,590
100 / 2000 / 0		Ψ 020,001,370

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

- (a) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (b) Non-income producing security.
- (c) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (d) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- (e) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$12,167,736 and an original cost of \$7,367,780, which was 1.5% of its net assets.

During the year ended December 31, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

						Change
		Share	S			in
	Shares	Held	d Value		Λ	let Unrealized
	Held at	Net a	t at		Realiz	eAppreciation
Affiliate	12/31/17	Activity06/30/18	806/30/18	Inco <b>Gae</b> ir	ı (Loss)	<b>D</b> epreciation)
BlackRock Liquidity Funds,						
T-Fund, Institutional Class <sup>(a)</sup>	13,118,524	(13,118,524)	\$	\$ 56,205	\$	\$

#### **Derivative Financial Instruments Outstanding as of Period End**

#### **Exchange-Traded Options Written**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amoun	it (000)	Value
Call							
Pfizer, Inc.	18	07/02/18	USD	36.25	USD	65	\$ (358)
Cisco Systems, Inc.	314	07/06/18	USD	44.50	USD	1,351	(785)
Coca-Cola Co.	556	07/06/18	USD	44.00	USD	2,439	(12,788)
Genuine Parts Co.	151	07/06/18	USD	93.00	USD	1,386	(5,285)
International Paper Co.	181	07/06/18	USD	55.00	USD	943	(1,267)
International Paper Co.	93	07/06/18	USD	56.00	USD	484	(372)
Johnson & Johnson	344	07/06/18	USD	122.00	USD	4,174	(24,252)
Pfizer, Inc.	19	07/06/18	USD	36.00	USD	69	(845)
Pfizer, Inc.	104	07/06/18	USD	36.50	USD	377	(1,352)

<sup>(</sup>a) No longer held by the Trust.

<sup>(</sup>b) Includes net capital gain distributions, if applicable.

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

Pfizer, Inc.	38	07/06/18	USD	37.00	USD	138	(171)
U.S. Bancorp	245	07/06/18	USD	52.50	USD	1,225	(490)
U.S. Bancorp	34	07/06/18	USD	53.00	USD	170	(340)
United Technologies Corp.	245	07/06/18	USD	128.00	USD	3,063	(3,675)
Wells Fargo & Co.	103	07/06/18	USD	55.50	USD	571	(6,334)
Wells Fargo & Co.	175	07/06/18	USD	55.00	USD	970	(15,838)
Altria Group, Inc.	478	07/13/18	USD	57.50	USD	2,715	(26,529)
Cisco Systems, Inc.	598	07/13/18	USD	45.00	USD	2,573	(3,588)
Coca-Cola Co.	158	07/13/18	USD	44.00	USD	693	(6,320)
Genuine Parts Co.	180	07/13/18	USD	92.00	USD	1,652	(23,400)
Genuine Parts Co.	163	07/13/18	USD	95.50	USD	1,496	(2,852)
International Paper Co.	181	07/13/18	USD	55.50	USD	943	(1,900)
Medtronic PLC	110	07/13/18	USD	88.50	USD	942	(1,210)
Microsoft Corp.	76	07/13/18	USD	103.00	USD	749	(1,824)
Microsoft Corp.	82	07/13/18	USD	102.00	USD	809	(3,280)
PepsiCo, Inc.	6	07/13/18	USD	102.00	USD	65	(4,320)
Pfizer, Inc.	156	07/13/18	USD	36.50	USD	566	(4,446)
Pfizer, Inc.	39	07/13/18	USD	37.00	USD	141	(429)
Procter & Gamble Co.	306	07/13/18	USD	74.00	USD	2,389	(132,345)
U.S. Bancorp	101	07/13/18	USD	50.50	USD	505	(4,898)
U.S. Bancorp	34	07/13/18	USD	52.50	USD	170	(187)
U.S. Bancorp	147	07/13/18	USD	51.00	USD	735	(4,336)
U.S. Bancorp	73	07/13/18	USD	51.50	USD	365	(1,241)
Wells Fargo & Co.	93	07/13/18	USD	56.50	USD	516	(6,231)
Wells Fargo & Co.	175	07/19/18	USD	56.25	USD	970	(16,699)
3M Co.	234	07/20/18	USD	200.00	USD	4,603	(51,831)
AbbVie, Inc.	67	07/20/18	USD	100.00	USD	621	(1,440)
Altria Group, Inc.	620	07/20/18	USD	57.50	USD	3,521	(50,840)
Cisco Systems, Inc.	811	07/20/18	USD	45.00	USD	3,490	(11,354)
Cisco Systems, Inc.	361	07/20/18	USD	44.00	USD	1,553	(12,094)
Citizens Financial Group, Inc.	507	07/20/18	USD	42.95	USD	1,972	(3,791)
Coca-Cola Co.	557	07/20/18	USD	44.00	USD	2,443	(28,686)

SCHEDULES OF INVESTMENTS 51

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call (continued)					
Genuine Parts Co.	151	07/20/18	USD 92.50	USD 1,386	\$ (26,803)
Genuine Parts Co.	163	07/20/18	USD 97.50	USD 1,496	(4,482)
International Paper Co.	153	07/20/18	USD 57.50	USD 797	(918)
Johnson & Johnson	286	07/20/18	USD 125.00	USD 3,470	(24,310)
M&T Bank Corp.	164	07/20/18	USD 190.00	USD 2,790	(2,460)
M&T Bank Corp.	163	07/20/18	USD 180.00	USD 2,773	(11,410)
Medtronic PLC	167	07/20/18	USD 87.50	USD 1,430	(7,432)
Microsoft Corp.	88	07/20/18	USD 100.00	USD 868	(17,776)
PepsiCo, Inc.	225	07/20/18	USD 102.95	USD 2,450	(138,873)
Pfizer, Inc.	612	07/20/18	USD 36.00	USD 2,220	(41,922)
Pfizer, Inc.	253	07/20/18	USD 35.00	USD 918	(37,444)
Pfizer, Inc.	158	07/20/18	USD 37.00	USD 573	(3,081)
Philip Morris International, Inc.	316	07/20/18	USD 85.00	USD 2,551	(20,540)
Procter & Gamble Co.	57	07/20/18	USD 76.00	USD 445	(14,250)
Rogers Communications, Inc.,					
Class B	247	07/20/18	CAD 62.00	CAD 1,542	(21,794)
TELUS Corp.	127	07/20/18	CAD 46.00	CAD 584	(9,322)
U.S. Bancorp	146	07/20/18	USD 51.50	USD 730	(5,402)
United Parcel Service, Inc.	57	07/20/18	USD 120.00	USD 606	(256)
Wells Fargo & Co.	93	07/20/18	USD 55.00	USD 516	(14,694)
3M Co.	34	07/27/18	USD 200.00	USD 669	(12,835)
AbbVie, Inc.	158	07/27/18	USD 102.00	USD 1,464	(4,582)
Cisco Systems, Inc.	998	07/27/18	USD 45.00	USD 4,294	(20,958)
Coca-Cola Co.	751	07/27/18	USD 44.50	USD 3,294	(39,803)
International Paper Co.	66	07/27/18	USD 59.00	USD 344	(594)
Medtronic PLC	177	07/27/18	USD 86.50	USD 1,515	(17,523)
Microsoft Corp.	76	07/27/18	USD 103.00	USD 749	(8,588)
Microsoft Corp.	55	07/27/18	USD 101.00	USD 542	(10,038)
PepsiCo, Inc.	223	07/27/18	USD 106.00	USD 2,428	(91,430)
Pfizer, Inc.	320	07/27/18	USD 37.00	USD 1,161	(8,640)
Pfizer, Inc.	26	07/27/18	USD 36.50	USD 94	(1,261)
U.S. Bancorp	77	07/27/18	USD 52.00	USD 385	(2,541)
United Parcel Service, Inc., Class	B 301	07/27/18	USD 118.00	USD 3,198	(7,374)
United Technologies Corp.	112	07/27/18	USD 128.00	USD 1,400	(16,800)
Wells Fargo & Co.	42	07/27/18	USD 56.50	USD 233	(4,158)
Pfizer, Inc.	25	07/30/18	USD 36.75		(1,093)
Pfizer, Inc.	54	07/30/18	USD 36.50		(2,622)
Cisco Systems, Inc.	360	07/31/18	USD 44.60	USD 1,549	(12,170)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

AbbVie, Inc.	67	08/03/18	USD	95.50	USD	621	(12,596)
Altria Group, Inc.	3	08/03/18	USD	58.50	USD	17	(279)
•							, ,
International Paper Co.	400	08/03/18	USD	54.50	USD	2,083	(32,400)
Johnson & Johnson	122	08/03/18	USD	126.00	USD	1,480	(12,566)
Medtronic PLC	110	08/03/18	USD	86.50	USD	942	(13,145)
Microsoft Corp.	45	08/03/18	USD	102.00	USD	444	(7,493)
Pfizer, Inc.	151	08/03/18	USD	36.50	USD	548	(9,136)
Procter & Gamble Co.	216	08/03/18	USD	78.50	USD	1,686	(29,700)
Wells Fargo & Co.	150	08/03/18	USD	55.00	USD	832	(27,075)
Genuine Parts Co.	152	08/10/18	USD	93.00	USD	1,395	(25,840)
Medtronic PLC	110	08/10/18	USD	87.00	USD	942	(12,980)
Microsoft Corp.	55	08/10/18	USD	102.00	USD	542	(10,285)
Pfizer, Inc.	54	08/10/18	USD	36.50	USD	196	(3,510)
U.S. Bancorp	97	08/10/18	USD	50.00	USD	485	(13,241)
Wells Fargo & Co.	92	08/10/18	USD	58.00	USD	510	(5,934)
3M Co.	89	08/17/18	USD	210.00	USD	1,751	(16,198)
AbbVie, Inc.	158	08/17/18	USD	105.00	USD	1,464	(8,058)
Altria Group, Inc.	620	08/17/18	USD	59.20	USD	3,521	(63,949)
Coca-Cola Co.	750	08/17/18	USD	45.00	USD	3,290	(38,250)
Genuine Parts Co.	178	08/17/18	USD	95.00	USD	1,634	(28,035)
International Paper Co.	353	08/17/18	USD	55.00	USD	1,838	(28,770)
Johnson & Johnson	123	08/17/18	USD	125.00	USD	1,492	(22,017)
Microsoft Corp.	29	08/17/18	USD	105.00	USD	286	(3,248)
PepsiCo, Inc.	481	08/17/18	USD	105.00	USD	5,237	(263,348)
Pfizer, Inc.	152	08/17/18	USD	37.00	USD	551	(6,992)

52

**BlackRock Enhanced Global Dividend Trust (BOE)** 

June 30, 2018

## **Exchange-Traded Options Written (continued)**

Description	Number of Contracts	Expiration Date	j	Exercise Price		otional at (000)	Value
Call (continued)						, ,	
Philip Morris International, Inc.	534	08/17/18	USD	82.50	USD	4,312	\$ (113,742)
Procter & Gamble Co.	458	08/17/18	USD	77.50	USD	3,575	(97,783)
Rogers Communications, Inc.,							
Class B	750	08/17/18	CAD	64.00	CAD	4,683	(38,794)
TELUS Corp.	666	08/17/18	CAD	46.00	CAD	3,110	(65,605)
U.S. Bancorp	220	08/17/18	USD	52.50	USD	1,100	(10,340)
United Technologies Corp.	126	08/17/18	USD	125.00	USD	1,575	(46,305)
Wells Fargo & Co.	150	08/17/18	USD	55.00	USD	832	(29,850)

\$ (2,243,866)

## **OTC Options Written**

elecommincations

	Λ	Number of	Expiration		Exercise		Notional	
escription	Counterparty	Contracts	Date		Price	Amo	ount (000)	Value
all								
ELUS Corp.	Goldman Sachs International	7,641	07/09/18	CAD	46.27	CAD	357	\$ (3,616
BS Group Holdings	<b>S</b>							
td.	Deutsche Bank AG	68,000	07/10/18	SGD	29.99	SGD	1,802	(42
BS Group Holdings	<b>S</b>							
td.	Deutsche Bank AG	67,000	07/10/18	SGD	29.91	SGD	1,776	(49
iageo PLC	Goldman Sachs International	12,800	07/10/18	GBP	26.86	GBP	348	(10,204
ar EasTone								
elecommincations								
o. Ltd.	Goldman Sachs International	136,000	07/10/18	USD	75.75	USD	10,711	(13,329
eineken NV	UBS AG	24,000	07/10/18	EUR	86.63	EUR	2,059	(18,269
GS SA, Registered								
nares	Goldman Sachs International	1,300	07/10/18	CHF	2,577.54	CHF	3,421	(92,472
chneider Electric								
E	UBS AG	22,000	07/10/18	EUR	79.66	EUR	1,567	(131
oost SA	Credit Suisse International	15,800	07/10/18	EUR	17.43	EUR	214	(9
straZeneca PLC	UBS AG	69,200	07/11/18	GBP	55.20	GBP	3,627	(4,820
eutsche Post AG,								
egistered Shares	Goldman Sachs International	128,000	07/11/18	EUR	33.57	EUR	3,561	(37
ar EasTone	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD	77.89	USD	17,170	(8,820

o. Ltd.

oninkliika Dhilina								ļ
oninklijke Philips V	Morgan Stanley & Co. International PLC	112,000	07/11/18	EUR	36.27	EUR	4,063	(73,730
ovo Nordisk A/S,	Thorgan Summey as a second	* * , -	077-				÷ y -	(,
lass B	Goldman Sachs International	26,100	07/11/18	DKK	306.74	DKK	7,691	(3,329
ogers								ļ
ommunications,								ļ
c., Class B	Morgan Stanley & Co. International PLC	44,000	07/11/18	CAD	63.00	CAD	2,747	(15,666
nsell Ltd.	JPMorgan Chase Bank N.A.	24,200	07/12/18	AUD	26.93	AUD	657	(8,916
ritish American								ļ
obacco PLC	Citibank N.A.	210,900	07/12/18	GBP	39.09	GBP	8,050	(97,123
pan Tobacco, Inc.	Goldman Sachs International	41,200	07/12/18	JPY	3,040.60	JPY	127,477	(30,331
one OYJ, Class B	UBS AG	38,800	07/12/18	EUR	43.39	EUR	1,689	(38,679
ELUS Corp.	Citibank N.A.	32,400	07/13/18	CAD	46.34	CAD	1,513	(16,442
mcor Ltd.	Goldman Sachs International	256,000	07/18/18	AUD	13.88	AUD	3,686	(109,795
nheuser-Busch					22.00		- 160	
Bev SA	Morgan Stanley & Co. International PLC	28,500	07/18/18	EUR	83.88	EUR	2,462	(101,994
nsell Ltd.	Goldman Sachs International	27,000	07/18/18	AUD	26.80	AUD	733	(12,577
eutsche Post AG,					53.40		. 700	
egistered Shares	Credit Suisse International	64,000	07/18/18	EUR	33.48	EUR	1,780	(614
ar EasTone								ļ
elecommunications		:=== 200		~-	== 10	~-	20 4 44	·== 000
o. Ltd.	Goldman Sachs International	370,000	07/18/18	USD	77.13	USD	29,141	(22,892
nperial Brands PLC		65,400	07/18/18	GBP	26.85	GBP	1,840	(126,258
one OYJ, Class B	Credit Suisse International	46,000	07/18/18	EUR	43.47	EUR	2,003	(51,419
anofi	Morgan Stanley & Co. International PLC	28,150	07/18/18	EUR	65.82	EUR	1,935	(108,851
chneider Electric		2.500	274040		7674	~~ r rD	CO.E.	(600
E ~ ~	Barclays Bank PLC	8,500	07/18/18	EUR	76.74	EUR	605	(699
ELUS Corp.	Citibank N.A.	16,700	07/18/18	CAD	45.85	CAD	780	(13,682
nited Overseas		120,000	274040	~ ~ D	20.77	~ ~ D	2.711	(4.216
ank Ltd.	JPMorgan Chase Bank N.A.	139,000	07/18/18	SGD	28.67	SGD	3,711	(4,316
oost SA	Credit Suisse International	42,000	07/18/18	EUR	15.21	EUR	568	(748
NTA Sports	Control Control	206,000	07/10/10	TIVD	4470	TIVD	0.500	(16.272
roducts Ltd.	Goldman Sachs International	206,000	07/19/18	HKD	44.78	HKD	8,522	(16,373
ovartis AG,	Control Of Literational DLC	106 400	07/10/10	CHE	76.10	CHE	7.000	(70.052
egistered Shares	Morgan Stanley & Co. International PLC	106,400	07/19/18	CHF	76.10	CHF	7,982	(79,253
onic Healthcare	TIDG AG	C9 700	07/04/19	ATID	22.80	ATID	1 401	(45.027
td. nited Oversees	UBS AG	68,700	07/24/18	AUD	23.80	AUD	1,684	(45,937
nited Overseas	LIDG A.C.	122 200	07/24/18	CCD	20.32	SCD	2 202	(2.207
ank Ltd. NTA Sports	UBS AG	123,300	07/24/18	SGD	29.32	SGD	3,292	(2,207
NTA Sports roducts Ltd.	UBS AG	295,000	07/25/18	HKD	49.34	HKD	12 204	(6,819
nsell Ltd.	Morgan Stanley & Co. International PLC	33,500	07/25/18	AUD	49.34 26.66	AUD	12,204 910	(0,819)
iageo PLC	Goldman Sachs International	68,800	07/25/18	GBP	26.66	GBP	1,873	(22,428
lageo PLC laxoSmithKline	Goldman Sachs international	00,000	U//23/10	GDi	21.70	GDi	1,075	(22,420
LC	Citibank N.A.	99,900	07/25/18	GBP	15.50	GBP	1,526	(23,619
eineken NV	Deutsche Bank AG	28,300	07/25/18	EUR	15.50 87.76	EUR	1,526 2,428	(23,619)
one OYJ, Class B	UBS AG	28,300 12,000	07/25/18	EUR	87.76 42.77	EUR	2,428 522	(24,416)
estle SA,	UBS AG	12,000	U//23/10	EUK	42.11	EUK	344	(20,071
estie SA, egistered Shares	Morgan Stanley & Co. International PLC	73,000	07/25/18	CHF	76.40	CHF	5,603	(96,268
egistereu shares	UBS AG	61,600	07/25/18	DKK	308.50	DKK	18,153	(17,246
	UBS AG	01,000	01123110	DIXIX	300.30	DIXIX	10,133	(17,2-70

ovo Nordisk A/S, lass B								
anofi	UBS AG	58,100	07/25/18	EUR	67.27	EUR	3,993	(153,582
onic Healthcare								
td.	UBS AG	60,300	07/25/18	AUD	24.52	AUD	1,478	(21,816
venska								
andelsbanken AB,								
lass A	UBS AG	206,500	07/25/18	SEK	101.02	SEK	20,485	(35,170

SCHEDULES OF INVESTMENTS 53

**BlackRock Enhanced Global Dividend Trust (BOE)** 

June 30, 2018

## **OTC Options Written (continued)**

scription	Counterparty	Number of Contracts	Expiration Date		Exercise Price	Ami	Notional ount (000)	Valu
ll (continued)	Counterparty	Communicis	Duic		17100	21///	Juni (000)	v ain
LUS Corp. iwan	Citibank N.A.	29,200	07/25/18	CAD	46.49	CAD	1,364	\$ (15,35
miconductor anufacturing Co.								
d.	UBS AG	844,000	07/25/18	USD	228.60	USD	182,726	(29,47
ost SA VTA Sports	Deutsche Bank AG	24,200	07/25/18	EUR	16.07	EUR	327	(44
oducts Ltd.	JPMorgan Chase Bank N.A.	192,000	07/26/18	HKD	50.34	HKD	7,943	(2,94
ncor Ltd.	UBS AG	398,100	07/26/18	AUD	14.13	AUD	5,733	(126,21
sell Ltd. EasTone	Morgan Stanley & Co. International PLC	31,200	07/26/18	AUD	27.05	AUD	847	(13,32
lecommunications . Ltd. r EasTone	Citibank N.A.	297,000	07/26/18	USD	78.15	USD	23,392	(13,29
lecommunications								
. Ltd. vartis AG,	Goldman Sachs International	250,000	07/26/18	USD	78.76	USD	19,690	(8,65
gistered Shares	Morgan Stanley & Co. International PLC	18,250	07/26/18	CHF	75.85	CHF	1,369	(18,18
ilever PLC	Citibank N.A.	141,100	07/26/18	GBP	41.71	GBP	5,906	(174,67
LUS Corp.	Goldman Sachs International	24,300	07/27/18	CAD	46.23	CAD	1,135	(16,40
LUS Corp.	Goldman Sachs International	24,300	07/31/18	CAD	46.46	CAD	1,135	(14,33
sell Ltd. utsche Post AG,	Citibank N.A.	32,000	08/01/18	AUD	26.57	AUD	869	(24,55
gistered Shares	HSBC Bank PLC	64,500	08/01/18	EUR	28.30	EUR	1,794	(46,69
ne OYJ, Class B nic Healthcare	Credit Suisse International	46,000	08/01/18	EUR	43.47	EUR	2,003	(60,57
1.	Morgan Stanley & Co. International PLC	95,000	08/01/18	AUD	24.40	AUD	2,328	(38,38
LUS Corp.	Citibank N.A.	29,200	08/01/18	CAD	46.49	CAD	1,364	(18,65
ost SA gers	Credit Suisse International	59,400	08/01/18	EUR	15.15	EUR	804	(4,24
mmunications,	M C 1 0 C I d C 1DIC	55 400	00/02/10	CAD	(2.10	CAD	2.450	(55.61
., Class B LUS Corp. S SA, Registered	Morgan Stanley & Co. International PLC Goldman Sachs International	55,400 33,800	08/02/18 08/03/18	CAD CAD	62.10 47.00	CAD CAD	3,459 1,578	(55,61 (10,60
ares	UBS AG	1,100	08/07/18	CHF	2,574.49	CHF	2,895	(101,34
isell Ltd.	Citibank N.A.	32,000	08/08/18	AUD	26.57	AUD	869	(26,60
traZeneca PLC	Goldman Sachs International	44,300	08/08/18	GBP	52.35	GBP	2,322	(80,37
	UBS AG	135,000	08/08/18	SGD	27.16	SGD	3,578	(47,79

1								
S Group Holdings								
1. ageo PLC axoSmithKline	Morgan Stanley & Co. International PLC	99,500	08/08/18	GBP	27.03	GBP	2,708	(108,77
C	Morgan Stanley & Co. International PLC	328,200	08/08/18	GBP	15.25	GBP	5,015	(164,19
perial Brands PLC	- ·	155,000	08/08/18	GBP	27.66	GBP	4,362	(219,95
an Tobacco, Inc.	Goldman Sachs International	71,700	08/08/18	JPY	3,078.48	JPY	221,846	(57,42
ne OYJ, Class B	Credit Suisse International	30,100	08/08/18	EUR	43.32	EUR	1,311	(45,58
nofi nneider Electric	Morgan Stanley & Co. International PLC	71,100	08/08/18	EUR	69.52	EUR	4,887	(100,39)
	Morgan Stanley & Co. International PLC	22,000	08/08/18	EUR	71.59	EUR	1,567	(48,91)
nic Healthcare								
d.	JPMorgan Chase Bank N.A.	89,300	08/08/18	AUD	25.08	AUD	2,189	(20,59)
enska								1
ndelsbanken AB,								1
ass A	JPMorgan Chase Bank N.A.	234,000	08/08/18	SEK	98.45	SEK	23,213	(72,72)
ilever PLC	Goldman Sachs International	60,000	08/08/18	GBP	41.88	GBP	2,512	(61,67
LUS Corp.	Citibank N.A.	16,600	08/09/18	CAD	45.90	CAD	775	(16,22)
VTA Sports								
oducts Ltd.	Goldman Sachs International	215,000	08/10/18	HKD	41.32	HKD	8,895	(75,47)
isell Ltd. vartis AG,	Citibank N.A.	31,200	08/14/18	AUD	26.94	AUD	847	(21,10
gistered Shares stle SA,	Morgan Stanley & Co. International PLC	38,800	08/14/18	CHF	73.40	CHF	2,911	(113,21)
gistered Shares	Morgan Stanley & Co. International PLC	70,800	08/15/18	CHF	77.24	CHF	5,434	(92,45
LUS Corp.	Royal Bank of Canada	30,600	08/15/18	CAD	47.24	CAD	1,429	(14,75
ncor Ltd. izens Financial	JPMorgan Chase Bank N.A.	364,000	08/16/18	AUD	14.52	AUD	5,242	(82,60)
oup, Inc.	Morgan Stanley & Co. International PLC	28,000	08/20/18	USD	41.84	USD	1,089	(15,17
sell Ltd.	Morgan Stanley & Co. International PLC	12,800	08/22/18	AUD	27.62	AUD	348	(4,79
gers mmunications,								
., Class B	Citibank N.A.	55,400	08/28/18	CAD	62.50	CAD	3,459	(64,02
LUS Corp.	Royal Bank of Canada	59,000	08/29/18	CAD	46.70	CAD	2,755	(44,83
1								

\$ (3,970,00

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 1,779,580	\$ (1,765,827)	\$ (6,213,872)

**BlackRock Enhanced Global Dividend Trust (BOE)** 

June 30, 2018

#### **Derivative Financial Instruments Categorized by Risk Exposure**

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity	Credit		Foreigi Eurrency	y Interes	
	Contracts		Contracts C	0		 Total
Liabilities Derivative Financial Instruments						
Options written Options written at value	\$	\$	\$6,213,872	\$	\$	\$ \$ 6,213,872

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

					Foreign	ı			
				C	<i>'urrenc</i> y	Interest			
	Commodity	Credit		EquityEx	xchange	e Rate	Other		
	ContractsC	Contracts	Co	ntractsCo	ontracts	Contracts	Contracts		Total
Net Realized Gain (Loss) fro	m:								
Options purchased <sup>(a)</sup>	\$	\$	\$	(687)	\$	\$	\$	\$	(687)
Options written			2,305,969				2,305,969		
	\$	\$	\$ 2,3	05,282	\$	\$	\$	\$ 2,3	305,282
(a) Options purchased are incl	uded in net rea	lized gain	(loss)	from inv	estment	cs.			
Net Change in Unrealized Appreciation on:									

(63,217) \$

\$

\$

### **Average Quarterly Balances of Outstanding Derivative Financial Instruments**

\$

\$

Options:

Options written

Average value of option contracts purchased

\$ (a)

\$ (63,217)

Average value of option contracts written

\$5,532,778

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments:</b> Options	\$	\$ 6,213,872
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	<b>(</b> )	(2,243,866)
Total derivative assets and liabilities subject to an MNA	\$	\$ 3,970,006

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

Countain arti	Li Si an	ıbject to MNA by	Derivatives Available for	$C_{\epsilon}$	Jon-cash ollateral	Cash Collateral	Net Amount of Derivative Liabilities
Counterparty		terparty	Offset		edged (a)	Pledged	(b)
Barclays Bank PLC	\$	699	\$	\$	(699)	\$	\$
Citibank N.A.		525,371		(	(525,371)		
Credit Suisse International		163,196		(	(163,196)		
Deutsche Bank AG		24,952			(24,952)		
Goldman Sachs International		662,326		(	(662,326)		
HSBC Bank PLC		172,956					172,956
JPMorgan Chase Bank N.A.		192,104		(	(138,470)	(53,634)	
Morgan Stanley & Co.							
International PLC	1,	278,672		(1,	278,672)		

Schedules of Investments 55

<sup>(</sup>a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

**BlackRock Enhanced Global Dividend Trust (BOE)** 

June 30, 2018

	Subject to an MNA by	Derivatives Available for	Non-cash Collateral	Cash Collateral	Net Amount of Derivative Liabilities	
Counterparty  David Dark of Canada	Counterparty 50,592	Offset	Pledged (a)	Pledged	(b)	
Royal Bank of Canada UBS AG	\$ 59,582 890,148	\$	\$ (890,148)	<b>5</b>	\$ 59,582	
	\$ 3,970,006	\$	\$ (3,683,834)	\$ (53,634)	\$ 232,538	

### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 44,735,932	\$	\$ 44,735,932
Belgium	5,897,538	6,095,366		11,992,904
Canada	54,679,533			54,679,533
China		7,983,785		7,983,785
Denmark		8,612,368		8,612,368
Finland		18,714,053		18,714,053
France		36,171,295		36,171,295
Germany		17,734,889		17,734,889
India		8,497,945		8,497,945
Ireland	12,285,206			12,285,206
Japan		8,677,361		8,677,361
Netherlands		21,227,719		21,227,719
Singapore		22,127,212		22,127,212
Sweden		10,378,079		10,378,079
Switzerland		63,921,237		63,921,237

<sup>(</sup>a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(</sup>b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Taiwan United Kingdom United States Preferred Stocks	321,444,035	19,740,982 118,357,635	4,411,841 7,749,870	19,740,982 118,357,635 325,855,876 7,749,870
	\$ 394,306,312	\$ 412,975,858	\$12,161,711	\$ 819,443,881
Derivative Financial Instruments <sup>(a)</sup> Liabilities: Equity contracts	\$ (1,994,988)	\$ (4,218,884)	\$	\$ (6,213,872)

<sup>(</sup>a) Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into Level 1 <sup>(a)</sup>	Transfers out of Level 1 <sup>(a)</sup>	Transfers Into Level 2 <sup>(a)</sup>	Transfers out of Level 2 (a)
Assets:				
Long-Term Investments:				
Common Stocks	\$ 11,359,711	\$ 19,072,931	\$ 19,072,931	\$ 11,359,711

<sup>(</sup>a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

56

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

**BlackRock Enhanced Global Dividend Trust (BOE)** 

June 30, 2018

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

Common Preferred Stocks Stocks	Total
Assets:	
Opening Balance, as of December 31, 2017 \$4,411,841 \$11,646,491 \$16,0	058,332
Transfers into Level 3	
Transfers out of Level 3	
Accrued discounts/premiums	
Net realized gain (loss) 2,510,578 2,5	510,578
Net change in unrealized appreciation (depreciation) $^{(a)(b)}$ (1,662,515)	562,515)
Purchases	
Sales (4,744,684) (4,7	744,684)
Closing Balance, as of June 30, 2018 \$4,411,841 \$ 7,749,870 \$12,1	161,711
Net change in unrealized appreciation (depreciation) on	
investments still held at June 30, $2018^{(b)}$ \$ (1,662,515) \$ (1,662,515)	562,515)

<sup>(</sup>a) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee ) to determine the value of certain of the Trust s Level 3 investments as of period end.

						Weighted
						Average
				Ra	inge of	of
				unobse	ervableUno	bservable
	Value	Valuation A	App <b>khadi</b> servable Inputs	Inputs U	Itilized	Inputs
<b>Assets:</b>						
Common						
Stocks	\$ 4,411,841	Market	Tangible Book Value Multiple(a)		1.90x	
Preferred						
Stocks	7,749,870	Market	Revenue Multiple(a)	7.50x	14.50x	13.23x
			=			

<sup>(</sup>b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

Time to Exit<sup>(b)</sup>

Volatility<sup>(b)</sup>

Recent Transactions<sup>(a)</sup>

2.5 years

35%

\$12,161,711

- (a) Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.
- (b) Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See notes to financial statements.

SCHEDULES OF INVESTMENTS 57

Schedule of Investments (unaudited)	BlackRock Enhanced International Dividend Trust (BGY)				
June 30, 2018	(Percentages shown are based	on Net Assets)			
Security Common Stocks 98.7%	Shares	Value			
Australia 8.7% Amcor Ltd. Ansell Ltd. Sonic Healthcare Ltd.	3,033,685 657,064 816,976	\$ 32,322,952 13,201,015 14,819,998			
Belgium 2.3% Anheuser-Busch InBev SA bpost SA	82,168 506,122	60,343,965 8,287,867 7,996,897			
Canada 10.6% Rogers Communications, Inc., Class B TELUS Corp.	743,612 1,076,118	16,284,764 35,318,247 38,226,684			
China 1.8% ANTA Sports Products Ltd.	2,377,600	73,544,931 12,537,812			
<b>Denmark 1.7%</b> Novo Nordisk A/S, Class B	252,763	11,675,264			
Finland 3.8% Kone OYJ, Class B	521,612	26,521,638			
France 7.3% Sanofi Schneider Electric SE	459,696 164,273	36,894,971 13,662,050			
Germany 4.3% Deutsche Post AG, Registered Shares	928,368	50,557,021 30,162,999			
India 1.7% Hero MotoCorp Ltd.	225,738	11,446,031			
Japan 1.7% Japan Tobacco, Inc.	421,300	11,773,823			
Netherlands 4.3% Heineken NV Koninklijke Philips NV	149,488 347,780	14,976,972 14,734,724			

		29,711,696
Singapore 2.9%  DBS Group Holdings Ltd.	511 200	0.042.260
United Overseas Bank Ltd.	511,300 507,200	9,943,260 9,940,475
Clifted Overseas Balik Etd.	307,200	9,940,473
		19,883,735
Sweden 2.3%		
Svenska Handelsbanken AB, Class A	1,471,323	16,295,557
C 4 1 1 120 <i>m</i>		
Switzerland 13.0% Nestle SA, Registered Shares	430,668	33,377,116
Novartis AG, Registered Shares	486,345	36,841,085
SGS SA, Registered Shares	7,522	19,987,410
505 571, Registered onares	7,522	17,707,410
Taiwan 4.3%		90,205,611
Taiwan 4.3% Far EasTone Telecommunications Co. Ltd.	3,663,000	9,462,123
Taiwan Semiconductor Manufacturing Co. Ltd.	2,845,000	20,202,554
Tarwan Schneonadetor Manufacturing Co. Etc.	2,043,000	20,202,334
		29,664,677
United Kingdom 23.4%		
AstraZeneca PLC	310,495	21,476,063
British American Tobacco PLC	608,013	30,627,664
Diageo PLC	596,483	21,429,193
GlaxoSmithKline PLC	1,291,186	26,031,515
Imperial Brands PLC	850,881	31,600,110
Unilever PLC	562,299	31,061,652
		162,226,197
Security	Shares	Value
United States 4.6%	2	
3M Co. <sup>(a)</sup>	102,009 \$	20,067,210
Microsoft Corp.(a)	116,534	11,491,418
		31,558,628
Total Common Stocks 98.7%		
(Cost \$715,814,039)		684,394,349
(0000 47124011,0007)		00.,65.,6.5
Preferred Stocks 0.7%		
China 0.6%		
Xiaoju Kuaizhi, Inc., Series A-17		
(Acquired 7/28/15, cost \$2,106,332),		
0.00%(b)(c)(d)	76,800	3,911,424
	-,	, , ,
India 0.1%		
Jasper Infotech Private Ltd., Series F,		
(Acquired 5/7/14, cost \$2,835,730),		
$0.00\%^{(b)(c)(d)}$	398	696,237

Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost \$1,112,870),		
$0.00\%^{(b)(c)(d)}$	132	281,943
		978,180
Total Preferred Stocks 0.7% (Cost \$6,054,932)		4,889,604
Total Long-Term Investments 99.4% (Cost \$721,868,971)		689,283,953
<b>Short-Term Securities 0.1%</b> BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(e)(f)</sup>	943,659	943,659
Total Short-Term Securities 0.1% (Cost \$943,659)		943,659
Total Investments Before Options Written 99.5% (Cost \$722,812,630)		690,227,612
Options Written (0.8)% (Premiums Received \$5,304,238)		(5,608,380)
Total Investments, Net of Options Written 98.7% (Cost \$717,508,392) Other Assets Less Liabilities 1.3%		684,619,232 8,816,866
Net Assets 100.0%		\$ 693,436,098

<sup>(</sup>a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(</sup>b) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

<sup>(</sup>c) Non-income producing security.

<sup>(</sup>d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$4,889,604 and an original cost of \$6,054,935, which was 0.7% of its net assets.

<sup>(</sup>e) Annualized 7-day yield as of period end.

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

(e) During the period ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change
							in
	Shares		Shares			Λ	Ne <b>U</b> nrealized
	Held at	Net	Held at	Value at		Realiz	Aeplpreciation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inc <b>6mi</b> en	(Loss)	(Pepreciation)
BlackRock Liquidity Funds,							
T-Fund, Institutional Class	5,073,700	(4,130,041)	943,659	\$ 943,659	\$53,789	\$	\$

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

#### **Derivative Financial Instruments Outstanding as of Period End**

### **Exchange-Traded Options Written**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amour	t (000)	Value
Call							
Microsoft Corp.	100	07/06/18	USD	101.00	USD	986	\$ (2,250)
Microsoft Corp.	71	07/13/18	USD	103.00	USD	700	(1,704)
Microsoft Corp.	80	07/13/18	USD	102.00	USD	789	(3,200)
3M Co.	268	07/20/18	USD	200.00	USD	5,272	(59,362)
Rogers Communications, Inc.,							
Class B	819	07/20/18	CAD	62.00	CAD	5,114	(72,266)
TELUS Corp.	265	07/20/18	CAD	46.00	CAD	1,238	(19,452)
3M Co.	60	07/27/18	USD	210.00	USD	1,180	(5,940)
3M Co.	34	07/27/18	USD	200.00	USD	669	(12,835)
Microsoft Corp.	71	07/27/18	USD	103.00	USD	700	(8,023)
Microsoft Corp.	299	08/03/18	USD	102.00	USD	2,948	(49,783)
3M Co.	117	08/17/18	USD	210.00	USD	2,302	(21,294)
Microsoft Corp.	57	08/17/18	USD	105.00	USD	562	(6,384)
Rogers Communications, Inc.,							
Class B	970	08/17/18	CAD	64.00	CAD	6,057	(50,173)
TELUS Corp.	947	08/17/18	CAD	46.00	CAD	4,422	(93,285)

<sup>(</sup>a) Includes net capital gain distributions, if applicable.

\$ (405,951)

# **OTC Options Written**

	Λ	lumber of	Expiration		Exercise		Notional	
n	Counterparty	Contracts	Date		Price	Amo	ount (000)	
orp.	Goldman Sachs International	15,959	07/09/18	CAD	46.27	CAD	745	\$
p Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD	29.99	SGD	1,590	
p Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD	29.91	SGD	1,590	
C	Goldman Sachs International	77,900	07/10/18	GBP	26.86	GBP	2,120	
ne Telecommincations Co. Ltd.	Goldman Sachs International	109,000	07/10/18	USD	75.75	USD	8,585	
NV	UBS AG	45,000	07/10/18	EUR	86.63	EUR	3,861	
legistered Shares	Goldman Sachs International	1,300	07/10/18	CHF	2,577.54	CHF	3,421	
Electric SE	UBS AG	29,500	07/10/18	EUR	79.66	EUR	2,101	
	Credit Suisse International	34,200	07/10/18	EUR	17.43	EUR	463	
ca PLC	UBS AG	129,800	07/11/18	GBP	55.20	GBP	6,803	
Post AG, Registered Shares	Goldman Sachs International	143,000	07/11/18	EUR	33.57	EUR	3,978	
ne Telecommincations Co. Ltd.	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD	77.89	USD	17,170	
e Philips NV	Morgan Stanley & Co. International PLC	163,000	07/11/18	EUR	36.27	EUR	5,914	
lisk A/S, Class B	Goldman Sachs International	74,100	07/11/18	DKK	306.74	DKK	21,837	
mmunications, Inc., Class B	Morgan Stanley & Co. International PLC	25,900	07/11/18	CAD	63.00	CAD	1,617	
	JPMorgan Chase Bank N.A.	32,000	07/12/18	AUD	26.93	AUD	869	
ierican Tobacco PLC	Citibank N.A.	296,800	07/12/18	GBP	39.09	GBP	11,329	
rands PLC	UBS AG	113,000	07/12/18	GBP	29.02	GBP	3,180	
acco, Inc.	Goldman Sachs International	44,000	07/12/18	JPY	3,040.60	JPY	136,140	
, Class B	UBS AG	34,600	07/12/18	EUR	43.39	EUR	1,506	
	Morgan Stanley & Co. International PLC	60,000	07/12/18	EUR	66.89	EUR	4,124	
miconductor Manufacturing Co.	·							
	Goldman Sachs International	350,000	07/12/18	USD	237.08	USD	75,775	
orp.	Citibank N.A.	33,400	07/13/18	CAD	46.34	CAD	1,560	

SCHEDULES OF INVESTMENTS 59

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

## **OTC Options Written (continued)**

		Number of	Expiration		Exercise		Notional	
Description	Counterparty	Contracts	-		Price	Amo	ount (000)	Value
Call (continued)								
Amcor Ltd.	Goldman Sachs International	624,700	07/18/18	AUD	13.88	AUD	8,996	\$ (267,926)
Anheuser-Busch								
nBev SA	Morgan Stanley & Co. International PLO	22,000	07/18/18	EUR	83.88	<b>EUR</b>	1,900	(78,733)
Ansell Ltd.	Goldman Sachs International	52,600	07/18/18	AUD	26.80	AUD	1,428	(24,501)
Deutsche Post AG,								
Registered Shares	Morgan Stanley & Co. International PLO	110,000	07/18/18	EUR	33.57	<b>EUR</b>	3,060	(959)
Diageo PLC	Goldman Sachs International	88,950	07/18/18	GBP	27.45	GBP	2,421	(44,068)
Far EasTone								
Telecommunications								
Co. Ltd.	Goldman Sachs International	544,000	07/18/18	USD	77.13	USD	42,845	(33,657)
mperial Brands PLC	HSBC Bank PLC	17,000	07/18/18	GBP	26.85	GBP	478	(32,820)
Kone OYJ, Class B	Credit Suisse International	52,000	07/18/18	EUR	43.47	<b>EUR</b>	2,264	(58,126)
Sanofi	Morgan Stanley & Co. International PLO			EUR	65.82	EUR	1,433	(80,623)
Schneider Electric	· ·							
SE	Barclays Bank PLC	18,500	07/18/18	EUR	76.74	EUR	1,318	(1,521)
TELUS Corp.	Citibank N.A.	46,000	07/18/18	CAD	45.85	CAD	2,148	(37,687)
Jnited Overseas								
Bank Ltd.	JPMorgan Chase Bank N.A.	126,500	07/18/18	SGD	28.67	SGD	3,378	(3,928)
post SA	Credit Suisse International	57,000	07/18/18	EUR	15.21	EUR	771	(1,014)
ANTA Sports								
Products Ltd.	Goldman Sachs International	550,000	07/19/18	HKD	44.78	HKD	22,754	(43,714)
Novartis AG,								
Registered Shares	Morgan Stanley & Co. International PLO	97,900	07/19/18	CHF	76.10	CHF	7,344	(72,921)
Jnilever PLC	Morgan Stanley & Co. International PLO	96,700	07/19/18	GBP	42.83	GBP	4,048	(37,595)
Sonic Healthcare								
Ltd.	UBS AG	62,300	07/24/18	AUD	23.80	AUD	1,527	(41,658)
United Overseas								
Bank Ltd.	UBS AG	111,900	07/24/18	SGD	29.32	SGD	2,988	(2,003)
ANTA Sports								
Products Ltd.	UBS AG	309,000	07/25/18	HKD	49.34	HKD	12,783	(7,142)
Anheuser-Busch								
nBev SA	UBS AG	16,700	07/25/18	EUR	84.29	EUR	1,442	(57,527)
Ansell Ltd.	Morgan Stanley & Co. International PLC	32,000	07/25/18	AUD	26.66	AUD	869	(19,748)
Diageo PLC	Goldman Sachs International	5,000	07/25/18	GBP	27.90	GBP	136	(1,630)
GlaxoSmithKline								
PLC	Citibank N.A.	572,700	07/25/18	GBP	15.50	GBP	8,751	(135,399)
Heineken NV	Deutsche Bank AG	25,300	07/25/18	EUR	87.76	EUR	2,170	(21,828)
Kone OYJ, Class B	UBS AG	83,000	07/25/18	EUR	42.77	EUR	3,614	(143,110)

İ								
Nestle S.A., Registered Shares	Morgan Stanley & Co. International PLC	68,000	07/25/18	CHF	76.40	CHF	5,219	(89,674)
Novo Nordisk A/S,		11.700	07/05/10	~ 1/1/	222.50	~ IZIZ	10 170	(10.515)
Class B	UBS AG	44,700	07/25/18				•	(12,515)
Sanofi Sonia Haalthaara	UBS AG	71,300	07/25/18	EUK	61.21	EUR	4,900	(188,475)
Sonic Healthcare	LIDG A.C.	122 000	07/25/18	ATID	24.52	ATID	2 282	(10 113)
Ltd. Svenska	UBS AG	133,900	07/25/18	AUD	24.32	AUD	3,282	(48,443)
Svenska Jandelsbanken AR								
Handelsbanken AB,	UBS AG	270,500	07/25/18	CEK	101.02	CEK	26 831	(46.070)
Class A FELUS Corp.	Citibank N.A.	270,500 28,500	07/25/18 07/25/18			CAD	26,834 1,331	(46,070) (14,982)
Taiwan	Справк в.А.	28,500	U//23/10	CAD	40.47	CAD	1,331	(14,702)
Semiconductor								
Manufacturing Co.								
td.	UBS AG	987,000	07/25/18	USD	228.60	USD	213,686	(34,466)
ppost SA	Deutsche Bank AG	28,800	07/25/18			EUR	390	(54,400)
ANTA Sports	Deutseile Daile 110	20,000	U1123110	LUX	10.0,	LUI	370	(32)
Products Ltd.	JPMorgan Chase Bank N.A.	258,000	07/26/18	нкр	50 34	HKD	10,673	(3,960)
Amcor Ltd.	UBS AG	317,300	07/26/18			AUD	· ·	(100,596)
Ansell Ltd.	Morgan Stanley & Co. International PLC		07/26/18			AUD	•	(100,390) $(23,397)$
Far EasTone	Morgan Stanicy & Co. International 1 20	27,000	01120110	AUL	41.00	AUL	1,700	(43,37,7
Telecommunications								
Co. Ltd.	Citibank N.A.	401,000	07/26/18	USD	78.15	USD	31,583	(17,953)
Far EasTone	Chlouik 1.7.1.	101,000	011=0, = :	0.52	70	0.0.2	J 1,0 0.	( - 1 , 2 )
Telecommunications								
Co. Ltd.	Goldman Sachs International	450,000	07/26/18	USD	78.76	USD	35,442	(15,575)
apan Tobacco, Inc.	Citibank N.A.	38,800	07/26/18		3,114.06		120,051	(15,119)
Novartis AG,	Chibank 1 112 1.	50,00	011=0.	JI _	J911	JI _	120,00	(10,-
Registered Shares	Morgan Stanley & Co. International PLC	6,750	07/26/18	CHF	75.85	CHF	506	(6,725)
Jnilever PLC	Citibank N.A.	123,300	07/26/18		41.71		5,161	(0,723) $(152,640)$
TELUS Corp.	Goldman Sachs International	24,600	07/27/18			CAD		(152,646) $(16,605)$
TELUS Corp.	Goldman Sachs International	24,600	07/31/18			CAD	•	(14,516)
Ansell Ltd.	Citibank N.A.	35,000	08/01/18			AUD	•	(26,861)
Deutsche Post AG,	Chiodin 1 vi 1	<i>55</i> ,.	00/ 0	110		110	# · ·	( <del>-</del> - , ·           ,
Registered Shares	HSBC Bank PLC	183,500	08/01/18	EUR	28.30	EUR	5,105	(132,854)
Diageo PLC	Citibank N.A.	26,200	08/01/18		27.89		713	(132,034) $(11,797)$
Kone OYJ, Class B	Credit Suisse International	52,000	08/01/18		43.47		2,264	(68,480)
Sonic Healthcare	Citati Saisse International	<i>5</i> <b>-</b> ,	00/ U = .	L.	•= :	L.	<del>-,</del> -	(00,
td.	Morgan Stanley & Co. International PLC	78,800	08/01/18	AUD	24.40	AUD	1,931	(31,841)
ΓELUS Corp.	Citibank N.A.	28,500	08/01/18			CAD	•	(18,211)
post SA	Credit Suisse International	76,800	08/01/18			EUR	1,039	(5,483)
Rogers	Citati Saisse International	, 0,	00/ U = .	L.		L.	* • • ·	ζ-,
Communications,								
nc., Class B	Morgan Stanley & Co. International PLC	72,300	08/02/18	CAD	62.10	CAD	4,514	(72,581)
TELUS Corp.	Goldman Sachs International	32,400	08/03/18			CAD	•	(10,165)
GS SA, Registered	Ordinal Suchs International	<i>52</i> ,	00,02.	C	• • • •	O	-,-	(**, - /
Shares	UBS AG	1,700	08/07/18	CHF	2,574.49	CHF	4,473	(156,618)
Ansell Ltd.	Citibank N.A.	35,000	08/08/18			AUD		(29,095)
AstraZeneca PLC	Goldman Sachs International	16,200	08/08/18			GBP	849	(29,391)
istrazeneea i ze	Goldman Saciis international	10,200	00/00/10	CD.	32.32	OL.	0.7	(2),0/-/

120,000 08/08/18 SGD

OBS Group Holdings

Ltd.

UBS AG

3,180

27.16 SGD

(42,486)

JlaxoSmithKline								
PLC	Morgan Stanley & Co. International PLC	34,100	08/08/18	GBP	15.25	GBP	521	(17,060)
mperial Brands PLC	UBS AG	165,000	08/08/18	GBP	27.66	GBP	4,643	(234,149)
apan Tobacco, Inc.	Goldman Sachs International	64,700	08/08/18	JPY	3,078.48	JPY	200,188	(51,819)
Kone OYJ, Class B	Credit Suisse International	23,600	08/08/18	EUR	43.32	EUR	1,028	(35,744)
Sanofi	Morgan Stanley & Co. International PLC	63,900	08/08/18	EUR	69.52	EUR	4,392	(90,225)
Schneider Electric								
SE	Morgan Stanley & Co. International PLC	29,300	08/08/18	EUR	71.59	EUR	2,087	(65,142)
4								

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

### **OTC Options Written (continued)**

Description	Counterparty	Number of Contracts	Expiration Date	E	xercise Price	_	Notional ınt (000)	Value
Call (continued)	Counterparty	Communicis	Buic		17100	111101	<i>iiii</i> (000)	v citic
Sonic Healthcare								
Ltd.	JPMorgan Chase Bank N.A.	109,000	08/08/18	AUD	25.08	AUD	2,672 \$	(25,136)
Svenska	V2112018un 011404 241111 1 1 1 1 1 1	105,000	00/00/10	1102	20.00	1102	<b>_</b> , 0 / <b>_</b>	(20,100)
Handelsbanken								
AB, Class A	JPMorgan Chase Bank N.A.	421,000	08/08/18	SEK	98.45	SEK	41,763	(130,843)
Unilever PLC	Goldman Sachs International	72,000	08/08/18	GBP	41.88		3,014	(74,014)
TELUS Corp.	Citibank N.A.	46,100	08/09/18	CAD	45.90		2,153	(45,062)
ANTA Sports		-,					,	( - , ,
Products Ltd.	Goldman Sachs International	310,000	08/10/18	HKD	41.32	HKD	12,825	(108,817)
Diageo PLC	Deutsche Bank AG	82,300	08/10/18	GBP	27.66	GBP	2,240	(41,224)
Ansell Ltd.	Citibank N.A.	28,800	08/14/18	AUD	26.94	AUD	782	(19,485)
Novartis AG,		,						
Registered Shares	Morgan Stanley & Co. International PLC	124,000	08/14/18	CHF	73.40	CHF	9,302	(361,833)
Nestle S.A.,	,							
Registered Shares	Morgan Stanley & Co. International PLC	134,500	08/15/18	CHF	77.24	CHF	10,323	(175,636)
TELUS Corp.	Royal Bank of Canada	63,500	08/15/18	CAD	47.24	CAD	2,965	(30,610)
Amcor Ltd.	JPMorgan Chase Bank N.A.	483,800	08/16/18	AUD	14.52	AUD	6,967	(109,795)
Ansell Ltd.	Morgan Stanley & Co. International PLC	38,600	08/22/18	AUD	27.62	AUD	1,048	(14,459)
Rogers								
Communications,								
Inc., Class B	Citibank N.A.	72,300	08/28/18	CAD	62.50	CAD	4,514	(83,559)
TELUS Corp.	Royal Bank of Canada	41,000	08/29/18	CAD	46.70	CAD	1,915	(31,154)

### \$ (5,202,429)

#### Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap						
	Premium	Premium	Unrealized	Unrealized				
	Paid	Received	Appreciation	Depreciation	Value			
Options Written	N/A	N/A	\$ 1,388,709	\$ (1,692,850)	\$ (5,608,380)			
Derivative Financial Instruments Categorized by Risk Exposure								

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity	Credit	C Equity E	0	Interess Rate	Other	
	Contracts C	Contracts	Contracts Contracts Contracts				Total
Liabilities Derivative							
Financial Instruments							
Options written							
Options written at value	\$	\$	\$5,608,380	\$	\$	\$	\$5,608,380

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodit	Foreign Currency Interest Commodity Credit EquityExchange Rate Other								
			1 -	O .		T . 1				
	Contracts	Contracts	ContractsContractsContractsContrac			Contracts	Total			
Net Realized Gain (Loss) from:	¢	¢	¢ 2 505 701	¢	¢	¢	¢ 2.505.791			
Options written	\$	\$	\$ 3,505,781	\$	\$	\$	\$ 3,505,781			
Net Change in Unrealized Appreciation (Depreciation										
on:			* /				* /			
Options written	\$	\$	\$ (1,888,476)	\$	\$	\$	\$ (1,888,476)			

### **Average Quarterly Balances of Outstanding Derivative Financial Instruments**

Options:

Average value of option contracts written

\$4,967,544

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Schedules of Investments 61

**BlackRock Enhanced International Dividend Trust (BGY)** 

June 30, 2018

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Options	Assets \$	<i>Liabilities</i> \$ 5,608,380
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(405,951)
Total derivative assets and liabilities subject to an MNA	\$	\$ 5,202,429

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

	Derivative Liabilities				Net Amount
	Subject to	Derivatives	Non-cash	Cash	of Derivative
	an MNA by	Availa $b$ l $e$	Collateral	Collateral	Liabilities
Counterparty	Counterparty	for Offset	Pledged (a)	Pledged	(b)
Barclays Bank PLC	\$ 1,521	\$	\$	\$	\$ 1,521
Citibank N.A.	761,481		(761,481)		
Credit Suisse International	168,867		(168,867)		
Deutsche Bank AG	63,662		(63,662)		
Goldman Sachs International	951,424		(951,424)		
HSBC Bank PLC	165,674				165,674
JPMorgan Chase Bank N.A.	285,452			(285,452)	
Morgan Stanley & Co.					
International PLC	1,517,647		(1,517,647)		
Royal Bank of Canada	61,764				61,764
UBS AG	1,224,937		(1,224,937)		
	\$ 5,202,429	\$	\$ (4,688,018)	\$ (285,452)	\$ 228,869

<sup>(</sup>a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

### Fair Value Hierarchy as of Period End

<sup>(</sup>b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 60,343,965	\$	\$ 60,343,965
Belgium	7,996,897	8,287,867		16,284,764
Canada	73,544,931			73,544,931
China		12,537,812		12,537,812
Denmark		11,675,264		11,675,264
Finland		26,521,638		26,521,638
France		50,557,021		50,557,021
Germany		30,162,999		30,162,999
India		11,446,031		11,446,031
Japan		11,773,823		11,773,823
Netherlands		29,711,696		29,711,696
Singapore		19,883,735		19,883,735
Sweden		16,295,557		16,295,557
Switzerland		90,205,611		90,205,611
Taiwan		29,664,677		29,664,677
United Kingdom		162,226,197		162,226,197
United States	31,558,628			31,558,628
Preferred Stocks			4,889,604	4,889,604
Short-Term Securities	943,659			943,659
	\$ 114,044,115	\$ 571,293,893	\$4,889,604	\$ 690,227,612

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

62

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments <sup>(a)</sup>				
Liabilities:				
Equity contracts	\$ (386,499)	\$ (5,221,881)	\$	\$ (5,608,380)

	Transfers into Level 1 <sup>(a)</sup>	Transfers out of Level 1 <sup>(a)</sup>	Transfers Into Level 2 <sup>(a)</sup>	Transfers out of Level 2 <sup>(a)</sup>
Assets:				
Long-Term Investments:				
Common Stocks	\$ 12,033,525	\$ 17,468,213	\$ 17,468,213	\$ 12,033,525

<sup>(</sup>a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Schedules of Investments 63

<sup>(</sup>a) Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

Schedule of Investments (unaudited)

# **BlackRock Health Sciences Trust (BME)**

June 30, 2018

## (Percentages shown are based on Net Assets)

Biotechnology 19.7%           ACADIA Pharmaceuticals, Inc. (a)(b)         37,400         \$ 571,098           Acceter on Pharma, Inc. (a)(b)         35,200         1,732,164           Accetra Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402)(c)(d)         15,706         1,322,41           Alexion Pharmaceuticals, Inc. (a)(b)         28,400         35,258,60           Almylam Pharmaceuticals, Inc. (a)(b)         28,400         5,980,53           Amgen, Inc. (b)         28,100         1,900           Amicus Therapeutics, Inc. (a)(b)         22,430         350,357           Amaptys Bio, Inc. (a)         15,00         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         15,00         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         25,14         1,006,278           Argenx SE, ADR(a)         4,53         375,853           Biochaven Pharmaceutical Holding Co. Ltd. (a)(b)         32,20         3,52,90           Biuebrid Bio, Inc. (a)(b)         32,00         3,52,90           Blueprint Medicines Corp. (a)(b)         35,00         222,18           Cellectis SA, ADR(a)         35,00         222,18           Cellectis SA, DR(a)         35,00         222,18           Cilyabericis, Inc. (a)(b)         35,00         222,18	Security	Shares	Value
ACDADA Pharmaceuticals, Inc. (a)(b)         37,400         \$71,008           Acceleron Pharma, Inc. (a)(b)         35,700         1,732,164           Acerta Pharma, Inc. (a)(b)         15,700         1,322,411           Alexion Pharmaceuticals, Inc. (a)(b)         28,400         3,253,803           Allexion Pharmaceuticals, Inc. (a)(b)         28,400         1,477,805           Almylam Pharmaceuticals, Inc. (a)(b)         22,430         5,198,054           Amjeus Therapeutics, Inc. (a)(b)         22,430         350,357           AmaptysBio, Inc. (a)         14,547         320,034           Apellis Pharmaceuticals, Inc. (a)(b)         14,547         320,034           Apellis Pharmaceuticals, Inc. (a)(b)         4,536         375,853           Biogen, Inc. (a)(b)         25,248         7,327,976           Biobaven Pharmaceutical, Inc. (a)(b)         25,248         7,327,976           Biobaven Pharmaceutical, Inc. (a)(b)         25,248         7,327,976           Biobaven Pharmaceutical, Inc. (a)(b)         3,052,080         22,200         345,290           Blueprint Medicines Corp. (a)(b)         3,052,080         22,200         345,290           Blueprint Medicines Corp. (a)(b)         3,052,080         22,200         345,290           Cloical Sciences, Inc. (a)(b)	Common Stocks 98.3%		
Acceleron Pharma, Inc. (a)(b)         35,700         1,73,2,164           Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402)(c)(d)         115,700         1,522,411           Alexion Pharmaceuticals, Inc. (a)(b)         28,400         3,525,800           Allexion Pharmaceuticals, Inc. (a)(b)         28,400         3,525,800           Almen, Inc. (b)         28,160         15,700         14,73,500           Amicus Therapeutics, Inc. (a)(b)         22,430         350,357         AnalysyBio, Inc. (a)         1,500         105,560           Apellis Pharmaceuticals, Inc. (a)         1,500         105,560         20,303         42,313         350,357           Argenx SE, ADR <sup>(a)</sup> 1,500         105,560         30,303         37,78,583         373,7879         30,003         42,720         3,728,797         30,004         4,753         372,879         30,004         4,75,50         27,861         372,879         30,004         4,861         372,879         30,004         3,000         22,789         30,003         22,209         3,009         22,2180         30,002         222,180         30,002         222,180         30,002         222,180         30,002         222,180         30,002         222,180         30,002         222,180         30,002         222,180	Biotechnology 19.7%		
Acetra Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402)cividi         17,146,440         18,39,813           Agios Pharmaceuticals, Inc. (a)(b)         15,000         1,322,816           Allexion Pharmaceuticals, Inc. (a)(b)         28,400         3,528,800           Alnylam Pharmaceuticals, Inc. (a)(b)         28,160         5,198,035           Amgen, Inc. (b)         22,430         35,357           AmptysBio, Inc. (a)         11,500         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         11,547         320,034           Aprens Pharmaceuticals, Inc. (a)(b)         25,144         7,902,738           Argenx SE, ADR(a)         4,536         375,853           Biogen, Inc. (a)(b)         25,248         7,327,979           BioMarin Pharmaceutical Holding Co. Ltd. (a)(b)         3,200         34           BioMarin Pharmaceutical, Inc. (a)(b)         3,200         34,520           Blueprint Medicines Corp. (a)(b)         2,200         345,200           Blueprint Medicines Corp. (a)(b)         2,200         345,200           Cylokinetics, Inc. (a)(b)         3,700         22,400           Glalapagos NV, ADR (a)(b)         3,700         25,426           Glalapagos NV, ADR (a)(b)         5,700         525,426           Global Blood Therapeutic	ACADIA Pharmaceuticals, Inc.(a)(b)	37,400	\$ 571,098
Agios Pharmaceuticals, Inc. (a)(b)         15,700         1322,411           Alexion Pharmaceuticals, Inc. (a)(b)         3,525,860         3,525,860           Alnylam Pharmaceuticals, Inc. (a)(b)         15,000         11,703           Amgen, Inc. (b)         28,160         5,198,054           Amicus Therapeutics, Inc. (a)(b)         22,430         350,357           Anaptysib, Inc. (a)         11,500         10,6560           Apellis Pharmaceuticals, Inc. (a)(b)         11,500         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         25,144         10,96,278           Argenx SE, ADR(a)         4,536         378,853           Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,000         345,290           Bluebird Bio, Inc. (a)(b)         3,200         345,290           Bluebird Bio, Inc. (a)(b)         3,500         222,180           Cylokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         5,388         245,538           Galapagos NV, ADR (a)         5,38	Acceleron Pharma, Inc.(a)(b)	35,700	1,732,164
Alexion Pharmaceuticals, Inc. (a)(b)         3,525,860           Alnylam Pharmaceuticals, Inc. (a)(b)         12,477,350           Amgen, Inc. (b)         28,160         5,198,054           Amicus Therapeutics, Inc. (a)(b)         22,430         350,357           AnaptysBio, Inc. (a)         1,500         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         25,144         1,096,278           Argena Pharmaceuticals, Inc. (a)(b)         25,144         1,096,278           Argens SE, ADR(a)         4,536         375,853           Biogen, Inc. (a)(b)         25,248         7,277,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           Biomari Pharmaceutical, Inc. (a)(b)         3,2400         3,052,080           Bluebird Bio, Inc. (a)(b)         22,248         3,252,080           Bluebird Bio, Inc. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,000         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR(a)(b)         5,700         525,426           Gilead Sciences, Inc. (a)         5,800         6,033,90           Global Blood Th	Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402)(c)(d)	17,146,440	1,839,813
Alnylam Pharmaceuticals, Inc. (a) (b)         15,000         1,477,350           Amgen, Inc. (b)         28,160         5,198,054           Amicus Therapeutics, Inc. (a) (a)         15,00         106,560           Apellis Pharmaceuticals, Inc. (a)         14,547         320,034           Arena Pharmaceuticals, Inc. (a) (b)         25,144         1,096,278           Argens SE, ADR (a)         4,536         378,853           Biogen, Inc. (a) (b)         25,248         7,327,979           Biohaven Pharmaceutical, Inc. (a) (b)         25,248         7,327,979           Biohaven Pharmaceutical, Inc. (a) (b)         2,200         345,290           Bluebird Bio, Inc. (a) (b)         2,200         345,290           Bluebird Bio, Inc. (a) (b)         2,200         345,290           Bluebird Bio, Inc. (a) (b)         3,500         222,180           Cellectis SA, ADR (a)         11,300         39,790           Eidos Therapeutics, Inc. (a) (b)         11,300         39,790           Eidos Therapeutics, Inc. (a) (b)         4,486         91,245           Galapagos NV, ADR (a) (b)         5,588         243,538           Haloxyme Therapeutics, Inc. (a) (b)         4,160         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) (b)         <	Agios Pharmaceuticals, Inc.(a)(b)	15,700	1,322,411
Amgen, Inc. (b)         28,160         5,198,054           Amicus Therapeutics, Inc. (a)(b)         350,357         350,357           AnaptysBio, Inc. (a)         1,500         106,560           Apellis Pharmaceuticals, Inc. (a)(b)         14,547         320,034           Arena Pharmaceuticals, Inc. (a)(b)         25,144         1,096,278           Argenx SE, ADR (a)         45,356         375,853           Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         447,038           Cytokinetics, Inc. (a)(b)         11,300         33,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a)(b)         5,780         525,426           Gilead Sciences Inc. (b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         19,58         260,147	Alexion Pharmaceuticals, Inc. (a)(b)	28,400	3,525,860
Amicus Therapeutics, Inc. (a) (b) (a) (a) (a) (a) (a) (a) (a) (a) (a) (a	Alnylam Pharmaceuticals, Inc.(a)(b)	15,000	1,477,350
AnaptysBio, Inc. (a)         1,500         106,506           Apellis Pharmaceuticals, Inc. (a) (b)         320,034         320,034           Arena Pharmaceuticals, Inc. (a) (b)         25,144         1,096,278           Argenx SE, ADR (a)         4,536         375,855           Biogen, Inc. (a) (b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a) (b)         32,400         305,2080           Bluebird Bio, Inc. (a) (b)         2,200         345,290           Blueprint Medicines Corp. (a) (b)         3,500         222,180           Cellectis SA, ADR (a)         15,095         427,038           Cytokinetics, Inc. (a) (b)         15,095         427,038           Cytokinetics, Inc. (a) (b)         15,095         427,038           Galapagos NV, ADR (a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Hola Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) (d)         19,558         260,147           Inflarx NV (Acquired 11/08/17, cost \$253,349) (d)         19,48         628,488	Amgen, Inc.(b)	28,160	5,198,054
AnaptysBio, Inc. (a)         1,500         106,506           Apellis Pharmaceuticals, Inc. (a) (b)         320,034         320,034           Arena Pharmaceuticals, Inc. (a) (b)         25,144         1,096,278           Argenx SE, ADR (a)         4,536         375,855           Biogen, Inc. (a) (b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a) (b)         32,400         305,2080           Bluebird Bio, Inc. (a) (b)         2,200         345,290           Blueprint Medicines Corp. (a) (b)         3,500         222,180           Cellectis SA, ADR (a)         15,095         427,038           Cytokinetics, Inc. (a) (b)         15,095         427,038           Cytokinetics, Inc. (a) (b)         15,095         427,038           Galapagos NV, ADR (a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Hola Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) (d)         19,558         260,147           Inflarx NV (Acquired 11/08/17, cost \$253,349) (d)         19,48         628,488	Amicus Therapeutics, Inc. (a)(b)	22,430	350,357
Arena Pharmaceuticals, Inc. (a)(b)         25,144         1,096,278           Argenx SE, ADR(a)         4,536         375,853           Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,400         3,052,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,90           Gilead Sciences, Inc. (a)(b)         85,600         6,063,90           Global Blood Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,588         628,488           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488 <tr< td=""><td>·</td><td>1,500</td><td>106,560</td></tr<>	·	1,500	106,560
Argenx SE, ADR(a)         4,536         375,853           Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,400         30,52,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         5,700         525,426           Galapagos NV, ADR(a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6063,904           Global Blood Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$82,789)(d)         19,558         260,147           Incyte Corp. (a)(b)         19,558         626,147           Incyte Corp. (a)(b)         2,900         1,534,300           InflaRx NV. (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           Inflage, Inc. (a)(b)<	Apellis Pharmaceuticals, Inc.(a)	14,547	320,034
Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,400         3052,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR(a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         4,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$82,789)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV (a)         19,488         628,488           Inflalax NV(a)         29,508         951,633           Insmed, Inc. (a)         2,600	Arena Pharmaceuticals, Inc.(a)(b)	25,144	1,096,278
Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,400         3052,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR(a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         4,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$82,789)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV (a)         19,488         628,488           Inflalax NV(a)         29,508         951,633           Insmed, Inc. (a)         2,600	Argenx SE, ADR <sup>(a)</sup>	4,536	375,853
Bionaven Pharmaceutical Holding Co. Ltd. (a) (b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a) (b)         32,400         3,052,080           Bluebird Bio, Inc. (a) (b)         2,200         345,290           Blueprint Medicines Corp. (a) (b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a) (b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a) (b)         5,388         243,538           Halozyme Therapeutics, Inc. (a) (b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) (d)         19,558         260,147           Incyte Corp. (a) (b)         22,900         1,534,300           Inflarx NV, (Acquired 11/08/17, cost \$253,349) (d)         19,488         628,488           Inflagar NV, (a)         29,508         951,633           Insmed, Inc. (a)         2,600         218,166           M			7,327,979
BioMarin Pharmaceutical, Inc. (a)(b)         32,400         3,052,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR (a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           Inflagar NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a)(b)         2,100         587,349           Madrigal Pharmaceuticals, Inc. (a)         2,10         587,349           Nyovant Sciences Ltd.			
Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           Inflaga NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a)(b)         20,000         218,166           Madrigal Pharmaceuticals, Inc. (a)         2,100         587,349           Neurocrine Biosciences, Inc. (a)(b)         9,300         913,632           Ovid therapeutics, Inc. (			3,052,080
Blueprint Medicines Corp. (a) (b)         3,500         222,180           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a) (b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR(a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a) (b)         5,388         243,538           Halozyme Therapeutics, Inc. (a) (b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) (d)         19,558         260,147           Incyte Corp. (a) (b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349) (d)         19,488         628,488           InflaRx NV(a)         19,488         628,488           Inflarecept Pharmaceuticals, Inc. (a) (b)         2,500         218,166           Madrigal Pharmaceuticals, Inc. (a) (b)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a) (b)         9,300         913,632           Ovid therapeutics, Inc. (a) (b)         9,300         913,632	Bluebird Bio, Inc. (a)(b)		345,290
Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR(a)(b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           InflaRx NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         2,100         587,349           Myovant Sciences Ltd. (a)         16,236         371,317           Neurocrine Biosciences, Inc. (a)(b)         9,300         913,632           Ovid therapeutics, Inc. (a)			
Cytokinetics, Inc. (a) (b)         11,300         93,790           Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a) (b)         5,388         243,538           Halozyme Therapeutics, Inc. (a) (b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         19,558         260,147           Incyte Corp. (a) (b)         19,558         260,147           Incyte Corp. (a) (b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349) (d)         19,488         628,488           InflaRx NV (a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a) (b)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a) (b)         2,100         587,349           Myovant Sciences Ltd. (a)         16,236         371,317           Neurocrine Biosciences, Inc. (a) (b)         9,300         913,632           Ovid therapeutics, Inc. (a) (b)         32,010         38,610         38,610           Sage Therapeu	Cellectis SA, ADR <sup>(a)</sup>		
Eidos Therapeutics, Inc. (a)         4,486         91,245           Galapagos NV, ADR (a) (b)         5,700         525,426           Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a) (b)         5,388         243,538           Halozyme Therapeutics, Inc. (a) (b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) (d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) (d)         19,558         260,147           Incyte Corp. (a) (b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349) (d)         19,488         628,488           InflaRx NV (a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a) (b)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         2,100         587,349           Myovant Sciences Ltd. (a)         16,236         371,317           Neurocrine Biosciences, Inc. (a) (b)         30         913,632           Ovid therapeutics, Inc. (a) (b)         4,958         1,710,460           Sage Therapeutics, Inc. (a) (b)         38,650         5,108,757			
Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           InflaRx NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         9,300         913,632           Ovid therapeutics, Inc. (a)         9,300         913,632           Ovid therapeutics, Inc. (a)         42,053         328,013           Regeneron Pharmaceuticals, Inc. (a)(b)         38,650         5,108,757           Sarepta Therapeutics, Inc. (a)(b)         38,650         5,108,757           Seattle Genetics, Inc. (a)(b)         50,467         3,350,504 <tr< td=""><td>·</td><td></td><td>91,245</td></tr<>	·		91,245
Gilead Sciences, Inc. (b)         85,600         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           InflaRx NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Intercept Pharmaceuticals, Inc. (a)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         2,600         218,166           Madrigal Pharmaceuticals, Inc. (a)         9,300         913,632           Ovid therapeutics, Inc. (a)         9,300         913,632           Ovid therapeutics, Inc. (a)         42,053         328,013           Regeneron Pharmaceuticals, Inc. (a)(b)         38,650         5,108,757           Sarepta Therapeutics, Inc. (a)(b)         38,650         5,108,757           Seattle Genetics, Inc. (a)(b)         50,467         3,350,504 <tr< td=""><td>•</td><td></td><td></td></tr<>	•		
Global Blood Therapeutics, Inc. (a)(b)       5,388       243,538         Halozyme Therapeutics, Inc. (a)(b)       41,600       701,792         HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)       7,449       82,789         HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)       19,558       260,147         Incyte Corp. (a)(b)       22,900       1,534,300         InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)       19,488       628,488         InflaRx NV(a)       29,508       951,633         Insmed, Inc. (a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc. (a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       49,58       1,710,460         Sage Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	2 -	85,600	6,063,904
HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)       7,449       82,789         HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)       19,558       260,147         Incyte Corp. (a)(b)       22,900       1,534,300         InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)       19,488       628,488         InflaRx NV(a)       29,508       951,633         Insmed, Inc. (a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc. (a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668			243,538
HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)       19,558       260,147         Incyte Corp.(a)(b)       22,900       1,534,300         InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)       19,488       628,488         InflaRx NV(a)       29,508       951,633         Insmed, Inc.(a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc.(a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc.(a)       2,100       587,349         Myovant Sciences Ltd.(a)       16,236       371,317         Neurocrine Biosciences, Inc.(a)(b)       9,300       913,632         Ovid therapeutics, Inc.(a)       42,053       328,013         Regeneron Pharmaceuticals, Inc.(a)(b)       4,958       1,710,460         Sage Therapeutics, Inc.(a)(b)       38,650       5,108,757         Seattle Genetics, Inc.(a)(b)       50,467       3,350,504         Spark Therapeutics, Inc.(a)(b)       9,010       745,668	Halozyme Therapeutics, Inc. (a)(b)	41,600	701,792
Incyte Corp. (a)(b)       22,900       1,534,300         InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)       19,488       628,488         InflaRx NV(a)       29,508       951,633         Insmed, Inc. (a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc. (a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup>	7,449	82,789
InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)       19,488       628,488         InflaRx NV(a)       29,508       951,633         Insmed, Inc.(a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc.(a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc.(a)       2,100       587,349         Myovant Sciences Ltd.(a)       16,236       371,317         Neurocrine Biosciences, Inc.(a)(b)       9,300       913,632         Ovid therapeutics, Inc.(a)       42,053       328,013         Regeneron Pharmaceuticals, Inc.(a)(b)       4,958       1,710,460         Sage Therapeutics, Inc.(a)(b)       38,650       5,108,757         Seattle Genetics, Inc.(a)(b)       50,467       3,350,504         Spark Therapeutics, Inc.(a)(b)       9,010       745,668	HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup>	19,558	260,147
InflaRx NV(a)       29,508       951,633         Insmed, Inc.(a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc.(a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc.(a)       2,100       587,349         Myovant Sciences Ltd.(a)       16,236       371,317         Neurocrine Biosciences, Inc.(a)(b)       9,300       913,632         Ovid therapeutics, Inc.(a)       42,053       328,013         Regeneron Pharmaceuticals, Inc.(a)(b)       4,958       1,710,460         Sage Therapeutics, Inc.(a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc.(a)(b)       38,650       5,108,757         Seattle Genetics, Inc.(a)(b)       50,467       3,350,504         Spark Therapeutics, Inc.(a)(b)       9,010       745,668	Incyte Corp. (a)(b)	22,900	1,534,300
InflaRx NV(a)       29,508       951,633         Insmed, Inc.(a)       67,286       1,591,314         Intercept Pharmaceuticals, Inc.(a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc.(a)       2,100       587,349         Myovant Sciences Ltd.(a)       16,236       371,317         Neurocrine Biosciences, Inc.(a)(b)       9,300       913,632         Ovid therapeutics, Inc.(a)       42,053       328,013         Regeneron Pharmaceuticals, Inc.(a)(b)       4,958       1,710,460         Sage Therapeutics, Inc.(a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc.(a)(b)       38,650       5,108,757         Seattle Genetics, Inc.(a)(b)       50,467       3,350,504         Spark Therapeutics, Inc.(a)(b)       9,010       745,668	InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup>	19,488	628,488
Intercept Pharmaceuticals, Inc. (a)(b)       2,600       218,166         Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	InflaRx NV <sup>(a)</sup>	29,508	
Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Insmed, Inc.(a)	67,286	1,591,314
Madrigal Pharmaceuticals, Inc. (a)       2,100       587,349         Myovant Sciences Ltd. (a)       16,236       371,317         Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Intercept Pharmaceuticals, Inc. (a)(b)	2,600	218,166
Myovant Sciences Ltd.(a)       16,236       371,317         Neurocrine Biosciences, Inc.(a)(b)       9,300       913,632         Ovid therapeutics, Inc.(a)       42,053       328,013         Regeneron Pharmaceuticals, Inc.(a)(b)       4,958       1,710,460         Sage Therapeutics, Inc.(a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc.(a)(b)       38,650       5,108,757         Seattle Genetics, Inc.(a)(b)       50,467       3,350,504         Spark Therapeutics, Inc.(a)(b)       9,010       745,668		2,100	587,349
Neurocrine Biosciences, Inc. (a)(b)       9,300       913,632         Ovid therapeutics, Inc. (a)       42,053       328,013         Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Myovant Sciences Ltd.(a)	16,236	371,317
Regeneron Pharmaceuticals, Inc. (a)(b)       4,958       1,710,460         Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Neurocrine Biosciences, Inc. (a)(b)	9,300	
Sage Therapeutics, Inc. (a)(b)       13,552       2,121,295         Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Ovid therapeutics, Inc. (a)	42,053	328,013
Sarepta Therapeutics, Inc. (a)(b)       38,650       5,108,757         Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Regeneron Pharmaceuticals, Inc.(a)(b)	4,958	1,710,460
Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668	Sage Therapeutics, Inc.(a)(b)	13,552	2,121,295
Seattle Genetics, Inc. (a)(b)       50,467       3,350,504         Spark Therapeutics, Inc. (a)(b)       9,010       745,668			
Spark Therapeutics, Inc. <sup>(a)(b)</sup> 9,010 745,668			
*			745,668
	Spectrum Pharmaceuticals, Inc. <sup>(a)(b)</sup>	55,600	1,165,376

Life Sciences Tools & Services 3.4%		
Teladoc, Inc. <sup>(a)(b)</sup>	37,100	2,153,655
Health Care Technology 0.6%		82,550,598
	-,	
WellCare Health Plans, Inc. (a)(b)	6,400	1,575,936
Universal Health Services, Inc., Class B <sup>(b)</sup>	16,800	1,872,192
UnitedHealth Group, Inc.	118,302	29,024,213
Quest Diagnostics, Inc. (b)	80,100	8,806,194
Molina Healthcare, Inc. (a)(b)	11,300	1,106,722
Humana, Inc.(b)	27,600	8,214,588
HealthEquity, Inc. (a)(b)	12,400	931,240
HCA Healthcare, Inc. <sup>(b)</sup>	18,094	1,856,444
DaVita, Inc.(a)(b)	55,694	3,867,391
Cigna Corp.(b)	39,500	6,713,025
Centene Corp. (a)	42,800	5,273,388
Anthem, Inc.	35,800	8,521,474
AmerisourceBergen Corp.(b)	16,300	1,389,901
Amedisys, Inc.(a)(b)	39,760	3,397,890
Health Care Providers & Services 24.1%		95,992,295
Varian Medical Systems, Inc. <sup>(a)(b)</sup>	14,900	1,694,428
Teleflex, Inc.(b)	8,400	2,252,964
Stryker Corp.(b)	69,200	11,685,112
ResMed, Inc. <sup>(b)</sup>	31,900	3,304,202
Nevro Corp. (a)(b)	24,600	1,964,310
Medtronic PLC <sup>(b)</sup>	169,100	14,476,651
Masimo Corp. (a)(b)	38,600 \$	3,769,290
Health Care Equipment & Supplies (continued)	20.600 f	2.760.200
Security Health Core Equipment & Supplies (continued)	Shares	Value
iRhythm Technologies, Inc. <sup>(a)(b)</sup>	15,083	1,223,684
Intuitive Surgical, Inc. (a)(b)	12,100	5,789,608
Globus Medical, Inc., Class A <sup>(a)(b)</sup>	24,500	1,236,270
Edwards Lifesciences Corp. (a)(b)	31,500	4,585,455
Cooper Cos., Inc.(b)	4,915	1,157,237
Boston Scientific Corp. (a)(b)	415,484	13,586,327
Becton Dickinson & Co. <sup>(b)</sup>	27,633	6,619,761
Baxter International, Inc. (b)	108,800	8,033,792
Abbott Laboratories <sup>(b)</sup>	239,600	14,613,204
Health Care Equipment & Supplies 28.0%		
Diversified Consumer Services 0.6% Service Corp. International <sup>(b)</sup>	59,800	2,140,242
		67,278,488
Vertex Pharmaceuticals, Inc. <sup>(a)(b)</sup>	34,005	5,779,490
Ultragenyx Pharmaceutical, Inc. (a)(b)	21,300	1,637,331
TESARO, Inc. <sup>(a)</sup>	17,831	792,945
Syndax Pharmaceuticals, Inc. <sup>(a)(b)</sup>	15,784	110,804

Agilent Technologies, Inc.(b)	32,200	1,991,248
Charles River Laboratories International, Inc. (a)(b)	7,771	872,372
QIAGEN NV <sup>(a)</sup>	48,300	1,746,528
Thermo Fisher Scientific, Inc. <sup>(b)</sup>	27,300	5,654,922
Wuxi Biologics Cayman, Inc. (a)(e)	120,500	1,336,723
		11,601,793
Pharmaceuticals 21.9%		
Allergan PLC <sup>(b)</sup>	34,985	5,832,699
Assembly Biosciences, Inc. <sup>(a)</sup>	2,200	86,262
AstraZeneca PLC	69,576	4,812,376
AstraZeneca PLC AD®	63,100	2,215,441
Bristol-Myers Squibb Co. <sup>(b)</sup>	104,762	5,797,529
Chugai Pharmaceutical Co. Ltd.	15,900	832,532
Eli Lilly & Co. <sup>(b)</sup>	65,800	5,614,714
Jazz Pharmaceuticals PLC <sup>(a)(b)</sup>	10,400	1,791,920
Johnson & Johnson <sup>(b)</sup>	41,970	5,092,640
Medicines Co. <sup>(a)(b)</sup>	18,600	682,620
Merck & Co., Inc.(b)	109,579	6,651,445
Merck KGaA	28,300	2,754,930
Nektar Therapeutics <sup>(a)(b)</sup>	7,400	361,342
Novartis AG, ADR <sup>(b)</sup>	33,900	2,560,806
Novo Nordisk A/S ADŔ)	74,300	3,426,716
Pfizer, Inc. (b)	465,298	16,881,012
Reata Pharmaceuticals, Inc., Class A <sup>(a)(b)</sup>	5,860	204,924
Sanofi	20,400	1,637,294
Sanofi ADR)	50,200	2,008,502
Teva Pharmaceutical Industries Ltd. ADR	35,500	863,360
Theravance Biopharma, Inc. (a)(b)	4,700	106,596
Tricida, Inc. (a)	9,249	276,545
Zoetis, Inc.(b)	54,500	4,642,855
		75,135,060
Total Common Stocks 98.3%		
(Cost \$226,041,590)		336,852,131

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

64

Schedule of Investments (unaudited) (continued)	BlackRock Health Sciences T	rust (BME)
June 30, 2018	(Percentages shown are based on	Net Assets)
Security Other Interests(f) 0.0%	Shares	Value
<b>Pharmaceuticals 0.0%</b> Afferent Pharmaceuticals, Inc., Series C, (Acquired 09/30/15, Cost \$0	) <sup>(c)(d)</sup> 190 \$	115,997
Total Other Interests 0.0% (Cost \$ )		115,997
Preferred Stock		
<b>Biotechnology 0.2%</b> Rubius Therapeutics, Inc., (Acquired 2/23/18, cost \$505,410), 0.00%	a)(c)(d) 39,516	505,410
Total Preferred Stocks 0.2% (Cost \$505,410)		505,410
Rights 0.0%		
<b>Health Care Technology 0.0%</b> Dyax Corp., CVR (Expires 12/31/19) <sup>(c)</sup>	61,727	141,355
Total Rights 0.0% (Cost \$25,848)		141,355
Total Long-Term Investments 98.5% (Cost \$226,572,848)	3	37,614,893
Security	Shares	Value
Short-Term Securities 2.1% BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(g)(h)</sup>	7,272,162 \$	7,272,162
Total Short-Term Securities 2.1% (Cost \$7,272,162)		7,272,162
Total Investments Before Options Written 100.6% (Cost \$233,845,010)	34	14,887,055
Options Written (0.8)% (Premiums Received \$2,899,524)	,	(2,688,836)
Total Investments, Net of Options Written 99.8% (Cost \$230,945,486)	34	12,198,219

#### Other Assets Less Liabilities 0.2%

531,212

Net Assets 100.0% \$ 342,729,431

- (a) Non-income producing security.
- (b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (c) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$3,432,644 and an original cost of \$2,088,097, which was 0.8% of its net assets.
- (e) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (f) Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
- (g) Annualized 7-day yield as of period end.
- (h) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares Held at	Net	Shares Held at	Value at		Real	Nem Azeptro		in zed
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Incon <b>G</b> ain	$(L\phi \mathbf{E}$	sepre	ciatio	on)
BlackRock Liquidity Funds, T-Fund,									
Institutional Class SL Liquidity Series,	14,301,421	(7,029,259)	7,272,162	\$7,272,162	\$ 83,489	\$		\$	
LLC, Money Market Series	120,903	(120,903)			1,241 <sup>(b)</sup>		13		7
				\$7,272,162	\$84,730	\$	13	\$	7

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

#### **Derivative Financial Instruments Outstanding as of Period End**

#### **Exchange-Traded Options Written**

<sup>(</sup>a) Includes net capital gain distributions, if applicable.

<sup>(</sup>b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

	Number of	Expiration Exercise Notional		Exercise		otional		
Description	Contracts	Date		Price	ce Amount (000)		Value	
Call								
Pfizer, Inc.	30	07/02/18	USD	36.25	USD	109	\$ (596)	
Allergan PLC	63	07/06/18	USD 1	157.50	USD	1,050	(61,583)	
Amgen, Inc.	7	07/06/18	USD 1	187.50	USD	129	(420)	
AstraZeneca PLC	247	07/06/18	USD	37.50	USD	867	(1,235)	
Baxter International, Inc.	45	07/06/18	USD	73.50	USD	332	(3,780)	

Schedules of Investments 65

**BlackRock Health Sciences Trust (BME)** 

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date	Price		Price Amount (000)		Value
Call (continued)							
Gilead Sciences, Inc.	65	07/06/18	USD	69.50	USD	460	\$ (10,693)
Humana, Inc.	67	07/06/18	USD	297.50	USD	1,994	(22,613)
Pfizer, Inc.	101	07/06/18	USD	36.00	USD	366	(4,494)
Pfizer, Inc.	101	07/06/18	USD	36.50	USD	366	(1,313)
Pfizer, Inc.	38	07/06/18	USD	37.00	USD	138	(171)
Zoetis, Inc.	148	07/06/18	USD	85.50	USD	1,261	(9,620)
Novo Nordisk A/S ADR	229	07/09/18	USD	50.00	USD	1,056	(85)
AmerisourceBergen Corp.	44	07/13/18	USD	87.00	USD	375	(5,500)
Amgen, Inc.	72	07/13/18	USD	182.50	USD	1,329	(29,160)
Becton Dickinson & Co.	61	07/13/18	USD	232.50	USD	1,461	(53,070)
Biogen, Inc.	26	07/13/18	USD	295.00	USD	755	(8,970)
Humana, Inc.	22	07/13/18	USD	307.50	USD	655	(2,255)
Medtronic PLC	37	07/13/18	USD	88.50	USD	317	(407)
Pfizer, Inc.	152	07/13/18	USD	36.50	USD	551	(4,332)
Pfizer, Inc.	38	07/13/18	USD	37.00	USD	138	(418)
Vertex Pharmaceuticals, Inc.	109	07/13/18	USD	157.50	USD	1,853	(148,240)
ACADIA Pharmaceuticals, Inc.	149	07/20/18	USD	18.00	USD	228	(4,097)
Acceleron Pharma, Inc.	142	07/20/18	USD	40.00	USD	689	(129,220)
Agilent Technologies, Inc.	40	07/20/18	USD	67.50	USD	247	(180)
Agios Pharmaceuticals, Inc.	62	07/20/18	USD	105.00	USD	522	(1,240)
Alexion Pharmaceuticals, Inc.	56	07/20/18	USD	125.00	USD	695	(19,600)
Allergan PLC	76	07/20/18	USD	180.00	USD	1,267	(4,902)
Alnylam Pharmaceuticals, Inc.	60	07/20/18	USD	120.00	USD	591	(2,400)
Amedisys, Inc.	102	07/20/18	USD	80.00	USD	872	(55,845)
Amedisys, Inc.	58	07/20/18	USD	85.00	USD	496	(16,066)
Arena Pharmaceuticals, Inc.	16	07/20/18	USD	50.00	USD	70	(704)
Baxter International, Inc.	69	07/20/18	USD	72.50	USD	509	(14,594)
BioMarin Pharmaceutical, Inc.	56	07/20/18	USD	95.00	USD	528	(17,500)
BioMarin Pharmaceutical, Inc.	73	07/20/18	USD	100.00	USD	688	(11,498)
Biogen, Inc.	24	07/20/18	USD	280.00	USD	697	(33,120)
Biohaven Pharmaceutical Holding							
Co. Ltd.	28	07/20/18	USD	40.00	USD	111	(6,300)
Bluebird Bio, Inc.	8	07/20/18	USD	195.00	USD	126	(620)
Blueprint Medicines Corp.	14	07/20/18	USD	85.00	USD	89	(1,260)
Boston Scientific Corp.	658	07/20/18	USD	31.00	USD	2,152	(135,548)
Bristol-Myers Squibb Co.	142	07/20/18	USD	55.00	USD	786	(16,046)
Cooper Cos., Inc.	19	07/20/18	USD	230.00	USD	447	(15,580)
Cytokinetics, Inc.	45	07/20/18	USD	10.00	USD	37	(450)

Edgar Filing: BlackRock Enhanced Equity Dividend Trust - Form N-CSRS

DaVita, Inc.	125	07/20/18	USD	70.00	USD	868	(19,375)
Edwards Lifesciences Corp.	33	07/20/18	USD	145.00	USD	480	(11,385)
Galapagos NV, ADR	22	07/20/18	USD	105.00	USD	203	(10,780)
Gilead Sciences, Inc.	156	07/20/18	USD	67.50	USD	1,105	(60,450)
Global Blood Therapeutics, Inc.	21	07/20/18	USD	50.00	USD	95	(3,202)
Globus Medical, Inc., Class A	88	07/20/18	USD	57.50	USD	444	(1,760)
HCA Healthcare, Inc.	41	07/20/18	USD	105.00	USD	421	(3,997)
Halozyme Therapeutics, Inc.	170	07/20/18	USD	20.00	USD	287	(1,700)
HealthEquity, Inc.	49	07/20/18	USD	85.00	USD	368	(980)
Incyte Corp.	82	07/20/18	USD	75.00	USD	549	(2,665)
Jazz Pharmaceuticals PLC	40	07/20/18	USD	180.00	USD	689	(7,300)
Johnson & Johnson	102	07/20/18	USD	125.00	USD	1,238	(8,670)
Masimo Corp.	151	07/20/18	USD	100.00	USD	1,475	(18,875)
Medicines Co.	74	07/20/18	USD	39.00	USD	272	(5,180)
Medtronic PLC	5	07/20/18	USD	87.50	USD	43	(222)
Medtronic PLC	21	07/20/18	USD	90.00	USD	180	(189)
Merck & Co., Inc.	25	07/20/18	USD	60.00	USD	152	(3,812)
Merck & Co., Inc.	106	07/20/18	USD	62.50	USD	643	(4,081)
Molina Healthcare, Inc.	45	07/20/18	USD	100.00	USD	441	(8,100)
Nektar Therapeutics	29	07/20/18	USD	65.00	USD	142	(1,087)
Neurocrine Biosciences, Inc.	36	07/20/18	USD	94.25	USD	354	(22,744)
Nevro Corp.	98	07/20/18	USD	85.00	USD	783	(8,330)
Novartis AG, ADR	86	07/20/18	USD	80.00	USD	650	(1,075)
Novo Nordisk A/S ADR	58	07/20/18	USD	48.90	USD	267	(1,097)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

**BlackRock Health Sciences Trust (BME)** 

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date	Price		Amount (000)		Value
Call (continued)							
Pfizer, Inc.	137	07/20/18	USD	36.00	USD	497	\$ (9,385)
Pfizer, Inc.	169	07/20/18	USD	35.00	USD	613	(25,012)
Pfizer, Inc.	139	07/20/18	USD	37.00	USD	504	(2,710)
Quest Diagnostics, Inc.	83	07/20/18	USD	106.90	USD	913	(31,349)
Regeneron Pharmaceuticals, Inc.	8	07/20/18	USD	320.00	USD	276	(22,200)
Resmed, Inc.	130	07/20/18	USD	106.95	USD	1,347	(9,808)
Sage Therapeutics, Inc.	39	07/20/18	USD	185.00	USD	610	(1,755)
Sanofi ADR	200	07/20/18	USD	40.00	USD	800	(13,000)
Seattle Genetics, Inc.	201	07/20/18	USD	75.00	USD	1,334	(4,522)
Spark Therapeutics, Inc.	36	07/20/18	USD	79.00	USD	298	(23,431)
Stryker Corp.	280	07/20/18	USD	175.00	USD	4,728	(36,400)
Syndax Pharmaceuticals, Inc.	63	07/20/18	USD	10.00	USD	44	(1,260)
Teladoc, Inc.	148	07/20/18	USD	60.00	USD	859	(26,270)
Theravance Biopharma, Inc.	18	07/20/18	USD	25.00	USD	41	(585)
Thermo Fisher Scientific, Inc.	109	07/20/18	USD	220.00	USD	2,258	(2,725)
Universal Health Services, Inc.,							
Class B	34	07/20/18	USD	120.00	USD	379	(1,020)
Varian Medical Systems, Inc.	59	07/20/18	USD	125.00	USD	671	(885)
Vertex Pharmaceuticals, Inc.	27	07/20/18	USD	160.00	USD	459	(33,345)
WellCare Health Plans, Inc.	25	07/20/18	USD	240.00	USD	616	(23,250)
iRhythm Technologies, Inc.	57	07/20/18	USD	85.00	USD	462	(8,408)
Universal Health Services, Inc.,							
Class B	33	07/23/18	USD	116.50	USD	368	(2,189)
Novartis AG, ADR	66	07/25/18	USD	76.45	USD	499	(7,301)
Abbott Laboratories	486	07/27/18	USD	63.00	USD	2,964	(25,029)
Baxter International, Inc.	71	07/27/18	USD	76.00	USD	524	(6,638)
Biogen, Inc.	8	07/27/18	USD	310.00	USD	232	(2,620)
Boston Scientific Corp.	181	07/27/18	USD	31.50	USD	592	(38,553)
Boston Scientific Corp.	186	07/27/18	USD	33.50	USD	608	(18,600)
Bristol-Myers Squibb Co.	73	07/27/18	USD	55.00	USD	404	(11,826)
Cigna Corp.	158	07/27/18	USD	180.00	USD	2,685	(16,432)
Edwards Lifesciences Corp.	60	07/27/18	USD	155.00	USD	873	(16,650)
Gilead Sciences, Inc.	63	07/27/18	USD	72.00	USD	446	(11,624)
Intercept Pharmaceuticals, Inc.	10	07/27/18	USD	85.00	USD	84	(4,600)
Medtronic PLC	61	07/27/18	USD	88.50	USD	522	(2,318)
Medtronic PLC	85	07/27/18	USD	86.50	USD	728	(8,415)
Merck & Co., Inc.	106	07/27/18	USD	63.50	USD	643	(4,982)
Pfizer, Inc.							